Fused thiazolopyrimidine derivatives as MNKS inhibitors

ABSTRACT

The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer&#39;s disease.

FIELD OF THE INVENTION

The present invention relates to fused thiazolopyrimidine compounds thatare capable of inhibiting one or more kinases, more particularly, MAPkinase-interacting serine/threonine-protein kinases (MNKs). Thecompounds have potential therapeutic applications in the treatment of avariety of disorders, including proliferative disorders, andneurodegenerative diseases such as Alzheimer's disease.

BACKGROUND TO THE INVENTION

The present invention relates to chemical compounds that inhibit theenzymatic activity of MAP kinase-interacting serine/threonine-proteinkinases (MNKs). MNK proteins are encoded by the two genes MKNK1 andMKNK2 which give rise to MNK1 and 2. Both proteins come in two isoformsgenerated by alternative splicing. The shorter isoform, referred to asMNK1b/2b, lacks the MAP kinase binding domain which results in low basalactivity (Buxade et al. Front Biosci 2008, 5359-5373). Mnk1a isactivated through ERK and p38 but not JNK binding, whereas MNK2a appearsto be only activated by ERK.

The catalytic domains of MNK1 and 2 are very similar. The domains are,however, very distinct from other kinases as they display a DFD motif inthe ATP binding site instead of the typical DFG motif, which suggests analtered activation loop confirmation (Jauch et al. EMBO J 2006,4020-4032). MNK1/2 are ubiquitously expressed with phosphorylateeukaryotic initiation factor 4E (eIF4E), cytoplasmic phospholipase A2(cPLA2) heterogeneous nuclear RNA-binding protein A1 (hnRNP A1),polypyrimidine-tract binding protein-associated splicing factors (PSF)and Sprouty 2 (hSPRY2) (Buxade et al. Front Biosci 2008, 5359-5373).

MNKs have been linked to cancer through the phosphorylation of eIF4E.eIF4E is an oncogene which is amplified in cancer and is solelyphosphorylated by MNKs (Konicek et al. Cell Cycle 2008, 2466-2471).eIF4E overexpression induces tumour formation in animals models.Increased phosphorylation of eIF4E has been observed in many solidtumours and lymph node metastasis where it correlates with poorprognosis. eIF4E is the rate limiting factor in cap-dependenttranslation where it directs ribosomes to the cap structure ofmRNA—freely or as part of the eIF4F pre-initiation complex. Almost allproteins require eIF4E for translation. Phosphorylation of eIF4E leadsto preferred translation of mRNA involved in cell survival, angiogenesisand cancer metastasis, such as mRNA for cyclin D1, Myc, Mcl-1, Bcl-2 andVEGF. These mRNAs are usually less efficiently translated due to longand complex 5′UTRs. Phosphorylation of eIF4 does not affect the overalltranslation rate but has been suggested to aid polysome formation, whichfacilitates more efficient translation.

A number of MNK1/MNK2 inhibitors are known in the art. For example, U.S.Pat. Nos. 8,754,079 and 8,853,193 (both in the name of BoehringerIngelheim International GMBH) disclose thienopyrimidine compounds thatare capable of inhibiting MNK1 and/or MNK2. Likewise, WO 2014/135480(Bayer Pharma Aktiengesellschaft) discloses thiazolopyrimidinessubstituted by an indazolyl or 2-oxo-2,3,dihydro-1,3-benzothiazolylgroup. WO 2014/118226 (Bayer Pharma Aktiengesellschaft) disclosessubstituted pyrazolylopyrimidinylamino-indazoles that are capable ofinhibiting MNK1 and/or MNK2.

The present invention seeks to provide alternative compounds that arecapable of interfering with the activity of MNK and its pathways. Suchcompounds have potential therapeutic applications in the treatment of avariety of disorders, including proliferative disorders andneurodegenerative disorders.

STATEMENT OF INVENTION

A first aspect of the invention relates to a compound of formula (I), ora pharmaceutically acceptable salt or ester thereof,

wherein:

R₁ is selected from:

-   -   CO—NR₁₂R₁₃, wherein R₁₂ and R₁₃ are each independently selected        from H, alkyl, cycloalkyl and heterocycloalkyl, wherein said        alkyl group is optionally substituted by one or more R₁₄ groups,        and said heterocycloalkyl is optionally substituted by one or        more R₁₀ groups; or R₁₂ and R₁₃ are linked, together with the        nitrogen to which they are attached, to form a heterocycloalkyl        group optionally containing one or more additional heteroatoms,        and optionally substituted by one or more R₁₀ groups;    -   hydroxyalkyl;    -   H;    -   NH₂;    -   NH-alkyl, wherein said alkyl group is optionally substituted        with one or more R₁₄ groups;    -   NH—CO-heterocycloalkyl;    -   heterocycloalkyl optionally substituted by one or more R₁₀        groups; and    -   alkoxy optionally substituted with one or more R₁₄ groups;

R₂, R₃, R₄ and R₅ are each independently selected from H, alkyl,hydroxyalkyl and (CH₂)_(n)—R_(12′);

or R₂ and R₃ are linked to form a cycloalkyl or heterocycloalkyl groupeach of which may be optionally further substituted with one or more R₁₀groups;

or R₄ and R₅ are linked to form a cycloalkyl or heterocycloalkyl groupeach of which may be optionally further substituted with one or more R₁₀groups;

or one of R₂ and R₃ is absent, one of R₄ and R₅ is absent, and thedashed line is a double bond;

Z₁, Z₂, Z₃ and Z₄ are all C;

R₆, R₇, R₈ and R₉ are each independently selected from H, CN, NO₂, OH,alkoxy, NHCO-alkyl, halo and haloalkyl; or

Z₁, Z₃ and Z₄ are all C, Z₂ is N, R₇ is absent and R₆, R₈ and R₉ are asdefined above; or

Z₂, Z₃ and Z₄ are all C, Z₁ is N, R₆ is absent and R₇, R₈ and R₉ are asdefined above;

n is an integer from 1 to 10;

each R_(12′) is independently selected from NH₂, NHR₁₀, NR₁₀R₁₁ andheterocycloalkyl, wherein said heterocycloalkyl is optionally furthersubstituted by one or more R₁₀ groups; each R₁₀ and R₁₁ is independentlyalkyl; and

each R₁₄ is independently selected from OH, alkoxy, haloalkyl, NH₂,NHR₁₀, NR₁₀R₁₁, heteroaryl and heterocycloalkyl, wherein saidheterocycloalkyl is optionally further substituted by one or more R₁₀groups.

A second aspect of the invention relates to a compound of formula (II),or a pharmaceutically acceptable salt or ester thereof,

wherein:

R_(b) is selected from alkyl, cycloalkyl and heterocycloalkyl, each ofwhich may be optionally substituted by one or more groups selected fromhalo and alkoxy;

R_(1a) is selected from:

-   -   CO—NR_(12a)R_(13a), wherein R_(12a) and R_(13a) are each        independently selected from H, alkyl, cycloalkyl and mono or        bicyclic heterocycloalkyl, wherein said alkyl group is        optionally substituted by one or more (CH₂)_(m)R_(14a) groups,        and said heterocycloalkyl is optionally substituted by one or        more groups selected from R₁₀ and (CH₂)_(m)R_(14a); or R_(12a)        and R_(13a) are linked, together with the nitrogen to which they        are attached, to form a heterocycloalkyl group optionally        containing one or more additional heteroatoms, and optionally        substituted by one or more groups selected from R₁₀ and        (CH₂)_(m)R_(14a);    -   hydroxyalkyl;    -   COOH; and    -   H;

Z₁, Z₂, Z₃ and Z₄ are all C;

R₆, R₇, R₈ and R₉ are each independently selected from H, CN, NO₂, OH,alkoxy, NHCO-alkyl, halo and haloalkyl; or

Z₁, Z₃ and Z₄ are all C, Z₂ is N, R₇ is absent and R₆, R₈ and R₉ are asdefined above; or

Z₂, Z₃ and Z₄ are all C, Z₁ is N, R₆ is absent and R₇, R₈ and R₉ are asdefined above;

m is an integer from 1 to 10;

each R₁₀ and R₁₁ is independently alkyl;

each R_(14a) is independently selected from CO₂R₁₀, COOH, OH, alkoxy,haloalkyl, NH₂, NHR₁₀, NR₁₀R₁₁, heteroaryl and heterocycloalkyl, whereinsaid heterocycloalkyl is optionally further substituted by one or moreR₁₀ groups.

Advantageously, the presently claimed compounds are capable ofinhibiting MNK1 and/or MNK2. Moreover, in one embodiment, the presentlyclaimed compounds advantageously exhibit improved selectivity for MNK1and/or MNK2 over other kinases compared to compounds known in the art.

A third aspect of the invention relates to a pharmaceutical compositioncomprising at least one compound as described above and apharmaceutically acceptable carrier, diluent or excipient.

A fourth aspect of the invention relates to a compound as describedabove for use in medicine.

A fifth aspect of the invention relates to a compound as described abovefor use in treating a proliferative disorder.

A sixth aspect of the invention relates to a compound as described abovefor use in treating a neurodegenerative disease such as Alzheimer'sDisease.

A seventh aspect of the invention relates to the use of a compound asdescribed above in the preparation of a medicament for treating orpreventing a proliferative disorder, or a neurodegenerative disease.

An eighth aspect of the invention relates to the use of a compound asdescribed above in the preparation of a medicament for the prevention ortreatment of a disorder caused by, associated with or accompanied by anyabnormal kinase activity, wherein the kinase is preferably MNK.

A ninth aspect of the invention relates to a method of treating a mammalhaving a disease state alleviated by inhibition of a kinase (preferablyMNK), wherein the method comprises administering to a mammal atherapeutically effective amount of a compound as described above.

A tenth aspect of the invention relates to the use of a compound asdescribed above in an assay for identifying further candidate compoundscapable of inhibiting a kinase, preferably MNK.

DETAILED DESCRIPTION

The present invention relates to fused thiazolopyrimidine compounds thatare capable of inhibiting one or more kinases, more particularly MNK.

“Alkyl” is defined herein as a straight-chain or branched alkyl radical,preferably C₁₋₂₀ alkyl, more preferably C₁₋₁₂ alkyl, even morepreferably C₁₋₁₀ alkyl or C₁₋₆ alkyl, for example, methyl, ethyl,propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl.

“Cycloalkyl” is defined herein as a monocyclic alkyl ring, preferably,C₃₋₇-cycloalkyl, more preferably C₃₋₆-cycloalkyl. Preferred examplesinclude cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl,or a fused bicyclic ring system such as norbornane.

“Halogen” is defined herein as chloro, fluoro, bromo or iodo.

As used herein, the term “aryl” refers to a C₆₋₁₂ aromatic group, whichmay be benzocondensed, for example, phenyl or naphthyl.

“Heteroaryl” is defined herein as a monocyclic or bicyclic C₂₋₁₂aromatic ring comprising one or more heteroatoms (that may be the sameor different), such as oxygen, nitrogen or sulphur. Examples of suitableheteroaryl groups include thienyl, furanyl, pyrrolyl, pyridinyl,oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl,oxadiazolyl, triazolyl, thiadiazolyl etc. and benzo derivatives thereof,such as benzofuranyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl,indazolyl etc.; or pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl,triazinyl etc. and benzo derivatives thereof, such as quinolinyl,isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,naphthyridinyl etc.

“Heterocycloalkyl” refers to a monocyclic or bicyclic aliphatic groupcontaining one or more heteroatoms selected from nitrogen, oxygen andsulphur, which is optionally interrupted by one or more —(CO)— groups inthe ring and/or which optionally contains one or more double bonds inthe ring. Where the heteroatom is sulphur, it can be in oxidised orreduced form, i.e. S, SO or SO₂. Preferably, the heterocycloalkyl groupis a C₃₋₇-heterocycloalkyl, more preferably a C₃₋₆-heterocycloalkyl.Alternatively, the heterocycloalkyl group is a C₄₋₇-heterocycloalkyl,more preferably a C₄₋₆-heterocycloalkyl. Preferred heterocycloalkylgroups include, but are not limited to, piperazinyl, piperidinyl,morpholinyl, thiomorpholinyl, pyrrolidinyl, tetrahydrofuranyl andtetrahydropyranyl.

Compounds of Formula (I)

One aspect of the invention relates to compounds of formula (I) asdescribed above.

In one aspect, the invention relates to a compound of formula (I), or apharmaceutically acceptable salt or ester thereof,

wherein:

R₁ is selected from:

-   -   CO—NR₁₂R₁₃, wherein R₁₂ and R₁₃ are each independently selected        from H, alkyl, cycloalkyl and heterocycloalkyl, wherein said        alkyl group is optionally substituted by one or more R₁₄ groups,        and said heterocycloalkyl is optionally substituted by one or        more R₁₀ groups; or R₁₂ and R₁₃ are linked, together with the        nitrogen to which they are attached, to form a heterocycloalkyl        group optionally containing one or more additional heteroatoms,        and optionally substituted by one or more R₁₀ groups;    -   hydroxyalkyl;    -   H;    -   NH₂;    -   NH-alkyl, wherein said alkyl group is optionally substituted        with one or more R₁₄ groups;    -   NH—CO-heterocycloalkyl;    -   heterocycloalkyl optionally substituted by one or more R₁₀        groups; and    -   alkoxy optionally substituted with one or more R₁₄ groups;

R₂, R₃, R₄ and R₅ are each independently selected from H, alkyl,hydroxyalkyl and (CH₂)_(n)—R₁₂;

or R₂ and R₃ are linked to form a cycloalkyl or heterocycloalkyl groupeach of which may be optionally further substituted with one or more R₁₀groups;

or R₄ and R₅ are linked to form a cycloalkyl or heterocycloalkyl groupeach of which may be optionally further substituted with one or more R₁₀groups;

or one of R₂ and R₃ is absent, one of R₄ and R₅ is absent, and thedashed line is a double bond;

Z₁, Z₂, Z₃ and Z₄ are all C;

R₆, R₇, R₈ and R₉ are each independently selected from H, CN, NO₂, OH,alkoxy, NHCO-alkyl, halo and haloalkyl; or

Z₁, Z₃ and Z₄ are all C, Z₂ is N, R₇ is absent and R₆, R₈ and R₉ are asdefined above; or

Z₂, Z₃ and Z₄ are all C, Z₁ is N, R₆ is absent and R₇, R₈ and R₉ are asdefined above;

n is an integer from 1 to 10;

each R₁₂ is independently selected from NH₂, NHR₁₀, NR₁₀R₁₁ andheterocycloalkyl, wherein said heterocycloalkyl is optionally furthersubstituted by one or more R₁₀ groups; each R₁₀ and R₁₁ is independentlyalkyl; and

each R₁₄ is independently selected from OH, alkoxy, haloalkyl, NH₂,NHR₁₀, NR₁₀R₁₁, heteroaryl and heterocycloalkyl, wherein saidheterocycloalkyl is optionally further substituted by one or more R₁₀groups.

Preferably, R₁, R₂, R₃ and R₄ are all present, i.e. there is a singlebond between the carbon bearing R₁/R₂ and the carbon bearing R₃/R₄.

In one preferred embodiment, Z₁, Z₂, Z₃ and Z₄ are all C.

In one preferred embodiment, R₂, R₃, R₄ and R₅ are each independentlyselected from H, alkyl, and (CH₂)_(n)—R₁₂.

In one preferred embodiment;

R₂, R₃, R₄ and R₅ are all H; or

R₂ and R₃ are both H, and R₄ and R₅ are both Me; or

R₂ and R₃ are both H, and R₄ and R₄ are linked to form a cycloalkyl orheterocycloalkyl group.

In one preferred embodiment, R₆, R₇, R₈ and R₉ are each independentlyselected from H and halo.

In one preferred embodiment:

Z₁, Z₂, Z₃ and Z₄ are all C;

R₆, R₇, R₈ and R₉ are all H; or

R₆, R₈ and R₉ are all H and R₇ is selected from fluoro, chloro, bromo,methyl and CF₃; and

R₂, R₃, R₄ and R₅ are each independently selected from H, alkyl, and(CH₂)_(n)—R₁₂.

In one preferred embodiment:

R₂, R₃, R₄ and R₅ are each independently selected from H, hydroxyalkyl,alkyl, and (CH₂)_(n)—R₁₂, where n is 1 or 2 and R₁₂ is selected fromNH₂, OH, NMe, NMe₂, pyrrolidin-1-yl, piperidin-1-yl and4-methylpiperazin-1-yl.

In one preferred embodiment, R₁ is CO—NR₁₂R₁₃.

In one preferred embodiment, R₁ is CO—NR₁₂R₁₃ wherein:

one of R₁₂ and R₁₃ is H and the other is selected from:

-   -   tetrahydropyran-4-yl;    -   piperidin-4-yl;    -   cyclopropyl;    -   tetrahydrofuran-4-yl;    -   N-methylpiperidin-4-yl;    -   alkyl optionally substituted by one or more groups selected from        NHMe, NH₂, NMe₂, piperidin-4-yl, N-methylpiperidin-4-yl,        tetrahydrofuranyl, OH, CF₃, OMe and pyrrolidin-1-yl; or

R₁₂ and R₁₃ are linked, together with the nitrogen to which they areattached, to form a piperazinyl or morpholinyl group optionallysubstituted by one or more R₁₀ groups.

Compounds of Formula (II)

One aspect of the invention relates to compounds of formula (II) asdescribed above.

In one preferred embodiment:

Z₁, Z₂, Z₃ and Z₄ are all C;

R₆, R₇, R₈ and R₉ are all H; or

R₆, R₈ and R₉ are all H and R₇ is halo.

In one preferred embodiment, Z₁, Z₂, Z₃ and Z₄ are all C, R₆, R₈ and R₉are all H, and R₇ is fluoro.

In one preferred embodiment, R_(b) is alkyl, more preferably, isopropyl.

In another embodiment, R_(b) can be linked to the nitrogen of the NHlinker group (the hydrogen of the NH group being absent) to form aheterocycloalkyl group, preferably a 5- or 6-membered heterocycloalkylgroup, more preferably, a 6-membered heterocycloalkyl group.

In another embodiment, R_(b) can be linked to R₆ (where Z₁ is carbon) toform a heterocycloalkyl group, preferably a 5- or 6-memberedheterocycloalkyl group.

In one preferred embodiment, R_(1a) is CO—NR_(12a)R_(13a) wherein:

one of R_(12a) and R_(13a) is H and the other is selected from:

-   -   alkyl optionally substituted by one or more groups selected from        NR₁₀R₁₁, COOH, OH and heterocycloalkyl; and    -   mono or bicyclic heterocycloalkyl optionally substituted by one        or more groups selected from R₁₀ and CO₂R₁₀; or

R_(12a) and R_(13a) are linked, together with the nitrogen to which theyare attached, to form a piperidinyl group optionally substituted by oneor more groups selected from R₁₀ and (CH₂)_(m)R_(14a).

In one preferred embodiment, R_(1a) is alkyl optionally substituted byone or more groups selected from NR₁₀R₁₁ and a heterocycloalkyl groupselected from piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl,tetrahydropyranyl, wherein said heterocycloalkyl group is optionallysubstituted by one or more R₁₀ groups.

In one preferred embodiment, R_(1a) is a heterocycloalkyl group selectedfrom, piperidinyl, quinuclidinyl, azetidinyl, morpholinyl, piperazinyl,pyrrolidinyl and tetrahydropyranyl, each of which is optionallysubstituted by one or more R₁₀ groups.

In one embodiment, the compound of the invention is selected from thefollowing:

and pharmaceutically acceptable salts thereof.

Therapeutic Applications

A further aspect of the invention relates to a compound as describedabove for use in medicine.

Another aspect of the invention relates to a compound as described abovefor use in treating a proliferative disorder.

In one preferred aspect, the compound of the invention is for use in thetreatment of a disease of uncontrolled cell growth, proliferation and/orsurvival, an inappropriate cellular immune response, or an inappropriatecellular inflammatory response, particularly in which the uncontrolledcell growth, proliferation and/or survival, inappropriate cellularimmune response, or inappropriate cellular inflammatory response ismediated by the MKNK-1 pathway.

In one preferred embodiment, the disease of uncontrolled cell growth,proliferation and/or survival, inappropriate cellular immune response,or inappropriate cellular inflammatory response is a haematologicaltumour, a solid tumour and/or metastases thereof.

More preferably, the compound is for use in treating a disorder selectedfrom leukaemias and myelodysplastic syndrome, malignant lymphomas, headand neck tumours including brain tumours and brain metastases, tumoursof the thorax including non-small cell and small cell lung tumours,gastrointestinal tumours, endocrine tumours, mammary and othergynaecological tumours, urological tumours including renal, bladder andprostate tumours, skin tumours, and sarcomas, and/or metastases thereof.

As MNKs are the only kinases known to phosphorylate eIF4E, inhibition ofeIF4E phosphorylation through inhibition of MNKs is expected tonegatively affect these pathways and hence interfere with progression ofcancer and metastases. Surprisingly, MNK1/2 double KO mice show no overtphenotype, which is unexpected given the central role of eIF4E. Still,MNK phosphorylation of eIF4E on Serin 209 is believed to be importantfor eIF4E's oncogenic activity as overexpression of constitutivelyactive MNK1 but not kinase-inactive MNK1 was shown to accelerate tumourformation in mouse embryonic fibroblasts (Chrestensen et al. Genes Cells2007, 1133-1140). Constitutively active MNK1 but not kinase dead wasalso shown to promote tumour growth in an Eμ-Myc transgenic model inhematopoietic stem cells. Vice versa, deficiency of MNKs (double KO) wasfound to delay the development of tumours in a lymphoma model induced bythe loss of PTEN (Ueda et al. Proc Natl Acad Sci USA 2010, 13984-13990).This is in line with results obtained using mutated forms of eIF4E.eIF4E S209D mimics the phosphorylated version eIF4E and eIF4E S209Acannot be phosphorylated. Mice reconstituted with cells expressing theS209A mutant were defective at promoting tumorigenesis. By contrast,mice reconstituted with cells expressing the phosphomimetic S209D mutantdisplayed accelerated tumor onset (Wendel et al. Genes Dev 2007,3232-3237).

Pharmacological inhibition of MNK using anti-fungal agent cercosporamidewas shown to effectively block eIF4E phosphorylation within 30 minutesafter oral administration in normal mouse tissues and xenograftedtumors, reducing tumor growth in HCT116 xenograft models, andsuppressing the outgrowth of B16 melanoma lung metastases. Collectively,these data substantiate the notion that blocking Mnk function, and eIF4Ephosphorylation, may be an attractive anticancer strategy (Konicek etal. Cancer Res 2011, 1849-1857). This notion has been further supportedby the use of more specific MNK inhibitory compounds in cellular modelsof leukemia, where MNK inhibitors were shown to have ananti-proliferative effect (Teo et al. Mol Pharmacol 2015, 380-389, Teoet al. Cancer Lett 2015, 612-623).

In addition to cancer MNKs are promising targets for anti-inflammatorytherapy. MNKs were shown to be involved in regulating TNF-production ona post transcriptional level. TNF expression is controlled via AU-richelements in the 3′UTR of its mRNA. MNK inhibition or knockdown of MNK1was shown to inhibit TNF production in Jurkat cells, whereasoverexpression of the 3′UTR of TNF enhanced the expression of a reporterconstruct (Buxade et al. Immunity 2005, 177-189). In the macrophage cellline RAW264.7 stimulation with different TLR agonists, LPS or CpG DNA inpresence of MNK inhibitor reduced TNF production, correlating with anincrease in TNF mRNA decay (Rowlett et al. Am J Physiol GastrointestLiver Physiol 2008, G452-459). In BMDMs isolated from a spontaneousmouse model of Crohn's disease-like ileitis, treatment with MNKinhibitor inhibited production of TNF and IL-6. A study in the monocyticcell line THP-1 showed that the release of IL-1β and IL-8 induced byShiga toxin could be blocked by MNK inhibitor CGP57380 by 73-96% (Cherlaet al. J Leukoc Biol 2006, 397-407). In neutrophils, it was shown thatMNK plays a role in the activation of neutrophils in response to LPS andTNF stimulation. MNK inhibition not only affected cytokine production byneutrophils but also inhibited the anti-apoptotic effect of TNF and LPSon neutrophils.

Another study shows reduced TNF-production in keratinocytes in thepresence of MNK inhibitor CGP57380 along with decreased expression ofIL-1β and IL-6, thereby implicating MNK in regulation ofpro-inflammatory cytokine expression in inflammatory skin diseases(Kjellerup et al. Exp Dermatol 2008, 498-504). Interleukin 17 ispro-inflammatory cytokine that acts synergistically with TNF and IL-1β.In murine CD4 T cells which were activated under Th17 conditions in thepresence of MNK inhibitor, blockage of eIF-4E phosphorylation wasdetected, resulting in reduced IL-17 production without affecting IL-17mRNA (Noubade et al. Blood 2011, 3290-3300). RANTES, which is achemokine involved in the terminal differentiation of T cells was foundto be indirectly regulated by MNK via its major transcriptionalregulator RFLAT1. Inhibition of MNK was shown to reduce RFLAT1production (Nikolcheva et al. J Clin Invest 2002, 119-126).

Another aspect of the invention relates to a compound as described abovefor use in treating a neurodegenerative disorder, more preferably atauopathy.

Tauopathies are a class of neurodegenerative diseases associated withthe pathological aggregation of tau protein-in the human brain. Thebest-known of these illnesses is Alzheimer's disease (AD), wherein tauprotein is deposited within neurons in the form of neurofibrillarytangles (NFTs). Tangles are formed by hyperphosphorylation of amicrotubule-associated protein known as tau, causing it to aggregate inan insoluble form. These aggregations of hyperphosphorylated tau proteinare also referred to as PHF, or “paired helical filaments”.

In one preferred embodiment of the invention, the tauopathy isAlzheimer's disease.

Another aspect relates to the use of a compound as described above inthe preparation of a medicament for treating or preventing aneurodegenerative disorder. Preferably, the neurodegenerative disorderis Alzheimer's Disease.

Another aspect relates to the use of a compound as described above inthe preparation of a medicament for treating or preventing aproliferative disorder, preferably cancer or leukemia.

Preferably, the compound is administered in an amount sufficient toinhibit one or more kinases, preferably MNK1 and/or MNK2.

In one preferred embodiment, the compound is administered in an amountto inhibit MNK1.

In one preferred embodiment, the compound is administered in an amountto inhibit MNK2.

Yet another aspect relates to the use of a compound of the invention inthe preparation of a medicament for the prevention or treatment of adisorder caused by, associated with or accompanied by any abnormalactivity against a biological target, wherein the target is a kinase,more preferably MNK.

Another aspect of the invention relates to a method of treating aprotein kinase related disease or disorder. The method according to thisaspect of the present invention is effected by administering to asubject in need thereof a therapeutically effective amount of a compoundof the present invention, as described hereinabove, either per se, or,more preferably, as a part of a pharmaceutical composition, mixed with,for example, a pharmaceutically acceptable carrier, as is detailedhereinafter.

Yet another aspect of the invention relates to a method of treating amammal having a disease state alleviated by inhibition of a proteinkinase, wherein the method comprises administering to a mammal atherapeutically effective amount of a compound according to theinvention.

Preferably, the disease state is alleviated by the inhibition of theprotein kinase MNK.

Preferably, the mammal is a human.

The term “method” refers to manners, means, techniques and proceduresfor accomplishing a given task including, but not limited to, thosemanners, means, techniques and procedures either known to, or readilydeveloped from known manners, means, techniques and procedures bypractitioners of the chemical, pharmacological, biological, biochemicaland medical arts.

The term “administering” as used herein refers to a method for bringinga compound of the present invention and a protein kinase together insuch a manner that the compound can affect the enzyme activity of theprotein kinase either directly; i.e., by interacting with the proteinkinase itself or indirectly; i.e., by interacting with another moleculeon which the catalytic activity of the protein kinase is dependent. Asused herein, administration can be accomplished either in vitro, i.e. ina test tube, or in vivo, i.e., in cells or tissues of a living organism.

Herein, the term “treating” includes abrogating, substantiallyinhibiting, slowing or reversing the progression of a disease ordisorder, substantially ameliorating clinical symptoms of a disease ordisorder or substantially preventing the appearance of clinical symptomsof a disease or disorder.

Herein, the term “preventing” refers to a method for barring an organismfrom acquiring a disorder or disease in the first place.

The term “therapeutically effective amount” refers to that amount of thecompound being administered which will relieve to some extent one ormore of the symptoms of the disease or disorder being treated.

For any compound used in this invention, a therapeutically effectiveamount, also referred to herein as a therapeutically effective dose, canbe estimated initially from cell culture assays. For example, a dose canbe formulated in animal models to achieve a circulating concentrationrange that includes the IC₅₀ or the IC₁₀₀ as determined in cell culture.Such information can be used to more accurately determine useful dosesin humans. Initial dosages can also be estimated from in vivo data.Using these initial guidelines one of ordinary skill in the art coulddetermine an effective dosage in humans.

Moreover, toxicity and therapeutic efficacy of the compounds describedherein can be determined by standard pharmaceutical procedures in cellcultures or experimental animals, e.g., by determining the LD₅₀ and theED₅₀. The dose ratio between toxic and therapeutic effect is thetherapeutic index and can be expressed as the ratio between LD₅₀ andED₅₀. Compounds which exhibit high therapeutic indices are preferred.The data obtained from these cell cultures assays and animal studies canbe used in formulating a dosage range that is not toxic for use inhuman. The dosage of such compounds lies preferably within a range ofcirculating concentrations that include the ED₅₀ with little or notoxicity. The dosage may vary within this range depending upon thedosage form employed and the route of administration utilized. The exactformulation, route of administration and dosage can be chosen by theindividual physician in view of the patient's condition. (see, e.g.,Fingl et al, 1975, The Pharmacological Basis of Therapeutics, chapter 1,page 1).

Dosage amount and interval may be adjusted individually to provideplasma levels of the active compound which are sufficient to maintaintherapeutic effect. Usual patient dosages for oral administration rangefrom about 50-2000 mg/kg/day, commonly from about 100-1000 mg/kg/day,preferably from about 150-700 mg/kg/day and most preferably from about250-500 mg/kg/day. Preferably, therapeutically effective serum levelswill be achieved by administering multiple doses each day. In cases oflocal administration or selective uptake, the effective localconcentration of the drug may not be related to plasma concentration.One skilled in the art will be able to optimize therapeuticallyeffective local dosages without undue experimentation.

As used herein, “kinase related disease or disorder” refers to a diseaseor disorder characterized by inappropriate kinase activity orover-activity of a kinase as defined herein. Inappropriate activityrefers to either; (i) kinase expression in cells which normally do notexpress said kinase; (ii) increased kinase expression leading tounwanted cell proliferation, differentiation and/or growth; or, (iii)decreased kinase expression leading to unwanted reductions in cellproliferation, differentiation and/or growth. Over-activity of kinaserefers to either amplification of the gene encoding a particular kinaseor production of a level of kinase activity, which can correlate with acell proliferation, differentiation and/or growth disorder (that is, asthe level of the kinase increases, the severity of one or more of thesymptoms of the cellular disorder increases). Over activity can also bethe result of ligand independent or constitutive activation as a resultof mutations such as deletions of a fragment of a kinase responsible forligand binding.

Preferred diseases or disorders that the compounds described herein maybe useful in preventing, include neurodegenerative disorders such asAlzheimer's Disease, and proliferative disorders, such as cancer.

Thus, the present invention further provides use of compounds as definedherein for the manufacture of medicaments for the treatment of diseaseswhere it is desirable to inhibit MNK. Such diseases includeproliferative disorders and neurodegenerative disorders such asAlzheimer's Disease, as described above.

Pharmaceutical Compositions

For use according to the present invention, the compounds orphysiologically acceptable salt, ester or other physiologicallyfunctional derivative thereof, described herein, may be presented as apharmaceutical formulation, comprising the compounds or physiologicallyacceptable salt, ester or other physiologically functional derivativethereof, together with one or more pharmaceutically acceptable carrierstherefore and optionally other therapeutic and/or prophylacticingredients. The carrier(s) must be acceptable in the sense of beingcompatible with the other ingredients of the formulation and notdeleterious to the recipient thereof. The pharmaceutical compositionsmay be for human or animal usage in human and veterinary medicine.

Examples of such suitable excipients for the various different forms ofpharmaceutical compositions described herein may be found in the“Handbook of Pharmaceutical Excipients, 2^(nd) Edition, (1994), Editedby A Wade and P J Weller.

Acceptable carriers or diluents for therapeutic use are well known inthe pharmaceutical art, and are described, for example, in Remington'sPharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).

Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol and the like. Examplesof suitable diluents include ethanol, glycerol and water.

The choice of pharmaceutical carrier, excipient or diluent can beselected with regard to the intended route of administration andstandard pharmaceutical practice. The pharmaceutical compositions maycomprise as, or in addition to, the carrier, excipient or diluent anysuitable binder(s), lubricant(s), suspending agent(s), coating agent(s),solubilising agent(s), buffer(s), flavouring agent(s), surface activeagent(s), thickener(s), preservative(s) (including anti-oxidants) andthe like, and substances included for the purpose of rendering theformulation isotonic with the blood of the intended recipient.

Examples of suitable binders include starch, gelatin, natural sugarssuch as glucose, anhydrous lactose, free-flow lactose, beta-lactose,corn sweeteners, natural and synthetic gums, such as acacia, tragacanthor sodium alginate, carboxymethyl cellulose and polyethylene glycol.

Examples of suitable lubricants include sodium oleate, sodium stearate,magnesium stearate, sodium benzoate, sodium acetate, sodium chloride andthe like.

Preservatives, stabilizers, dyes and even flavoring agents may beprovided in the pharmaceutical composition. Examples of preservativesinclude sodium benzoate, sorbic acid and esters of p-hydroxybenzoicacid. Antioxidants and suspending agents may be also used.

Pharmaceutical formulations include those suitable for oral, topical(including dermal, buccal and sublingual), rectal or parenteral(including subcutaneous, intradermal, intramuscular and intravenous),nasal and pulmonary administration e.g., by inhalation. The formulationmay, where appropriate, be conveniently presented in discrete dosageunits and may be prepared by any of the methods well known in the art ofpharmacy. All methods include the step of bringing into association anactive compound with liquid carriers or finely divided solid carriers orboth and then, if necessary, shaping the product into the desiredformulation.

Pharmaceutical formulations suitable for oral administration wherein thecarrier is a solid are most preferably presented as unit doseformulations such as boluses, capsules or tablets each containing apredetermined amount of active compound. A tablet may be made bycompression or moulding, optionally with one or more accessoryingredients. Compressed tablets may be prepared by compressing in asuitable machine an active compound in a free-flowing form such as apowder or granules optionally mixed with a binder, lubricant, inertdiluent, lubricating agent, surface-active agent or dispersing agent.Moulded tablets may be made by moulding an active compound with an inertliquid diluent. Tablets may be optionally coated and, if uncoated, mayoptionally be scored. Capsules may be prepared by filling an activecompound, either alone or in admixture with one or more accessoryingredients, into the capsule shells and then sealing them in the usualmanner. Cachets are analogous to capsules wherein an active compoundtogether with any accessory ingredient(s) is sealed in a rice paperenvelope. An active compound may also be formulated as dispersiblegranules, which may for example be suspended in water beforeadministration, or sprinkled on food. The granules may be packaged,e.g., in a sachet. Formulations suitable for oral administration whereinthe carrier is a liquid may be presented as a solution or a suspensionin an aqueous or non-aqueous liquid, or as an oil-in-water liquidemulsion.

Formulations for oral administration include controlled release dosageforms, e.g., tablets wherein an active compound is formulated in anappropriate release—controlling matrix, or is coated with a suitablerelease—controlling film. Such formulations may be particularlyconvenient for prophylactic use.

Pharmaceutical formulations suitable for rectal administration whereinthe carrier is a solid are most preferably presented as unit dosesuppositories. Suitable carriers include cocoa butter and othermaterials commonly used in the art. The suppositories may beconveniently formed by admixture of an active compound with the softenedor melted carrier(s) followed by chilling and shaping in moulds.Pharmaceutical formulations suitable for parenteral administrationinclude sterile solutions or suspensions of an active compound inaqueous or oleaginous vehicles.

Injectable preparations may be adapted for bolus injection or continuousinfusion. Such preparations are conveniently presented in unit dose ormulti-dose containers which are sealed after introduction of theformulation until required for use. Alternatively, an active compoundmay be in powder form which is constituted with a suitable vehicle, suchas sterile, pyrogen-free water, before use.

An active compound may also be formulated as long-acting depotpreparations, which may be administered by intramuscular injection or byimplantation, e.g., subcutaneously or intramuscularly. Depotpreparations may include, for example, suitable polymeric or hydrophobicmaterials, or ion-exchange resins. Such long-acting formulations areparticularly convenient for prophylactic use.

Formulations suitable for pulmonary administration via the buccal cavityare presented such that particles containing an active compound anddesirably having a diameter in the range of 0.5 to 7 microns aredelivered in the bronchial tree of the recipient.

As one possibility such formulations are in the form of finelycomminuted powders which may conveniently be presented either in apierceable capsule, suitably of, for example, gelatin, for use in aninhalation device, or alternatively as a self-propelling formulationcomprising an active compound, a suitable liquid or gaseous propellantand optionally other ingredients such as a surfactant and/or a soliddiluent. Suitable liquid propellants include propane and thechlorofluorocarbons, and suitable gaseous propellants include carbondioxide. Self-propelling formulations may also be employed wherein anactive compound is dispensed in the form of droplets of solution orsuspension.

Such self-propelling formulations are analogous to those known in theart and may be prepared by established procedures. Suitably they arepresented in a container provided with either a manually-operable orautomatically functioning valve having the desired spraycharacteristics; advantageously the valve is of a metered typedelivering a fixed volume, for example, 25 to 100 microlitres, upon eachoperation thereof.

As a further possibility an active compound may be in the form of asolution or suspension for use in an atomizer or nebuliser whereby anaccelerated airstream or ultrasonic agitation is employed to produce afine droplet mist for inhalation.

Formulations suitable for nasal administration include preparationsgenerally similar to those described above for pulmonary administration.When dispensed such formulations should desirably have a particlediameter in the range 10 to 200 microns to enable retention in the nasalcavity; this may be achieved by, as appropriate, use of a powder of asuitable particle size or choice of an appropriate valve. Other suitableformulations include coarse powders having a particle diameter in therange 20 to 500 microns, for administration by rapid inhalation throughthe nasal passage from a container held close up to the nose, and nasaldrops comprising 0.2 to 5% w/v of an active compound in aqueous or oilysolution or suspension.

Pharmaceutically acceptable carriers are well known to those skilled inthe art and include, but are not limited to, 0.1 M and preferably 0.05 Mphosphate buffer or 0.8% saline. Additionally, such pharmaceuticallyacceptable carriers may be aqueous or non-aqueous solutions,suspensions, and emulsions. Examples of non-aqueous solvents arepropylene glycol, polyethylene glycol, vegetable oils such as olive oil,and injectable organic esters such as ethyl oleate. Aqueous carriersinclude water, alcoholic/aqueous solutions, emulsions or suspensions,including saline and buffered media. Parenteral vehicles include sodiumchloride solution, Ringer's dextrose, dextrose and sodium chloride,lactated Ringer's or fixed oils. Preservatives and other additives mayalso be present, such as, for example, antimicrobials, antioxidants,chelating agents, inert gases and the like.

Formulations suitable for topical formulation may be provided forexample as gels, creams or ointments. Such preparations may be appliede.g. to a wound or ulcer either directly spread upon the surface of thewound or ulcer or carried on a suitable support such as a bandage,gauze, mesh or the like which may be applied to and over the area to betreated.

Liquid or powder formulations may also be provided which can be sprayedor sprinkled directly onto the site to be treated, e.g. a wound orulcer. Alternatively, a carrier such as a bandage, gauze, mesh or thelike can be sprayed or sprinkle with the formulation and then applied tothe site to be treated.

According to a further aspect of the invention, there is provided aprocess for the preparation of a pharmaceutical or veterinarycomposition as described above, the process comprising bringing theactive compound(s) into association with the carrier, for example byadmixture.

In general, the formulations are prepared by uniformly and intimatelybringing into association the active agent with liquid carriers orfinely divided solid carriers or both, and then if necessary shaping theproduct. The invention extends to methods for preparing a pharmaceuticalcomposition comprising bringing a compound of general formula (I) or(II) in conjunction or association with a pharmaceutically orveterinarily acceptable carrier or vehicle.

Salts/Esters

The compounds of the invention can be present as salts or esters, inparticular pharmaceutically and veterinarily acceptable salts or esters.

Pharmaceutically acceptable salts of the compounds of the inventioninclude suitable acid addition or base salts thereof. A review ofsuitable pharmaceutical salts may be found in Berge et al, J Pharm Sci,66, 1-19 (1977). Salts are formed, for example with strong inorganicacids such as mineral acids, e.g. hydrohalic acids such ashydrochloride, hydrobromide and hydroiodide, sulphuric acid, phosphoricacid sulphate, bisulphate, hemisulphate, thiocyanate, persulphate andsulphonic acids; with strong organic carboxylic acids, such asalkanecarboxylic acids of 1 to 4 carbon atoms which are unsubstituted orsubstituted (e.g., by halogen), such as acetic acid; with saturated orunsaturated dicarboxylic acids, for example oxalic, malonic, succinic,maleic, fumaric, phthalic or tetraphthalic; with hydroxycarboxylicacids, for example ascorbic, glycolic, lactic, malic, tartaric or citricacid; with aminoacids, for example aspartic or glutamic acid; withbenzoic acid; or with organic sulfonic acids, such as (C₁-C₄)-alkyl- oraryl-sulfonic acids which are unsubstituted or substituted (for example,by a halogen) such as methane- or p-toluene sulfonic acid. Salts whichare not pharmaceutically or veterinarily acceptable may still bevaluable as intermediates.

Preferred salts include, for example, acetate, trifluoroacetate,lactate, gluconate, citrate, tartrate, maleate, malate, pantothenate,adipate, alginate, aspartate, benzoate, butyrate, digluconate,cyclopentanate, glucoheptanate, glycerophosphate, oxalate, heptanoate,hexanoate, fumarate, nicotinate, palmoate, pectinate,3-phenylpropionate, picrate, pivalate, proprionate, tartrate,lactobionate, pivolate, camphorate, undecanoate and succinate, organicsulphonic acids such as methanesulphonate, ethanesulphonate,2-hydroxyethane sulphonate, camphorsulphonate, 2-naphthalenesulphonate,benzenesulphonate, p-chlorobenzenesulphonate and p-toluenesulphonate;and inorganic acids such as hydrochloride, hydrobromide, hydroiodide,sulphate, bisulphate, hemisulphate, thiocyanate, persulphate, phosphoricand sulphonic acids.

Esters are formed either using organic acids or alcohols/hydroxides,depending on the functional group being esterified. Organic acidsinclude carboxylic acids, such as alkanecarboxylic acids of 1 to 12carbon atoms which are unsubstituted or substituted (e.g., by halogen),such as acetic acid; with saturated or unsaturated dicarboxylic acid,for example oxalic, malonic, succinic, maleic, fumaric, phthalic ortetraphthalic; with hydroxycarboxylic acids, for example ascorbic,glycolic, lactic, malic, tartaric or citric acid; with aminoacids, forexample aspartic or glutamic acid; with benzoic acid; or with organicsulfonic acids, such as (C₁-C₄)-alkyl- or aryl-sulfonic acids which areunsubstituted or substituted (for example, by a halogen) such asmethane- or p-toluene sulfonic acid. Suitable hydroxides includeinorganic hydroxides, such as sodium hydroxide, potassium hydroxide,calcium hydroxide, aluminium hydroxide. Alcohols include alkanealcoholsof 1-12 carbon atoms which may be unsubstituted or substituted, e.g. bya halogen).

Enantiomers/Tautomers

In all aspects of the present invention previously discussed, theinvention includes, where appropriate all enantiomers, diastereoisomersand tautomers of the compounds of the invention. The person skilled inthe art will recognise compounds that possess optical properties (one ormore chiral carbon atoms) or tautomeric characteristics. Thecorresponding enantiomers and/or tautomers may be isolated/prepared bymethods known in the art.

Enantiomers are characterised by the absolute configuration of theirchiral centres and described by the R- and S-sequencing rules of Cahn,Ingold and Prelog. Such conventions are well known in the art (e.g. see‘Advanced Organic Chemistry’, 3^(rd) edition, ed. March, J., John Wileyand Sons, New York, 1985).

Compounds of the invention containing a chiral centre may be used as aracemic mixture, an enantiomerically enriched mixture, or the racemicmixture may be separated using well-known techniques and an individualenantiomer may be used alone.

Stereo and Geometric Isomers

Some of the compounds of the invention may exist as stereoisomers and/orgeometric isomers—e.g. they may possess one or more asymmetric and/orgeometric centres and so may exist in two or more stereoisomeric and/orgeometric forms. The present invention contemplates the use of all theindividual stereoisomers and geometric isomers of those compounds, andmixtures thereof. The terms used in the claims encompass these forms,provided said forms retain the appropriate functional activity (thoughnot necessarily to the same degree).

The present invention also includes all suitable isotopic variations ofthe compound or a pharmaceutically acceptable salt thereof. An isotopicvariation of a compound of the present invention or a pharmaceuticallyacceptable salt thereof is defined as one in which at least one atom isreplaced by an atom having the same atomic number but an atomic massdifferent from the atomic mass usually found in nature. Examples ofisotopes that can be incorporated into the agent and pharmaceuticallyacceptable salts thereof include isotopes of hydrogen, carbon, nitrogen,oxygen, phosphorus, sulphur, fluorine and chlorine such as ²H, ³H, ¹³C,¹⁴C, ¹⁵N, ¹⁷O, ¹⁸O, ³¹P, ³²P, ³⁵S, ¹⁸F and ³⁶Cl, respectively. Certainisotopic variations of the agent and pharmaceutically acceptable saltsthereof, for example, those in which a radioactive isotope such as ³H or¹⁴C is incorporated, are useful in drug and/or substrate tissuedistribution studies. Tritiated, i.e., ³H, and carbon-14, i.e., ¹⁴C,isotopes are particularly preferred for their ease of preparation anddetectability. Further, substitution with isotopes such as deuterium,i.e., ²H, may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example, increased in vivo half-life orreduced dosage requirements and hence may be preferred in somecircumstances. For example, the invention includes compounds of generalformula (I) or (II) where any hydrogen atom has been replaced by adeuterium atom. Isotopic variations of the agent of the presentinvention and pharmaceutically acceptable salts thereof of thisinvention can generally be prepared by conventional procedures usingappropriate isotopic variations of suitable reagents.

Prodrugs

The invention further includes the compounds of the present invention inprodrug form, i.e. covalently bonded compounds which release the activeparent drug according to general formula (I)/(II) in vivo. Such prodrugsare generally compounds of the invention wherein one or more appropriategroups have been modified such that the modification may be reversedupon administration to a human or mammalian subject. Reversion isusually performed by an enzyme naturally present in such subject, thoughit is possible for a second agent to be administered together with sucha prodrug in order to perform the reversion in vivo. Examples of suchmodifications include ester (for example, any of those described above),wherein the reversion may be carried out be an esterase etc. Other suchsystems will be well known to those skilled in the art.

Solvates

The present invention also includes solvate forms of the compounds ofthe present invention. The terms used in the claims encompass theseforms.

Polymorphs

The invention further relates to the compounds of the present inventionin their various crystalline forms, polymorphic forms and (an)hydrousforms. It is well established within the pharmaceutical industry thatchemical compounds may be isolated in any of such forms by slightlyvarying the method of purification and or isolation form the solventsused in the synthetic preparation of such compounds.

Administration

The pharmaceutical compositions of the present invention may be adaptedfor rectal, nasal, intrabronchial, topical (including buccal andsublingual), vaginal or parenteral (including subcutaneous,intramuscular, intravenous, intraarterial and intradermal),intraperitoneal or intrathecal administration. Preferably theformulation is an orally administered formulation. The formulations mayconveniently be presented in unit dosage form, i.e., in the form ofdiscrete portions containing a unit dose, or a multiple or sub-unit of aunit dose. By way of example, the formulations may be in the form oftablets and sustained release capsules, and may be prepared by anymethod well known in the art of pharmacy.

Formulations for oral administration in the present invention may bepresented as: discrete units such as capsules, gellules, drops, cachets,pills or tablets each containing a predetermined amount of the activeagent; as a powder or granules; as a solution, emulsion or a suspensionof the active agent in an aqueous liquid or a non-aqueous liquid; or asan oil-in-water liquid emulsion or a water-in-oil liquid emulsion; or asa bolus etc. Preferably, these compositions contain from 1 to 250 mg andmore preferably from 10-100 mg, of active ingredient per dose.

For compositions for oral administration (e.g. tablets and capsules),the term “acceptable carrier” includes vehicles such as commonexcipients e.g. binding agents, for example syrup, acacia, gelatin,sorbitol, tragacanth, polyvinylpyrrolidone (Povidone), methylcellulose,ethylcellulose, sodium carboxymethylcellulose,hydroxypropyl-methylcellulose, sucrose and starch; fillers and carriers,for example corn starch, gelatin, lactose, sucrose, microcrystallinecellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride andalginic acid; and lubricants such as magnesium stearate, sodium stearateand other metallic stearates, glycerol stearate stearic acid, siliconefluid, talc waxes, oils and colloidal silica. Flavouring agents such aspeppermint, oil of wintergreen, cherry flavouring and the like can alsobe used. It may be desirable to add a colouring agent to make the dosageform readily identifiable. Tablets may also be coated by methods wellknown in the art.

A tablet may be made by compression or moulding, optionally with one ormore accessory ingredients. Compressed tablets may be prepared bycompressing in a suitable machine the active agent in a free flowingform such as a powder or granules, optionally mixed with a binder,lubricant, inert diluent, preservative, surface-active or dispersingagent. Moulded tablets may be made by moulding in a suitable machine amixture of the powdered compound moistened with an inert liquid diluent.The tablets may be optionally be coated or scored and may be formulatedso as to provide slow or controlled release of the active agent.

Other formulations suitable for oral administration include lozengescomprising the active agent in a flavoured base, usually sucrose andacacia or tragacanth; pastilles comprising the active agent in an inertbase such as gelatin and glycerin, or sucrose and acacia; andmouthwashes comprising the active agent in a suitable liquid carrier.

Other forms of administration comprise solutions or emulsions which maybe injected intravenously, intraarterially, intrathecally,subcutaneously, intradermally, intraperitoneally or intramuscularly, andwhich are prepared from sterile or sterilisable solutions. Injectableforms typically contain between 10-1000 mg, preferably between 10-250mg, of active ingredient per dose.

The pharmaceutical compositions of the present invention may also be inform of suppositories, pessaries, suspensions, emulsions, lotions,ointments, creams, gels, sprays, solutions or dusting powders.

An alternative means of transdermal administration is by use of a skinpatch. For example, the active ingredient can be incorporated into acream consisting of an aqueous emulsion of polyethylene glycols orliquid paraffin. The active ingredient can also be incorporated, at aconcentration of between 1 and 10% by weight, into an ointmentconsisting of a white wax or white soft paraffin base together with suchstabilisers and preservatives as may be required.

Dosage

A person of ordinary skill in the art can easily determine anappropriate dose of one of the instant compositions to administer to asubject without undue experimentation. Typically, a physician willdetermine the actual dosage which will be most suitable for anindividual patient and it will depend on a variety of factors includingthe activity of the specific compound employed, the metabolic stabilityand length of action of that compound, the age, body weight, generalhealth, sex, diet, mode and time of administration, rate of excretion,drug combination, the severity of the particular condition, and theindividual undergoing therapy. The dosages disclosed herein areexemplary of the average case. There can of course be individualinstances where higher or lower dosage ranges are merited, and such arewithin the scope of this invention.

In accordance with this invention, an effective amount of a compound ofthe invention may be administered to inhibit the kinase implicated witha particular condition or disease. Of course, this dosage amount willfurther be modified according to the type of administration of thecompound. For example, to achieve an “effective amount” for acutetherapy, parenteral administration of a compound of general formula (I)or (II) is preferred. An intravenous infusion of the compound in 5%dextrose in water or normal saline, or a similar formulation withsuitable excipients, is most effective, although an intramuscular bolusinjection is also useful. Typically, the parenteral dose will be about0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg, in amanner to maintain the concentration of drug in the plasma at aconcentration effective to inhibit a kinase. The compounds may beadministered one to four times daily at a level to achieve a total dailydose of about 0.4 to about 400 mg/kg/day. The precise amount of aninventive compound which is therapeutically effective, and the route bywhich such compound is best administered, is readily determined by oneof ordinary skill in the art by comparing the blood level of the agentto the concentration required to have a therapeutic effect.

The compounds of this invention may also be administered orally to thepatient, in a manner such that the concentration of drug is sufficientto achieve one or more of the therapeutic indications disclosed herein.Typically, a pharmaceutical composition containing the compound isadministered at an oral dose of between about 0.1 to about 50 mg/kg in amanner consistent with the condition of the patient. Preferably the oraldose would be about 0.5 to about 20 mg/kg.

No unacceptable toxicological effects are expected when compounds of thepresent invention are administered in accordance with the presentinvention. The compounds of this invention, which may have goodbioavailability, may be tested in one of several biological assays todetermine the concentration of a compound which is required to have agiven pharmacological effect.

Combinations

In a particularly preferred embodiment, the one or more compounds of theinvention are administered in combination with one or more other activeagents, for example, existing drugs available on the market. In suchcases, the compounds of the invention may be administered consecutively,simultaneously or sequentially with the one or more other active agents.

Drugs in general are more effective when used in combination. Inparticular, combination therapy is desirable in order to avoid anoverlap of major toxicities, mechanism of action and resistancemechanism(s). Furthermore, it is also desirable to administer most drugsat their maximum tolerated doses with minimum time intervals betweensuch doses. The major advantages of combining chemotherapeutic drugs arethat it may promote additive or possible synergistic effects throughbiochemical interactions and also may decrease the emergence ofresistance.

Beneficial combinations may be suggested by studying the inhibitoryactivity of the test compounds with agents known or suspected of beingvaluable in the treatment of a particular disorder. This procedure canalso be used to determine the order of administration of the agents,i.e. before, simultaneously, or after delivery. Such scheduling may be afeature of all the active agents identified herein.

In one preferred embodiment, the additional active agent is selectedfrom an antidiabetic agent, a lipid lowering agent, a cardiovascularagent, an antihypertensive agent, a diuretic agent, a thrombocyteaggregation inhibitor, an antineoplastic agent and an anti-obesityagent.

In one preferred embodiment, the additional active agent is selectedfrom a histamine antagonist, a bradikinin antagonist, serotoninantagonist, leukotriene, an anti-astinnatic, an NSAID, an antipyretic, acorticosteroid, an antibiotic, an analgetic, a uricosuric agentchemotherapeutic agent, an anti gout agent, a bronchodilator, acyclooxygenase-2 inhibitor, a steroid, a 5-lipoxygenase inhibitor, animmunosuppressive agent, a leukotriene antagonist, a cytostatic agent,an antineoplastic agent, am Tor inhibitor, a Tyrosine kinase inhibitor,antibodies or fragments thereof against cytokines and soluble parts(fragments) of cytokine receptors.

Assay

A further aspect of the invention relates to the use of a compound asdescribed above in an assay for identifying further candidate compoundscapable of inhibiting one or more kinases, more preferably MNK.

Preferably, the assay is a competitive binding assay.

More preferably, the competitive binding assay comprises contacting acompound of the invention with a kinase, preferably MNK, and a candidatecompound and detecting any change in the interaction between thecompound according to the invention and the kinase.

Preferably, the candidate compound is generated by conventional SARmodification of a compound of the invention.

As used herein, the term “conventional SAR modification” refers tostandard methods known in the art for varying a given compound by way ofchemical derivatisation.

Thus, in one aspect, the identified compound may act as a model (forexample, a template) for the development of other compounds. Thecompounds employed in such a test may be free in solution, affixed to asolid support, borne on a cell surface, or located intracellularly. Theabolition of activity or the formation of binding complexes between thecompound and the agent being tested may be measured.

The assay of the present invention may be a screen, whereby a number ofagents are tested. In one aspect, the assay method of the presentinvention is a high through-put screen.

This invention also contemplates the use of competitive drug screeningassays in which neutralising antibodies capable of binding a compoundspecifically compete with a test compound for binding to a compound.

Another technique for screening provides for high throughput screening(HTS) of agents having suitable binding affinity to the substances andis based upon the method described in detail in WO 84/03564.

It is expected that the assay methods of the present invention will besuitable for both small and large-scale screening of test compounds aswell as in quantitative assays.

Preferably, the competitive binding assay comprises contacting acompound of the invention with a kinase in the presence of a knownsubstrate of said kinase and detecting any change in the interactionbetween said kinase and said known substrate.

A further aspect of the invention provides a method of detecting thebinding of a ligand to a kinase, said method comprising the steps of:

-   (i) contacting a ligand with a kinase in the presence of a known    substrate of said kinase;-   (ii) detecting any change in the interaction between said kinase and    said known substrate;

and wherein said ligand is a compound of the invention.

One aspect of the invention relates to a process comprising the stepsof:

(a) performing an assay method described hereinabove;

(b) identifying one or more ligands capable of binding to a ligandbinding domain; and

(c) preparing a quantity of said one or more ligands.

Another aspect of the invention provides a process comprising the stepsof:

-   (a) performing an assay method described hereinabove;-   (b) identifying one or more ligands capable of binding to a ligand    binding domain; and-   (c) preparing a pharmaceutical composition comprising said one or    more ligands.

Another aspect of the invention provides a process comprising the stepsof:

-   (a) performing an assay method described hereinabove;-   (b) identifying one or more ligands capable of binding to a ligand    binding domain;-   (c) modifying said one or more ligands capable of binding to a    ligand binding domain;-   (d) performing the assay method described hereinabove;-   (e) optionally preparing a pharmaceutical composition comprising    said one or more ligands.

The invention also relates to a ligand identified by the methoddescribed hereinabove. Yet another aspect of the invention relates to apharmaceutical composition comprising a ligand identified by the methoddescribed hereinabove.

Another aspect of the invention relates to the use of a ligandidentified by the method described hereinabove in the preparation of apharmaceutical composition for use in the treatment of one or moredisorders as described above.

The above methods may be used to screen for a ligand useful as aninhibitor of one or more kinases.

Compounds of the invention are useful both as laboratory tools and astherapeutic agents. In the laboratory certain compounds of the inventionare useful in establishing whether a known or newly discovered kinasecontributes a critical or at least significant biochemical functionduring the establishment or progression of a disease state, a processcommonly referred to as ‘target validation’.

The present invention is further described by way of the followingnon-limiting examples.

EXAMPLES

General Procedures for Synthesis of Compounds

Chromatography

Preparative high pressure liquid chromatography was carried out usingapparatus made by Agilent. The apparatus is constructed such that thechromatography is monitored by a multi-wavelength UV detector (G1365Bmanufactured by Agilent) and an MM−ES+APCI mass spectrometer (G-1956A,manufactured by Agilent) connected in series, and if the appropriatecriteria are met the sample is collected by an automated fractioncollector (G1364B manufactured by Agilent). Collection can be triggeredby any combination of UV or mass spectrometry or can be based on time.Typical conditions for the separation process are as follows:Chromatography column was an Xbridge C-18 (19×100 mm); the gradient wasrun over a 7 minute period at a flow rate of 40 ml/min (gradient atstart: 10% methanol and 90% water, gradient at finish: 100% methanol and0% water; as buffer: either 0.1% formic acid, 0.1% ammonium hydroxide or0.1% trifluoroacetic acid was added to the water). It will beappreciated by those skilled in the art that it may be necessary ordesirable to modify the conditions for each specific compound, forexample by changing the solvent composition at the start or at the end,modifying the solvents or buffers, changing the run time, changing theflow rate and/or the chromatography column. Flash chromatography refersto silica gel chromatography and carried out using an SP4 or an Isolara4 MPLC system (manufactured by Biotage); pre-packed silica gelcartridges (supplied by Biotage); or using conventional glass columnchromatography.

Analytical Methods

¹H Nuclear magnetic resonance (NMR) spectroscopy was carried out usingan ECX400 spectrometer (manufactured by JEOL) in the stated solvent ataround room temperature unless otherwise stated. In all cases, NMR datawere consistent with the proposed structures. Characteristic chemicalshifts (δ) are given in parts-per-million using conventionalabbreviations for designation of major peaks: e.g. s, singlet; d,doublet; t, triplet; q, quartet; dd, doublet of doublets; br, broad.

Analytical LCMS was typically carried out using an Agilent HPLCinstrument with C-18 Xbridge column (3.5 μm, 4.6×30 mm, gradient atstart: 10% organic phase and 90% water, gradient at finish: organic and0% water; as buffer: either 0.1% ammonium hydroxide or 0.1%trifluoroacetic acid was added to the water). The organic solvent waseither acetonitrile or methanol. A flow rate of 3 mL/min was used withUV detection at 254 and 210 nm.

Mass spectra were recorded using a MM−ES+APCI mass spectrometer(G-1956A, manufactured by Agilent). Where thin layer chromatography(TLC) has been used it refers to silica gel TLC using silica gel MK6F 60Å plates, R_(f) is the distance travelled by the compound divided by thedistance travelled by the solvent on a TLC plate.

Compound Preparation

Where the preparation of starting materials is not described, these arecommercially available, known in the literature, or readily obtainableby those skilled in the art using standard procedures. Where it isindicated that compounds were prepared analogously to earlier examplesor intermediates, it will be appreciated by the skilled person that thereaction time, number of equivalents of reagents, solvent, concentrationand temperature can be modified for each specific reaction and that itmay be necessary or desirable to employ different work-up orpurification techniques.

Where reactions are carried out using microwave irradiation, themicrowave used is an Initiator 60 supplied by Biotage. The actual powersupplied varies during the course of the reaction in order to maintain aconstant temperature.

Some hydrogenations were carried out using an H-Cube® Continuous-flowHydrogenation Reactor manufactured by ThalesNano. The catalysts aresupplied by ThalesNano as cartridges “CatCarts” The pressure, flow rate,temperature and cartridge are indicated in the experimental section. Theequipment was used in accordance with the manufacturer operatingprocedure. The person skilled in the art will appreciate that it may benecessary or desirable to run repeat cycles of the reaction mixture andin some instances, replace the cartridge between cycles to improve theyield of the reaction.

Abbreviations

A list of some common abbreviations are shown below—where otherabbreviations are used which are not listed, these will be understood bythe person skilled in the art.

-   DCM=Dichloromethane-   DMF=N,N-Dimethylformamide-   THF=Tetrahydrofuran-   MeOH=Methanol-   TFA=Trifluoroacetic acid-   Xantphos=4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene-   HATU=N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uronium-hexafluorophospate-   EDCI=1,3-Propanediamine, N3-(ethylcarbonimidoyl)-N1,N1-dimethyl-,    hydrochloride-   DCC=1,3-Dicyclohexylcarbodiimide-   Pd₂(dba)₃₌tris(dibenzylideneacetone)dipalladium(0)-   TEA=Triethylamine-   rm=Reaction mixture-   rt=Room temperature-   AcOH=Acetic acid-   IPA=Isopropanol-   DIPEA=N,N-diisopropylethylamine-   TBSMSCI=Tertiarybutyldimethylsilyl chloride-   MeCN=Acetonitrile-   NH₃=Ammonia-   EtOH=Ethanol-   EtOAc=Ethyl Acetate-   LCMS=Mass spectrometry directed high pressure liquid chromatography-   UV=Ultraviolet-   SCX=Strong cation exchange-   TPAP=Tetrapropylammonium perruthenate-   DMSO=Dimethylsulphoxide-   BINAP=2,2′-bis(diphenylphosphino)-1,1′-binaphthyl-   TPAP=Tetrapropylammonium perruthenate-   DIAD=Diisopropyl azodicarboxylate-   NMO=N-Methylmorpholine N-oxide

Intermediate 1 Ethyl7-(4-fluoro-2-isopropoxy-anilino)thiazolo[5,4-d]pyrimidine-2-carboxylate

To a solution of ethyl7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylate (0.5 g, 1.9mmol) in DCM (20 ml) was added m-CPBA (675 mg, 3.9 mmol) and stirred for2 hours at room temperature. 4-Fluoro-2-isopropxyaniline (331 mg, 1.9mmol) in dioxane (20 ml) was then added and stirred for 1.5 hours. Themixture was diluted with DCM and water, the organic layer separated,dried and concentrated onto silica. The compound was purified via columnchromatography (20-80% EtOAc in Pet. Ether) to give an orange solid (706mg, 95%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45 (d, J=5.95 Hz, 6H),1.50 (t, J=6.90 Hz, 3H), 4.52-4.58 (m, 2H), 4.58-4.67 (m, 1H), 6.69-6.81(m, 2H), 8.55 (dd, J=8.93, 6.18 Hz, 1H), 8.68 (s, 1H), 8.69-8.73 (m,1H); LC-MS (ESI): (MH⁺) 377.1.

Intermediate 2 7-Methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylicacid

To a solution of ethyl7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylate (5 g, 19.6 mmol)in THF (100 ml) was added 15% NaOH_((aq)) (40 ml, 98 mmol) and stirredfor 2 hours. The mixture was acidified with 2M HCl_((aq)) and theresulting pale yellow solid collected and dried via vacuum filtration togive 7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylic acid (4.45g, 100%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.70 (s, 3H), 8.94-9.10 (m,1H).

Intermediate 3 Tert-butyl4-[[(7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carbonyl)amino]methyl]piperidine-1-carboxylate

Thionyl chloride (30 ml) was added to Intermediate 2 (4.45 g, 19.6 mmol)and the mixture heated at reflux for 2.5 hours, until an orange solutionwas formed. The mixture was cooled and concentrated to give a yellowsolid, which was taken up in DCM (30 ml) and cooled to 0° C.Triethylamine (8.48 ml, 58.8 mmol) was added to the mixture, followed bydropwise addition of tert-butyl 4-(aminomethyl)piperidine-1-carboxylate(4.61 g, 21.6 mmol) and stirring was continued overnight. The mixturewas diluted with DCM and water, the organic phase separated, dried andconcentrated onto silica. Purification by flash column chromatography(gradient elution from 10-50% EtOAc in Pet. Ether) gave a peach solid(5.49 g, 68%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.19-1.28 (m, 2H),1.46 (s, 9H), 1.73-1.80 (m, 2H), 1.82-1.91 (m, 1H), 2.73 (m, 5H), 3.42(m, 2H), 4.10-4.21 (m, 2H), 7.49 (br. t, J=6.4 Hz, 1H), 8.89 (s, 1H);LC-MS (ESI): (MH⁺—BOC) 324.0.

Intermediate 4N-[3-(dimethylamino)propyl]-7-methylsulfanyl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 2 (2 g, 8.81 mmol) was refluxed in thionyl chloride (20 ml)for 4 h and the mixture was concentrated under reduced pressure. Theresidue was dissolved in DCM (50 ml), cooled to 0° C. and triethylamine(3.67 ml, 26.3 mmol) followed by N′,N′-dimethylpropane-1,3-diamine (1.67ml, 10.6 mmol) was added, and the resulting mixture was stirred at roomtemperature for 18 h. The mixture was diluted with DCM and quenched withwater. The layers were separated, the aqueous phase was extracted withDCM, the combined organic phases were washed (brine), dried (MgSO₄) andconcentrated under reduced pressure. Purification by flashchromatography (gradient elution from 0-10% (2M ammonia in methanol) indichloromethane) gave a pale yellow solid (1.75 g, 64%). ¹H NMR (400MHz, DMSO-d₆) δ ppm 1.72 (quin, J=6.87 Hz, 2H), 2.22 (s, 6H), 2.37 (t,J=6.64 Hz, 2H), 2.71 (s, 3H), 3.34-3.41 (m, 2H), 9.01 (s, 1H), 9.53 (t,J=5.72 Hz, 1H); LC-MS (ESI): (MH⁺) 312.

Intermediate 5 1-(4-Nitrophenyl)-3-[3-(trifluoromethyl)phenyl]urea

To a solution of 4-nitroaniline (1 g, 7.25 mmol and triethylamine (3.14ml, 21.7 mmol) in THF (20 ml) was added 3-(trifluoromethyl)phenylisothiocyanate (1.5 g, 7.97 mmol) and stirred overnight. The mixture wasdiluted with EtOAc and water, the organic layer separated, dried andconcentrated onto silica. The compound was purified via columnchromatography (gradient elution from 20-100% EtOAc in Pet. Ether) togive a yellow solid (1.047 g, 45%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm7.25-7.36 (m, 2H), 7.49 (m, 2H), 7.54-7.60 (m, 1H), 7.65-7.71 (m, 1H),7.98 (s, 1H), 8.13-8.21 (m, 1H), 9.10-9.30 (m, 1H), 9.51-9.67 (m, 1H).

Intermediate 6 1-(4-Aminophenyl)-3-[3-(trifluoromethyl)phenyl]urea

A solution of Intermediate 5 (100 mg, 0.31 mmol) in MeOH (5 ml) andEtOAc (5 ml) was hydrogenated using the H-Cube flow reactor (Cartridge:10% Pd/C; flow rate: 1 ml/min⁻¹; temperature: 35° C.; H₂ pressure: FullH₂ Pressure. The final solution was concentrated to give1-(4-aminophenyl)-3-[3-(trifluoromethyl)phenyl]urea (71 mg, 79%), awhite solid; ¹H NMR (400 MHz, DMSO-d₆) δ ppm 4.74 (br. s, 2H), 6.47 (m,2H), 7.03 (m, 2H), 7.18-7.25 (m, 1H), 7.40-7.50 (m, 2H), 7.96 (s, 1H),8.20 (s, 1H), 8.82 (s, 1H); LC-MS (ESI): (MH⁺) 296.1.

Intermediate 7 Ethyl7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

To a solution of ethyl7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylate (8.25 g, 32mmol) in DCM (50 ml) was added m-CPBA (11.05 g, 64 mmol) and theresulting mixture stirred for 2 hours, prior to addition of5-fluoroindoline (4.43 g, 32 mmol) in 1,4-dioxane (20 ml) was added andstirring was continued overnight. A yellow precipitate formed, which wascollected and dried via vacuum filtration to afford ethyl7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate, ayellow solid (8.8 g, 80%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34 (t,J=7.3 Hz, 3H), 3.33 (t, 2H), 4.43 (q, J=6.9 Hz, 2H), 4.81 (t, J=7.8 Hz,2H), 7.04-7.12 (m, 1H), 7.18-7.25 (m, 1H), 8.59-8.70 (m, 2H); LC-MS(ESI): (MH⁺) 345.0.

Intermediate 87-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid

To a solution of Intermediate 7 (5.46 g, 16 mmol) in THF (70 ml) wasadded 2M NaOH_((aq)) (24 ml, 48 mmol) and the mixture stirred for 2hours. The mixture was acidified with 2M HCl_((aq)) at which point ayellow precipitate was formed. The precipitate was collected and driedvia vacuum filtration to give a yellow solid (3.2 g, 82%); ¹H NMR (400MHz, DMSO-d₆) δ ppm 3.20-3.28 (m, 2H), 4.82 (t, J=8.7 Hz, 2H), 7.02 (td,J=9.2, 2.8 Hz, 1H), 7.16 (dd, J=8.2, 2.3 Hz, 1H), 8.52 (s, 1H), 8.56(dd, J=9.2, 5.0 Hz, 1H); LC-MS (ESI): (MH⁺) 273.0.

Intermediate 9 N-(7-Chlorothiazolo[5,4-d]pyrimidin-2-yl)benzamide

To a solution of 4,6-dichloropyrimidin-5-amine (250 mg, 1.5 mmol) inacetone (15 ml) was added benzyl isothiocyanate (300 mg, 1.8 mmol) andthe mixture heated at 60° C. for 4 hours. The mixture was cooled andconcentrated by approximately half, at which point a yellow solidprecipitated. The solid was collected and dried under vacuum filtrationto give yellow solid (248 mg, 56%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm7.54-7.63 (m, 2H), 7.67-7.75 (m, 1H), 8.12-8.23 (m, 2H), 8.90 (s, 1H).

Intermediate 10N-[7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl]benzamide

Intermediate 9 (100 mg, 0.34 mmol), 5-fluoroindoline (81 mg, 0.34 mmol),4M HCl in dioxane (0.1 ml) and propan-2-ol (2 ml) were combined, sealedin a microwave vial and heated at 140° C. under microwave irradiationfor 20 minutes. The mixture was cooled and the solid collected by vacuumfiltration to giveN-[7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl]benzamide, ayellow solid (135 mg, 80%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.29 (t,J=8.70 Hz, 2H), 4.90 (t, J=8.47 Hz, 2H), 7.06 (td, J=9.04, 2.98 Hz, 1H),7.19 (dd, J=8.47, 2.98 Hz, 1H), 7.55-7.62 (m, 2H), 7.66-7.74 (m, 1H),8.10-8.17 (m, 2H), 8.52-8.59 (m, 2H); LC-MS (ESI): (MH⁺) 392.0.

Intermediate 112-Bromo-7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine

Tert-butyl nitrite (72 mg, 0.697 mmol) was added to a solution of7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-amine (100 mg, 30.35mmol) and copper (II) bromide (181 mg, 0.523 mmol) in acetonitrile (4mL) to give a brown suspension. The mixture was heated at 80° C. for 24hours to give a green precipitate. The precipitate was collected byvacuum filtration, washed with diethyl ether (2×5 mL) and dried undervacuum to give a green solid (10 mg, 82%); ¹H NMR (400 MHz, DMSO-d₆) δppm 8.75 (br. s, 1H), 8.52 (dd, J=8.70, 5.04 Hz, 1H), 7.17 (dd, J=9.16,2.75 Hz, 1H), 7.04 (dd, J=9.16, 2.75 Hz, 1H), 4.68 (s, 2H), 3.24 (t,J=8.24 Hz, 2H); LC-MS (ESI): (MH⁺) 350.9/352.9.

Intermediate 12 7-Fluoroindoline

To a solution of 7-fluoroindole (1 g, 7.4 mmol) in DCM (20 ml) was addedTFA (5 ml) and cooled to 0° C. Sodium borohydride (562 mg, 14.8 mmol)was added portion wise and stirred overnight. The mixture was basifiedwith sat. Na₂CO_(3 (aq)) the organic layer separated, dried andconcentrated to give 7-fluoroindoline, as a brown oil (986 mg, 97%); ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 3.07 (t, J=8.50 Hz, 2H), 3.61 (t,J=8.50 Hz, 2H), 6.59-6.67 (m, 1H), 6.89 (dd, J=7.33, 0.92 Hz, 2H).

Intermediate 13 Ethyl7-(7-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

To a solution of ethyl7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylate (750 mg, 2.9mmol) in DCM (30 ml) was added m-CPBA (1.38 g, 6.2 mmol) at 0° C. andthe mixture was stirred for 2 hours. Intermediate 12 (443 mg, 3.2 mmol)in dioxane (20 ml) was then added and stirring was continued overnight.The mixture was diluted with DCM and water, the organic layer separated,dried and concentrated onto silica. The compound was purified via columnchromatography (2-20% EtOAc in Pet. Ether) to give a yellow gum (260 mg,25%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.46 (t, J=7.10 Hz, 3H), 3.26(t, J=7.90 Hz, 2H), 4.51 (q, J=7.40 Hz, 2H), 4.77 (t, J=7.90 Hz, 2H),6.97-7.11 (m, 3H), 8.67 (s, 1H); LC-MS (ESI): (MH⁺) 345.0.

Intermediate 147-(7-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid

To a solution of Intermediate 13 (260 mg, 0.76 mmol) in THF (2 ml) wasadded 15% NaOH_((aq)) (2 ml) and stirred for 3 hours. The mixture wasacidified with 2M HCl_((aq)) and the resulting precipitate collected anddried via vacuum filtration to give7-(7-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid (210mg, 88%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.25 (t, J=7.80 Hz, 2H), 4.67(t, J=7.80 Hz, 2H), 7.03-7.28 (m, 3H), 8.67 (s, 1H); LC-MS (ESI): (MH⁺)317.0.

Intermediate 15 Ethyl7-(indolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

To a stirred solution of ethyl7-(methylthio)thiazolo[5,4-d]pyrimidine-2-carboxylate (2.50 g, 9.80mmol) in DCM (20 mL) at 0° C. was added m-CPBA (3.37 g, 19.6 mmol). Theresultant mixture was stirred at 0° C. and allowed to warm up to roomtemperature over 2 hours. Indoline (1.17 g, 9.80 mmol) in dioxane (5 mL)was added and the solution was stirred at room temperature overnight.The mixture was quenched by addition of DCM and water, the organic layerseparated and washed with water (2×10 mL). The organic layer wasseparated, dried and concentrate onto silica. The crude solid waspurified by column chromatography (10% EtOAc in Pet. Ether) to give ayellow solid (1.94 g, 61%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.63 (m,2H), 7.32 (d, J=7.33 Hz, 1H), 7.24 (t, J=7.33 Hz, 1H), 7.07 (d, J=7.79Hz, 1H), 4.78 (m, 2H), 4.44 (d, J=6.87 Hz, 2H), 3.30 (t, J=6.87 Hz, 2H),1.34 (t, J=7.10 Hz, 3H); LC-MS (ESI): (MH⁺) 327.0.

Intermediate 16 7-(Indolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylicacid

Intermediate 15 (1.94 g, 5.95 mmol) was suspended in THF (25 mL) and 2MNaOH_((aq)) (12 mL) added at 0° C. The mixture was acidified to pH 1 andthe yellow solid collected via vacuum filtration. The solid was washedwith ether (2×10 mL) and dried to give7-(indolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid (1.70 g,96%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.66 (s, 1H), 8.62 (d, J=7.80 Hz,1H), 7.32 (d, J=7.33 Hz, 1H), 7.23 (t, J=8.70 Hz, 1H), 7.06 (t, J=7.30Hz, 1H), 4.78 (t, J=8.20 Hz, 2H), 3.28 (t, J=8.70 Hz, 2H); LC-MS (ESI):(MH⁺—COOH), 255.0.

Intermediate 177-Methylsulfanyl-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 2 (1.38 g, 6.1 mmol) was to added thionyl chloride (12 ml)and the mixture heated at reflux for 4 hours, until an orange solutionwas formed. The mixture was cooled and concentrated to give a yellowsolid, which was taken up in DCM (30 ml). Triethylamine (2.5 ml, 18mmol) added at 0° C., followed by dropwise addition of4-aminotetrahydropyran (920 mg, 9.1 mmol), and the mixture was stirredovernight. The mixture was diluted with DCM and water, the organic phaseseparated, dried and concentrated onto silica. The compound was purifiedvia column chromatography (gradient elution from 0-60% EtOAc in Pet.Ether) to give a white solid (1.28 g, 68%); ¹H NMR (400 MHz, DMSO-d₆) δppm 1.66-1.86 (m, 4H), 2.70 (s, 3H), 3.35-3.43 (m, 2H), 3.84-3.93 (m,2H), 3.99-4.11 (m, 1H), 9.00 (s, 1H), 9.16 (d, J=8.24 Hz, 1H); LC-MS(ESI): (MH⁺) 311.0.

Intermediate 187-Chloro-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Sulfuryl chloride (1.95 ml, 24 mmol) in DCM (20 ml) was added slowly toa suspension of Intermediate 17 (1.49 g, 4.8 mmol) in acetonitrile (40mL) at 0° C. and the resulting mixture stirred for 1.5 hours. Themixture was basified with sat. NaHCO_(3 (aq)), the organic phaseseparated, dried and concentrated to give an off white solid (1.2 g,83%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.67-1.86 (m, 4H), 3.34-3.44 (m,2H), 3.85-3.94 (m, 2H), 4.01-4.13 (m, 1H), 9.12 (s, 1H), 9.36 (d, J=8.20Hz, 1H);

Intermediate 19 1-Acetyl-5-fluoro-indolin-2-one

5-fluoroindolin-2-one (250 mg, 1.6 mmol) was added to acetic anhydride(1 ml, 8.3 mmol) and heated at reflux for 2 hours. The mixture wascooled, poured onto iced water and which point a precipitate formed. Thesolid was filtered, washed with water and dried by vacuum filtration togive 1-acetyl-5-fluoro-indolin-2-one (279 mg, 87%); ¹H NMR (400 MHz,DMSO-d₆) δ ppm 2.54 (s, 3H), 3.84 (s, 2H), 7.09-7.18 (m, 1H), 7.20-7.30(m, 1H), 8.08 (dd, J=8.93, 4.81 Hz, 1H).

Intermediate 20 1-Acetyl-5-fluoro-3,3-dimethyl-indolin-2-one

To a solution of Intermediate 19 (279 mg, 1.4 mmol) in DMF (5 ml) wasadded a 60% dispersion of NaH in mineral oil (127 mg, 3.2 mmol) and themixture was stirred for 30 minutes prior to addition of methyl iodide(0.23 ml, 3.6 mmol) and stirring was continued overnight. The mixturewas concentrated and water added, and the resulting precipitate wascollected and dried by vacuum filtration to give a dark red solid (271mg, 85%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.38 (s, 6H), 2.56 (s, 3H),7.12-7.19 (m, 1H), 7.41-7.46 (m, 1H), 8.09-8.15 (m, 1H).

Intermediate 21 5-Fluoro-3,3-dimethyl-indolin-2-one

To a solution of Intermediate 20 (270 mg, 1.2 mmol) in propan-2-ol (5ml) was added water (1 mL) and 12M HCl (1 ml) and the mixture heated atreflux for 1.5 hours. The mixture was cooled, concentrated, water addedand the resulting solid collected via vacuum filtration to give a yellowsolid (200 mg, 91%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.24 (s, 6H), 6.81(dd, J=8.70, 4.58 Hz, 1H), 6.94-7.02 (m, 1H), 7.25 (dd, J=8.24, 2.75 Hz,1H), 10.35 (br. s, 1H).

Intermediate 22 5-Fluoro-3,3-dimethyl-indoline

To a solution of Intermediate 21 (200 mg, 1.1 mmol) in THF (5 ml) wasadded a 1.6M solution of lithium aluminium hydride in diethyl ether(1.34 ml, 1.34 mmol) drop wise and the mixture heated at reflux for 1hour. The mixture was cooled, water added (2 ml) carefully and the solidfiltered. The filtrate was concentrated to give5-fluoro-3,3-dimethyl-indoline, as dark red oil (120 mg, 65%); ¹H NMR(400 MHz, DMSO-d₆) δ ppm 1.21 (s, 6H), 3.17 (d, J=2.29 Hz, 2H), 5.35(br. s, 1H), 6.43 (dd, J=8.24, 4.58 Hz, 1H), 6.71 (ddd, J=9.62, 8.70,2.75 Hz, 1H), 6.83-6.87 (m, 1H); LC-MS (ESI): (MH⁺) 166.1.

Intermediate 231′-Acetyl-5′-fluoro-spiro[cyclopropane-1,3′-indoline]-2′-one

To a solution of Intermediate 19 (250 mg, 1.3 mmol) in DMF (5 ml) wasadded a 60% dispersion of NaH in mineral oil (110 mg, 2.8 mmol) and leftto stir for 30 minutes. 1,2-dibromoethane (258 mg, 1.4 mmol) was addedand the mixture stirred overnight. EtOAc and water were added to themixture, the organic layer separated, washed with water (×3) and brine.The organic phase was dried, concentrated onto silica and purified viacolumn chromatography (gradient elution from 10-100% EtOAc in Pet.Ether) to give an off white solid (120 mg, 42%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.58-1.64 (m, 2H) 1.85-1.91 (m, 2H) 2.70 (s, 3H)6.56 (dd, J=7.79, 2.75 Hz, 1H) 6.96-7.01 (m, 1H) 8.25-8.31 (m, 1H).

Intermediate 24 5′-Fluorospiro[cyclopropane-1,3′-indolin]

Intermediate 24 was made in an analogous manner to Intermediate 22, fromIntermediate 23 to give1′-acetyl-5′-fluoro-spiro[cyclopropane-1,3′-indoline]-2′-one; LC-MS(ESI): (MH⁺) 164.1.

Intermediate 25 Spiro[indoline-3,4′-tetrahydropyran]

To a solution of phenyl hydrazine (500 mg, 4.6 mmol) in acetic acid (15ml) was added tetrahydropyran-4-carbaldehyde (528 mg 4.6 mmol) andheated at 80° C. for 3 hours. The mixture was cooled, DCE (15 ml) andsodium triacetoxyborohydride (1.28 g, 6.0 mmol) added and stirred for 1hour. Another 0.5 equivalents of sodium triacetoxyborohydride were addedand stirred for a further hour. The mixture was concentrated, taken upin EtOAc, washed with 2M Na₂CO_(3 (aq)) and the organic phase separated,dried and concentrated onto silica. The compound was purified via columnchromatography (gradient elution from 5-15% EtOAc in Pet. Ether) to givea yellow solid (151 mg, 17%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.64-1.71 (m, 2H), 2.00 (ddd, J=13.62, 12.02, 4.58 Hz, 2H), 3.55 (s,2H), 3.57-3.62 (m, 2H), 3.94-4.02 (m, 2H), 6.67 (dt, J=7.80, 0.90 Hz,1H), 6.78 (td, J=7.30, 0.90 Hz, 1H), 7.07 (td, J=7.80, 1.20 Hz, 1H),7.11 (d, J=7.33 Hz, 1H); LC-MS (ESI): (MH⁺) 190.1.

Intermediate 26 O1-tert-butyl O3-methyl indole-1,3-dicarboxylate

To a solution of methyl-3-indolecarboxylate (2 g, 11.4 mmol) in THF (40ml) was added a 60% dispersion of sodium hydride in mineral oil (594 mg,14.8 mmol) and the mixture was stirred for 20 min. BOC anhydride (3.22g, 14.8 mmol) was added and stirred overnight. The mixture was dilutedwith EtOAc and water, the organic layer separated, dried andconcentrated onto silica. The compound was purified by columnchromatography (gradient elution from 2-5% EtOAc in Pet. Ether) to givea white solid (2.3 g, 74%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.70(s, 9H), 3.96 (s, 3H), 7.32-7.42 (m, 2H), 8.14-8.22 (m, 2H), 8.28 (s,1H).

Intermediate 27 O1-tert-butyl O3-methyl indoline-1,3-dicarboxylate

To a solution of Intermediate 26 (1 g, 3.6 mmol) in MeOH (100 ml) andDCM (30 ml), at 0° C., was added magnesium powder (438 mg, 18.2 mmol)and the mixture was stirred for 3 hours. More magnesium powder (250 mg,10.4 mmol) was added and stirring was continued overnight. The mixturewas decanted into sat NH₄Cl_((aq)) and acidified to approximately pH 4.DCM was added, the organic phase was separated, dried and concentratedto give a light yellow oil (953 mg, 95%); ¹H NMR (400 MHz, CHLOROFORM-d)δ ppm 1.57 (br. s., 9H), 3.80 (s, 3H), 4.06-4.16 (m, 1H), 4.18-4.26 (m,1H), 4.34-4.48 (m, 1H), 6.93-7.00 (m, 1H), 7.24 (t, J=8.01 Hz, 1H),7.34-7.39 (m, 1H), 7.70-7.96 (m, 1H).

Intermediate 28 Methyl indoline-3-carboxylate

To a solution of Intermediate 27 (953 mg, 3.45 mmol) in DCM (10 ml) wasadded TFA (3 ml) and the mixture was stirred for 1 hour. The mixture wasneutralised with sat. NaHCO_(3(aq)) and extracted with DCM. The organicphase was separated, dried and concentrated to give a brown oil (455 mg,75%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.73-3.78 (m, 1H), 3.78 (s,3H), 3.94-3.98 (m, 1H), 4.17-4.25 (m, 1H), 6.68 (d, J=7.79 Hz, 1H),6.72-6.80 (m, 1H), 7.07-7.13 (m, 1H), 7.29-7.33 (m, 1H); LC-MS (ESI):(MH⁺) 178.0.

Intermediate 29 Indolin-3-ylmethanol

To a solution of Intermediate 28 (100 mg, 0.57 mmol) in THF (5 ml) wasadded a 1M solution of lithium aluminium hydride in THF (1.1 ml, 1.1mmol) dropwise and the mixture heated at reflux for 45 minutes. Themixture was cooled, 1 ml of water added and the solids removed viafiltration. The filtrate was concentrated to give indolin-3-ylmethanol,a brown oil (65 mg, 76%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.45-3.54(m, 2H), 3.66-3.72 (m, 1H), 3.79-3.83 (m, 2H), 6.67 (d, J=7.79 Hz, 1H),6.75 (td, J=7.30, 0.90 Hz, 1H), 7.08 (td, J=7.79, 0.92 Hz, 1H), 7.16 (d,J=6.87 Hz, 1H); LC-MS (ESI): (MH⁺) 150.2.

Intermediate 30 2-(1H-indol-3-yl)ethanol

To a solution of 3-indoleacetic acid (1 g, 5.7 mmol) in THF (30 ml) wasadded a 1M solution of lithium aluminium hydride in THF (11.4 ml, 11.4mmol) and the mixture refluxed for 3 hours. The mixture was cooled, 0.43ml of water carefully added, followed by 0.43 ml of 15% NaOH_((aq)) andfinally 1.5 ml of water. The solids were filtered from the mixture,washed with EtOAc and the filtrate concentrated to give2-(1H-indol-3-yl)ethanol (919 mg, 100%); ¹H NMR (400 MHz, CHLOROFORM-d)δ ppm 3.06 (t, J=6.40 Hz, 2H), 3.93 (t, J=6.40 Hz, 2H), 7.10 (d, J=2.29Hz, 1H), 7.12-7.18 (m, 1H), 7.20-7.26 (m, 1H), 7.36-7.41 (m, 1H), 7.64(dd, J=8.01, 1.14 Hz, 1H), 8.10 (br. s., 1H).

Intermediate 31 2-Indolin-3-ylethanol

To a solution of Intermediate 30 (919 mg, 5.7 mmol) in DCM (20 ml) wasadded TFA (5 ml) followed by sodium borohydride (434 mg, 11.4 mmol) andstirred overnight. The mixture was diluted with DCM and neutralised withsat. Na₂CO_(3(aq)). The organic phase was separated, dried andconcentrated onto silica. The compound was purified via columnchromatography (10-100% EtOAc in Pet. Ether) to give2-indolin-3-ylethanol, as an orange oil (157 mg, 17%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.82 (m, 1H), 2.11 (m, 1H), 3.33 (dd, J=8.70, 5.95Hz, 1H), 3.43-3.52 (m, 1H), 3.56-3.64 (m, 1H), 3.67-3.76 (m, 2H), 6.70(d, J=7.79 Hz, 1H), 6.75-6.81 (m, 1H), 7.03-7.10 (m, 1H), 7.12 (d,J=7.60 Hz, 1H); LC-MS (ESI): (MH⁺) 164.1.

Intermediate 32 Tert-butyl N-(2-indolin-3-ylethyl)carbamate

To a solution of tyrptamine (1 g, 6.25 mmol) in DCM (10 ml) was addedTFA (2 ml) followed by sodium borohydride (475 mg, 12.5 mmol) andstirred overnight. The mixture was diluted with DCM and neutralised withsat. Na₂CO_(3(aq)). The organic phase was separated, dried andconcentrated to give 2-indolin-3-ylethanamine, a yellow oil. This wastaken up in DCM (30 ml), triethylamine (0.90 ml, 6.2 mmol) addedfollowed by BOC anhydride (1.35 g, 6.2 mmol) and stirred overnight. Themixture was diluted with DCM and water. The organic layer separated,dried and concentrated onto silica. The compound was purified via columnchromatography (gradient elution from 5-25% EtOAc in Pet. Ether) to givea yellow oil (684 mg, 42%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.46(s, 9H), 1.72 (m, 1H), 1.90-2.04 (m, 1H), 3.15-3.28 (m, 2H), 3.28-3.41(m, 1H), 3.58-3.77 (m, 1H), 4.06-4.11 (m, 1H), 4.57 (m, 1H), 6.90-6.99(m, 1H), 7.08-7.22 (m, 2H), 7.37-8.06 (m, 1H); LC-MS (ESI): (MH⁺) 263.2.

Intermediate 33 5-(Trifluoromethyl)indoline

To a solution of 5-(trifluoromethyl)indole (100 mg, 0.55 mmol) and TFA(0.5 mL) in DCM (10 mL) was added NaBH₄ (42 mg, 1.10 mmol) and themixture stirred overnight. The reaction mixture was diluted with DCM (10mL) and quenched with sat. NaHCO₃ (5 mL). The organic layer was washedwith water (2×10 mL), dried and concentrated in vacuo to give an orangegum (126 mg, 122% mass recovery); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm7.66 (m, 1H), 7.61 (m, 1H), 7.44 (m, 1H), 3.95 (t, J=7.79 Hz, 2H), 3.39(t, J=8.24 Hz, 2H); LC-MS (ESI): (MH⁺) 188.2. Used without furtherpurification.

Intermediate 34 Ethyl7-(2-methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

Intermediate 34 was made analogously to Intermediate 15 from ethyl7-(methylthio)thiazolo[5,4-d]pyrimidine-2-carboxylate and2-methylindoline. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.40 (d, J=6.41Hz, 3H), 1.47 (t, J=6.90 Hz, 3H), 2.83 (d, J=15.60 Hz, 1H), 3.52 (dd,J=15.60, 8.70 Hz, 1H), 4.44-4.57 (m, 2H), 5.92-6.07 (m, 1H), 7.08-7.14(m, 1H), 7.28-7.33 (m, 2H), 8.65-8.71 (m, 2H); LC-MS (ESI): (MH⁺) 341.1.

Intermediate 35 Ethyl7-(3-methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

Intermediate 35 was made analogously to Intermediate 14 from 3-methylindoline and ethyl 7-(methylthio)thiazolo[5,4-d]pyrimidine-2-carboxylateLC-MS (ESI): (MH⁺) 341.1.

Intermediate 367-(2-Methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid

To a solution of Intermediate 34 (943 mg, 2.8 mmol) in THF (10 ml) wasadded 15% NaOH_((aq)) (5 ml) and stirred for 1 hour. The mixture wasacidified to pH 1 with 2M HCl and the resulting precipitate was filteredand dried to give a brown solid (852 mg, 98%); ¹H NMR (400 MHz, DMSO-d₆)δ ppm 1.28 (d, J=5.95 Hz, 3H), 2.83 (d, J=16.03 Hz, 1H), 3.50 (dd,J=15.80, 8.93 Hz, 1H), 5.84-5.98 (m, 1H), 7.06-7.15 (m, 1H), 7.28 (t,J=8.01 Hz, 1H), 7.37 (d, J=7.33 Hz, 1H), 8.62 (d, J=8.24 Hz, 1H), 8.67(s, 1H);

Intermediate 37 (S)-indolin-2-ylmethanol

Borane (38 ml, 1.0M in THF, 38 mmol) was added drop wise to a suspensionof (S)-indoline-2-carboxylic acid (2.50 g, 15.2 mmol) at 0° C. and theresultant solution stirred at RT for 48 hours. To this was added DCM andwater and the organic phase washed with water (2×20 ml). The organicphase was separated, dried and concentrated to give an orange oil (856mg, 38%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.08 (d, J=7.33 Hz, 1H),7.02 (d, J=1.37 Hz, 1H), 6.72 (td, J=7.44, 1.14 Hz, 1H), 6.64 (d, J=7.79Hz, 1H), 4.02 (m, 1H), 3.70 (dd, J=10.76, 3.89 Hz, 1H), 3.56 (dd,J=10.76, 6.64 Hz, 1H), 3.08 (d, J=9.16 Hz, 1H), 2.83 (d, J=7.78 Hz, 1H);LC-MS (ESI): (MH⁺) 150.

Intermediate 38 (S)-tert-butyl 2-(hydroxymethyl)indoline-1-carboxylate

To a solution of Intermediate 37 (856 mg, 5.74 mmol) in DCM (5 mL) wasadded BOC₂O (1.38 g, 6.32 mmol) and the solution stirred at room tempfor 48 hours. To the resultant yellow solution was added DCM (5 mL) andsat. NaHCO_(3 (aq)) (5 mL). The organic layer was washed with sat.NaHCO_(3 (aq)) (2×5 mL), separated and concentrated to give a yellow oil(1.40 g, 89%) ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.51 (br. s, 1H),7.14 (m, 2H), 6.94 (t, J=7.33 Hz, 1H), 4.59 (br. s, 1H), 3.69 (s, 2H),3.33 (m, 1H), 2.79 (br. s, 1H), 1.58 (s, 9H); LC-MS (ESI): (MH⁺—BOC)150.1.

Intermediate 39 (S)-tert-butyl2-((tosyloxy)methyl)indoline-1-carboxylate

Tosyl chloride (2.13 g, 11.20 mmol) and pyridine (12 mL) were added to asolution of Intermediate 38 in DCM (6 mL) and the resulting mixture wasstirred at room temp for 16 hours. The mixture was quenched by additionof DCM and water and the organic layer separated and washed with water(2×10 mL). The organic layer was separated, dried and concentrated togive a pink oil (1.46 g, 64%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.68(d, J=8.70 Hz, 2H), 7.29 (d, J=8.23 Hz, 2H), 7.11 (m, 2H), 6.93 (t,J=7.33 Hz, 1H), 4.59 (m, 1H), 4.18 (m, 1H), 3.97 (br. s., 1H), 3.27 (m,1H), 2.93 (dd, J=16.49, 1.83 Hz, 1H), 2.42 (s, 3H), 1.47 (br. s., 9H);LC-MS (ESI): (MH⁺) 400.0.

Intermediate 40 (R)-tert-butyl 2-methylindoline-1-carboxylate

Sodium borohydride (335 mg, 9.06 mmol) was added to a solution ofIntermediate 39 (1.46 g, 3.62 mmol) in DMSO (20 mL) and the reactionmixture stirred at 100° C. for 18 hours. To the resultant yellowsolution was added DCM and water, the organic layer separated and washedwith water (2×10 mL). The organic layer was separated, dried andconcentrated to give a yellow oil (547 mg, 65%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.27 (d, J=6.41 Hz, 3H) 1.56 (s, 9H) 2.57-2.61 (m,2H) 3.33 (dd, J=16.03, 9.62 Hz, 1H) 4.42-4.57 (m, 1H) 6.89-6.95 (m, 1H)7.10-7.19 (m, 2H).

Intermediate 41 (R)-2-Methylindoline

To a solution of Intermediate 40 (547 mg, 235 mmol) in DCM (5 mL) wasadded TFA (2 mL) and the reaction mixture was stirred at room temp for 1hour. The solution was concentrated and the resultant orange oil takenup in methanol and passed through an SCX cartridge. The product waseluted with 2M ammonia in methanol and the eluent concentrated to givean orange oil (547 mg, 65%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 7.10(d, J=7.33 Hz, 1H), 7.03 (t, J=7.80 Hz, 1H), 6.70 (t, J=8.70 Hz, 1H),6.63 (d, J=7.79 Hz, 1H), 4.01 (m, 1H), 3.16 (dd, J=15.11, 8.70 Hz, 1H),2.66 (dd, J=15.11, 7.79 Hz, 1H), 1.31 (d, J=5.95 Hz, 3H).

Intermediate 42 (R)-Ethyl7-(2-methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

m-CPBA (639 mg, 3.70 mmol) was added to a stirring solution of ethyl7-(methylthio)thiazolo[5,4-d]pyrimidine-2-carboxylate (472 mg, 1.85mmol) in DCM (10 mL) at 0° C. The resultant mixture was stirred at 0° C.and allowed to warm up to room temperature over 2 hours after whichIntermediate 41 (264 mg, 1.85 mmol) and dioxane (5 mL) was added toyield a dark green solution. The solution was left to stir at roomtemperature for 16 hours. To this was added DCM and water, the organiclayer separated and washed with water (2×10 mL). The organic layer wasseparated, dried and concentrated to give a yellow solid. This was takenup in methanol and passed through an SCX cartridge. The product waseluted with 2M ammonia in methanol and the eluent concentrated to give ayellow solid (350 mg, 65%). ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.38-1.41 (d, 3H) 1.47 (t, 3H) 2.83 (d, J=15.57 Hz, 1H) 3.52 (dd,J=15.57, 9.16 Hz, 1H) 4.48-4.55 (q, 2H) 5.95-6.03 (m, 1H) 7.11 (td,J=7.33, 0.92 Hz, 1H) 7.31 (dt, J=7.67, 3.72 Hz, 2H) 8.65-8.67 (m, 1H)8.67-8.71 (m, 1H); LC-MS (ESI): (MH⁺) 341.0.

Intermediate 43(R)-7-(2-methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid

Intermediate 42 (5.46 g, 16.2 mmol) was suspended in THF (70 mL) and 2MNaOH_((aq)) (24 mL) added at 0° C. and stirred for 30 mins. The mixturewas acidified to pH 1 and the yellow solid collected via vacuumfiltration. The solid was washed with ether (2×10 mL) and dried to givea yellow solid (350 mg, 93%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.65 (s,1H), 8.59 (d, J=8.24 Hz, 1H), 7.35 (d, J=7.33 Hz, 1H), 7.25 (t, J=7.30Hz, 1H), 7.08 (t, J=8.20 Hz, 1H), 5.87 (m, 1H), 3.48 (dd, J=15.57, 8.70Hz, 1H), 2.81 (d, J=15.57 Hz, 1H), 1.25 (d, J=5.95 Hz, 3H).

Intermediate 44 Tert-butyl4-[[(7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carbonyl)amino]methyl]piperidine-1-carboxylate

Thionyl chloride (30 ml) was added to Intermediate 2 (4.45 g, 19.6 mmol)and heated at reflux for 2 hours. The mixture was cooled, concentratedand the residue taken up in DCM. To this was added triethylamine (8.48ml, 58.8 mmol), followed by a solution of tert-butyl4-(aminomethyl)piperidine-1-carboxylate (4.61 g, 21.6 mmol) in DCM andstirred overnight. DCM and water were added to the mixture, the organicphase was separated, dried and concentrated onto silica. Purification bycolumn chromatography (gradient elution from 10-50% EtOAc in Pet. Ether)gave a peach solid (5.49 g, 68%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.23-1.31 (m, 2H), 1.46 (s, 9H), 1.72-1.80 (m, 2H), 1.81-1.90 (m, 1H),2.69-2.76 (m, 5H), 3.43 (t, J=6.64 Hz, 2H), 4.11-4.21 (m, 2H), 7.49 (br.t, J=6.00, 6.00 Hz, 1H), 8.90 (s, 1H); LC-MS (ESI): (MH⁺—BOC) 324.0.

Intermediate 45 Tert-butyl4-[[(7-chlorothiazolo[5,4-d]pyrimidine-2-carbonyl)amino]methyl]piperidine-1-carboxylate

To a solution of Intermediate 44 (2.5 g, 5.9 mmol) in acetonitrile (50ml) and DCM (20 ml), at −10° C. in an ice/salt bath, was added asolution of sulfuryl chloride (0.96 ml, 11.8 mmol) in DCM (10 ml)dropwise. The reaction was left to stir at −10° C. for 1 hour. Themixture was concentrated to give tert-butyl4-[[(7-chlorothiazolo[5,4-d]pyrimidine-2-carbonyl)amino]methyl]piperidine-1-carboxylate,a yellow solid (2.51 g, 112% mass recovery); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.21-1.31 (m, 2H), 1.46 (s, 9H), 1.75-1.81 (m, 2H),1.85-1.91 (m, 1H), 2.65-2.76 (m, 2H), 3.45 (t, J=6.60 Hz, 2H), 4.14-4.20(m, 2H), 7.55 (br. t, J=6.00, 6.00 Hz, 1H), 9.00 (s, 1H); LC-MS (ESI):(MH⁺—BOC) 312.0.

Intermediate 46 2-(5-Fluoro-1H-indol-3-yl)ethanol

To a solution of 5-fluoroindole-3-acetic acid (1 g, 5.2 mmol) in THF (20ml) was added a 1M solution of lithium aluminium hydride in THF (10.4ml, 10.4 mmol) and the mixture refluxed for 1.5 hours. The mixture wascooled, 0.39 ml of water and then 0.39 ml of 15% NaOH_((aq)) added,followed by 1.2 ml of water. The precipitate was collected via vacuumfiltration and the filtrate concentrated to give2-(5-fluoro-1H-indol-3-yl)ethanol, an orange oil (0.927 g, 100%); ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 2.98 (t, J=6.41 Hz, 2H), 3.89 (t, J=6.18Hz, 2H), 6.95 (td, J=9.04, 2.52 Hz, 1H), 7.12 (s, 1H), 7.22-7.30 (m,2H), 8.06 (br. s., 1H).

Intermediate 47 2-(5-Fluoroindolin-3-yl)ethanol

To a solution of Intermediate 46 (927 mg, 5.2 mmol) in DCM (20 ml) andTFA (5 ml) was added sodium borohydride (393 mg, 10.4 mmol) and stirredfor 4 hours. The mixture was diluted with DCM and basified with sat.NaHCO_(3(aq)). The organic layer was separated, dried and concentratedonto silica. The compound was purified via column chromatography(gradient elution from 20-100% EtOAc in Pet. Ether) to give a yellow oil(416 mg, 44%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.74-1.85 (m, 1H),2.06-2.14 (m, 1H), 3.28-3.36 (m, 1H), 3.40-3.50 (m, 1H), 3.55-3.63 (m,1H), 3.67-3.78 (m, 2H), 6.59 (dd, J=8.47, 4.35 Hz, 1H), 6.75 (td,J=8.82, 2.52 Hz, 1H), 6.83 (dd, J=8.47, 2.52 Hz, 1H); LC-MS (ESI): (MH⁺)312.0.

Intermediate 48 Methyl 3-methylindoline-3-carboxylate

To a solution of Intermediate 27 (250 mg, 0.92 mmol) in DMF (10 ml) wasadded a 60% dispersion of sodium hydride in mineral oil (41 mg, 1.0mmol), immediately followed by methyl iodide (0.17 ml, 2.8 mmol) andstirred for 2 h. The mixture was diluted with EtOAc and washed withwater (×3). The organic phase was separated, dried and concentrated toan oil. The oil was taken up in DCM (5 ml), TFA (1 ml) added and stirredfor 1 hour. The mixture was passed through a SCX cartridge, the productbeing eluted with 2M NH₃ in MeOH to give methyl3-methylindoline-3-carboxylate, a brown oil (118 mg, 67%); ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 1.59 (s, 3H), 3.38 (d, J=9.62 Hz, 1H), 3.73 (s,3H), 4.16 (d, J=9.16 Hz, 1H), 6.70 (d, J=8.24 Hz, 1H), 6.80 (td, J=7.50,1.10 Hz, 1H), 7.11 (td, J=7.50, 1.14 Hz, 1H), 7.27-7.31 (m, 1H); LC-MS(ESI): (MH⁺) 192.1.

Intermediate 49 (3-Methylindolin-3-yl)methanol

To a solution of Intermediate 48 (118 mg, 0.62 mmol) in THF (5 ml) wasadded a 1M solution of lithium aluminium hydride in THF (1.24 ml, 1.2mmol) dropwise and the reaction stirred for 2 hours at room temperature.The reaction mixture was quenched by addition of water and 15%NaOH_((aq)). The solids were removed via vacuum filtration and thefiltrate concentrated to give a yellow oil (100 mg, 99%); ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 1.34 (s, 3H), 3.28 (d, J=9.16 Hz, 1H),3.54-3.58 (m, 2H), 3.61 (d, J=8.20 Hz, 1H), 3.63-3.68 (m, 1H), 6.63-6.69(m, 1H), 6.72-6.79 (m, 1H), 7.07 (m, J=7.30 Hz, 2H); LC-MS (ESI): (MH⁺)164.1.

Intermediate 50 (5-Fluoro-3-methyl-indolin-3-yl)methanol

Intermediate 50 was made in an analogous manner to Intermediate 49starting from methyl 5-fluoro-1H-indole-3-carboxylate; ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.31 (s, 3H), 3.28-3.32 (m, 1H), 3.57-3.63 (m, 3H),6.56-6.60 (m, 1H), 6.78 (m, 2H); LC-MS (ESI): (MH⁺) 182.1.

Intermediate 51 Methyl 2-(1H-indol-3-yl)acetate

To a solution of 3-indole acetic acid (500 mg, 2.9 mmol) in MeOH (20 ml)was added conc. H₂SO₄ (1 ml) and the mixture stirred for 1 hour. Themixture was quenched with sat. NaHCO_(3(aq)) and extracted with DCM. Theorganic phase was separated, dried and concentrated to give a yellow oil(531 mg, 99%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.72 (s, 3H), 3.82(s, 2H), 7.13-7.19 (m, 2H), 7.20-7.25 (m, 1H), 7.34-7.39 (m, 1H),7.61-7.66 (m, 1H), 8.02-8.23 (m, 1H).

Intermediate 52 Methyl 2-indolin-3-ylacetate

To a solution of Intermediate 51 (311 mg, 1.6 mmol) in DCM (10 ml) andTFA (2 ml) was added sodium borohydride (125 mg, 3.2 mmol) and stirredfor 2 hours. The mixture was diluted with DCM and quenched with sat.NaHCO_(3(aq)). The organic phase was separated, dried and concentratedto give a yellow oil (302 mg, 96%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm2.60 (dd, J=16.50, 9.10 Hz, 1H), 2.80 (dd, J=16.50, 5.50 Hz, 1H), 3.31(dd, J=8.93, 6.18 Hz, 1H), 3.43-3.60 (m, 1H), 3.71-3.78 (m, 4H),3.79-3.86 (m, 1H), 6.72 (d, J=7.79 Hz, 1H), 6.78 (td, J=7.33, 0.92 Hz,1H), 7.06-7.13 (m, 2H); LC-MS (ESI): (MH⁺) 192.1.

Intermediate 53 Tert-butyl3-(2-methoxy-2-oxo-ethyl)indoline-1-carboxylate

To a solution of Intermediate 52 (140 mg, 0.73 mmol) in triethylamine(0.21 ml, 1.4 mmol) and DCM (5 ml) was added DMAP (9 mg, 0.07 mmol),followed by BOC anhydride (168 mg, 0.77 mmol). The mixture was stirredovernight. The mixture was diluted with DCM and water, the organic layerseparated, dried and concentrated onto silica. The compound was purifiedvia column chromatography (gradient elution from 5-50% EtOAc in Pet.Ether) to give a yellow oil (148 mg, 70%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.55 (br. s., 9H), 2.50-2.59 (m, 1H), 2.69-2.86 (m,1H), 3.59-3.69 (m, 1H), 3.70-3.78 (m, 4H), 4.15-4.23 (m, 1H), 6.93 (td,J=7.30, 0.90 Hz, 1H), 7.11 (d, J=7.30 Hz, 1H), 7.18 (t, J=7.78 Hz, 1H),7.34-7.93 (m, 1H); LC-MS (ESI): (MH⁺—BOC) 192.1.

Intermediate 54 Tert-butyl3-(2-hydroxy-2-methyl-propyl)indoline-1-carboxylate

To a solution of Intermediate 53 (148 mg, 0.51 mmol) in THF (5 ml) wasadded a 3M solution of methyl magnesium bromide in THF (0.84 ml, 2.5mmol) and stirred for 1 hour. The reaction was quenched with sat.NH₄Cl_((aq)) and extracted with DCM. The organic layer was separated,dried and concentrated to give a yellow oil (150 mg, 99%); ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 1.32 (s, 6H), 1.58 (s, 9H), 1.76 (dd, J=14.20,10.53 Hz, 1H), 1.97-2.09 (m, 1H), 3.41-3.54 (m, 1H), 3.73 (d, J=6.87 Hz,1H), 4.16-4.35 (m, 1H), 6.94 (td, J=7.33, 0.92 Hz, 1H), 7.07-7.19 (m,2H), 7.35-8.01 (m, 1H); LC-MS (ESI): (MH⁺—BOC) 192.1.

Intermediate 55 1-Indolin-3-yl-2-methyl-propan-2-ol

To a solution of Intermediate 54 (150 mg, 0.51 mmol) in DCM (10 ml) wasadded TFA (1 ml) and stirred for 3 hours. The mixture was passed througha SCX cartridge, the product being eluted with 2M NH₃ in MeOH to give1-indolin-3-yl-2-methyl-propan-2-ol, a yellow oil (76 mg, 78%); ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 1.32 (d, J=8.24 Hz, 6H), 1.78 (dd,J=14.43, 9.85 Hz, 1H), 2.12 (dd, J=14.43, 2.52 Hz, 1H), 3.33 (t, J=8.70Hz, 1H), 3.42-3.51 (m, 1H), 3.84 (t, J=8.70 Hz, 1H), 6.70 (d, J=7.30 Hz,1H), 6.78 (td, J=7.30, 0.90 Hz, 1H), 7.03-7.08 (m, 1H), 7.10 (d, J=7.30Hz, 1H); LC-MS (ESI): (MH⁺) 192.1.

Intermediate 56 1-(5-Fluoroindolin-3-yl)-2-methyl-propan-2-ol

Intermediate 56 was made in an analogous manner to Intermediate 55starting from 5-fluoro-3-indole acetic acid to give1-(5-fluoroindolin-3-yl)-2-methyl-propan-2-ol; ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.30 (d, J=9.16 Hz, 6H), 1.74-1.82 (m, 1H),1.98-2.05 (m, 1H), 3.46-3.53 (m, 2H), 3.86-3.94 (m, 1H), 6.75-6.81 (m,2H), 6.83-6.88 (m, 1H); LC-MS (ESI): (MH⁺) 210.1.

Intermediate 57 O1-tert-butyl O3-methyl3-methylindoline-1,3-dicarboxylate

To a solution of Intermediate 27 (1 g, 3.7 mmol) in DMF (25 ml) wasadded a 60% dispersion of sodium hydride in mineral oil (162 mg, 4.0mmol), immediately followed by methyl iodide (0.68 ml, 11.0 mmol) andstirred for 2 hours. The mixture was diluted with EtOAc and washed withwater (×3). The organic phase was separated, dried and concentrated togive an orange oil (1.07 g, 100%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.56-1.61 (m, 12H), 3.67-3.79 (m, 4H), 4.58 (d, J=11.40 Hz, 1H), 6.98(td, J=7.30, 0.90 Hz, 1H), 7.20-7.26 (m, 1H), 7.31 (dd, J=7.80, 0.90 Hz,1H), 7.38-7.94 (m, 1H); LC-MS (ESI): (MH⁺—BOC) 192.1.

Intermediate 58 1-Tert-butoxycarbonyl-3-methyl-indoline-3-carboxylicacid

To a solution of Intermediate 57 (1.07 g, 3.7 mmol) in THF (20 ml) wasadded 15% NaOH_((aq)) (20 ml) and the mixture heated at 50° C. for 3hours, then at room temperature overnight. The mixture was acidifiedwith 1M HCl_((aq)) and extracted with ethyl acetate. The organic phasewas separated, dried and concentrated to give an orange oil (1 g, 100%);¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.54 (br. s, 9H), 1.61 (s, 3H),3.66-3.77 (m, 1H), 4.57 (d, J=11.45 Hz, 1H), 6.98 (td, J=7.80, 0.90 Hz,1H), 7.23 (t, J=7.80 Hz, 1H), 7.34 (dd, J=7.30, 0.90 Hz, 1H), 7.40-7.92(m, 1H); LC-MS (ESI): (MH⁺—BOC) 178.1.

Intermediate 592-(1-Tert-butoxycarbonyl-3-methyl-indolin-3-yl)-2-oxo-ethanediazonium

To a solution of Intermediate 58 (1 g, 3.6 mmol) and triethylamine (1.04ml, 7.2 mmol) in DCM (20 ml) at 0° C. was added DMF (56 μL, 0.72 mmol)followed by the dropwise addition of oxalyl chloride (0.45 ml, 5.4mmol). The reaction was stirred for 4 hours, warming to roomtemperature. More oxalyl chloride (0.3 ml, 3.6 mmol) was added andstirring was continued overnight. The mixture was concentrated and theresidue taken up in THF (20 ml) and acetonitrile (10 ml). A 2M solutionof trimethylsilane diazomethane in diethyl ether (3.6 ml, 7.2 mmol) wasadded and the mixture was stirred for 2 hours. The mixture was quenchedwith 10% Citric acid_((aq)) until effervescence ceased. DCM and waterwere added, the organic layer separated, dried and concentrated ontosilica. The compound was purified via column chromatography (gradientelution from 2-10% EtOAc in Pet. Ether) to give a yellow oil (401 mg,37%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.52-1.61 (m, 12H), 3.72 (br.d, J=11.90 Hz, 1H), 4.35 (d, J=11.90 Hz, 1H), 5.12 (s, 1H), 7.01 (td,J=7.80, 0.90 Hz, 1H), 7.16 (dd, J=7.80, 0.90 Hz, 1H), 7.24-7.30 (m, 1H),7.37-8.01 (m, 1H).

Intermediate 60 Tert-butyl3-(2-methoxy-2-oxo-ethyl)-3-methyl-indoline-1-carboxylate

To a solution of Intermediate 59 (401 mg, 1.3 mmol) and triethylamine(0.58 ml, 4.0 mmol) in methanol (10 ml) was added silver benzoate (152mg, 0.66 mol). The mixture was stirred for 1.5 hours. DCM and water wereadded to the mixture, the organic layer separated, dried andconcentrated onto silica. The compound was purified via columnchromatography (gradient elution from 2-12% EtOAc in Pet. Ether) to givea colourless oil (230 mg, 57%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.38 (s, 3H), 1.55 (br. s, 9H), 2.54-2.72 (m, 2H), 3.62 (s, 3H), 3.75(d, J=11.40 Hz, 1H), 4.10 (d, J=11.40 Hz, 1H), 6.95 (td, J=7.30, 0.90Hz, 1H), 7.08 (d, J=7.30 Hz, 1H), 7.18 (t, J=7.30 Hz, 1H), 7.34-8.10 (m,1H); LC-MS (ESI): (MH⁺—BOC) 206.1.

Intermediate 61 Methyl 2-(3-methylindolin-3-yl)acetate

To a solution of Intermediate 60 (230 mg, 0.75 mmol) in DCM (10 ml) wasadded TFA (2 ml) and stirred for 15 minutes. Sat. NaHCO_(3 (aq)) wasadded to neutralise the mixture, the organic layer was separated, driedand concentrated to give methyl 2-(3-methylindolin-3-yl)acetate, anorange oil (140 mg, 90%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.41 (s,3H) 2.62 (d, J=1.37 Hz, 2H) 3.36 (d, J=9.16 Hz, 1H) 3.63-3.66 (m, 3H)3.67-3.70 (m, 1H) 6.65-6.68 (m, 1H) 6.72-6.77 (m, 1H) 7.02-7.08 (m, 2H);LC-MS (ESI): (MH⁺) 206.1.

Intermediate 62 2-(3-Methylindolin-3-yl)ethanol

To a solution of Intermediate 61 (140 mg, 0.68 mmol) in THF (5 ml) wasadded a 1M solution of lithium aluminium hydride in THF (1.36 ml, 1.4mmol) drop wise and stirred for 30 min. 52 μL of water was carefullyadded, followed by 52 μL 15% NaOH_((aq)) and finally 0.15 ml of water.The solids were removed via vacuum filtration and the filtrateconcentrated to give a light brown oil (108 mg, 90%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.40 (s, 3H), 1.61-1.70 (m, 1H), 1.90-2.00 (m, 1H),3.16-3.24 (m, 1H), 3.30 (d, J=8.70 Hz, 1H), 3.49-3.54 (m, 2H), 6.72 (d,J=7.78 Hz, 1H), 6.79-6.86 (m, 1H), 7.01 (d, J=7.33 Hz, 1H), 7.07 (td,J=7.80, 0.90 Hz, 1H); LC-MS (ESI): (MH⁺) 178.1.

Intermediate 637-[5-Fluoro-3-(2-hydroxyethyl)indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 18 (200 mg, 0.67 mmol), Intermediate 47 and propan-2-olwere combined, sealed in a vial and heated at 50° C. for 3 hours. Themixture was cooled and concentrated to give a yellow solid (300 mg,100%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.67-1.76 (m, 2H), 1.90-1.96(m, 1H), 1.98-2.04 (m, 2H), 2.13-2.21 (m, 1H), 3.50-3.57 (m, 2H),3.68-3.76 (m, 1H), 3.83-3.91 (m, 1H), 3.92-3.98 (m, 1H), 3.99-4.04 (m,2H), 4.14-4.26 (m, 1H), 4.79 (dd, J=12.59, 6.18 Hz, 1H), 5.23 (dd,J=12.36, 9.16 Hz, 1H), 6.98-7.06 (m, 2H), 7.31 (d, J=8.24 Hz, 1H),8.59-8.66 (m, 2H); LC-MS (ESI): (MH⁺) 444.0.

Intermediate 647-[-3-(2-Hydroxyethyl)indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 18 (114 mg, 0.38 mmol), Intermediate 31 (62 mg, 0.38 mmol)and propan-2-ol were combined, sealed in a vial and heated at 80° C. for3 hours. The mixture was cooled and concentrated onto silica, andpurified via column chromatography (gradient elution from 0-5% MeOH inEtOAc) to give a yellow solid (210 mg); ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.71-1.91 (m, 4H) 3.35-3.46 (m, 2H) 3.59-3.72 (m, 3H) 3.92 (dd, J=11.22,2.98 Hz, 2H) 4.00-4.13 (m, 1H) 4.70 (dd, J=12.59, 4.35 Hz, 1H) 4.96 (dd,J=12.59, 8.47 Hz, 1H) 7.10 (td, J=7.44, 1.14 Hz, 1H) 7.25-7.33 (m, 1H)7.39-7.48 (m, 1H) 8.62 (d, J=8.24 Hz, 1H) 8.67 (s, 1H) 8.71 (d, J=8.24Hz, 1H); LC-MS (ESI): (MH⁺) 412.1.

Intermediate 657-Chloro-N-methyl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 65 was prepared analogously to Intermediate 18. ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 8.97 (s, 1H), 7.44 (br. s, NH), 3.12 (d, J=5.50Hz, 3H).

Intermediate 66 Ethyl 7-chlorothiazolo[5,4-d]pyrimidine-2-carboxylate

To a solution of ethyl7-methylsulfanylthiazolo[5,4-d]pyrimidine-2-carboxylate (1 g, 3.9 mmol)in DCM (20 ml) at 0° C. was added sulfuryl chloride (0.63 ml, 7.8 mmol)dropwise. The mixture was stirred for 1 hour and then concentrated togive a yellow solid (952 mg, 100%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.51 (t, J=7.20 Hz, 3H), 4.60 (q, J=7.17 Hz, 2H), 9.02 (s, 1H).

Intermediate 67 Ethyl7-(3,3-dimethylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate

Intermediate 66 (300 mg, 1.2 mmol), 3,3-dimethylindoline (182 mg, 1.2mmol) and propan-2-ol (3 ml) were sealed in a vial and heated at 70° C.for 4 hours. The mixture was cooled, at which point a precipitateformed. This was collected and dried via vacuum filtration to affordethyl7-(3,3-dimethylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylate, asa yellow solid (322 mg, 74%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48(m, 9H), 4.56 (q, J=7.33 Hz, 2H), 4.80 (s, 2H), 7.31-7.41 (m, 3H), 8.65(d, J=7.78 Hz, 1H), 8.75 (s, 1H); LC-MS (ESI): (MH⁺) 355.0.

Intermediate 687-(3,3-Dimethylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid

To a solution of Intermediate 67 (322 mg, 0.9 mmol) in THF (10 ml) wasadded 15% NaOH_((aq)) and stirred for 1 hour. The mixture was acidified,at which point a precipitate formed. This was collected and dried byvacuum filtration to give a yellow solid (243 mg, 82%); ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.42 (s, 6H), 4.60 (s, 2H), 7.10-7.18 (m, 1H), 7.25-7.32(m, 1H), 7.38 (dd, J=7.80, 0.90 Hz, 1H), 8.61 (d, J=7.78 Hz, 1H), 8.71(s, 1H).

Intermediate 69 (1R,2R)-2-(5-fluoro-2-nitro-phenoxy)cyclohexanol

LiHMDS (8.6 ml, 8.6 mmol, 1M in THF) was added slowly to(1R,2R)-cyclohexane-1,2-diol (1 g, 8.6 mmol) in THF (10 ml) at roomtemperature. An additional (5 ml) of THF was added and the mixture wasstirred for 5 minutes, then 2,4-difluoro-1-nitro-benzene (0.943 ml, 8.6mmol) was added dropwise. The mixture stirred at room temperatureovernight. The mixture was diluted with EtOAc and 2M HCl (aq), theorganic layer separated and washed with 2M NaOH (aq), then elutedthrough a phase separator and concentrated. Purification by columnchromatography, eluting with 0-15% EtOAc/petroleum ether gave a yellowsolid (1.2 g, 55%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.97-1.44 (m, 4H),1.48-1.65 (m, 2H), 1.69-1.85 (m, 1H), 1.87-2.10 (m, 1H), 3.41-3.68 (m,1H), 4.12-4.41 (m, 1H), 4.92 (br. s, 1H), 6.76-7.02 (m, 1H), 7.39 (dd,J=11.45, 2.75 Hz, 1H), 7.91 (dd, J=9.16, 6.41 Hz, 1H).

Intermediate 70 (1R,2R)-2-(2-amino-5-fluoro-phenoxy)cyclohexanol

A solution of Intermediate 69 (1.2 g, 4.7 mmol) in 5:1 EtOH:EtOAc (120ml) was passed through an H-Cube reactor (Cartridge: 10% Pd/C; flowrate: 1 ml/min-1; temperature: room temperature; pressure: 1 bar). Thesolution was concentrated to give(1R,2R)-2-(2-amino-5-fluoro-phenoxy)cyclohexanol as a brown gum (1.05mg, 99%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16-1.37 (m, 4H), 1.51-1.64(m, 2H), 1.78-1.88 (m, 1H), 1.95 (s, 1H), 3.44-3.56 (m, 1H), 3.69-3.81(m, 1H), 4.66 (br. s., 2H), 5.04 (d, J=4.58 Hz, 1H), 6.47 (m, 1H),6.50-6.58 (m, 1H), 6.65-6.73 (m, 1H); LC-MS (ESI): (MH⁺) 226.1.

Intermediate 714-Fluoro-2-[(1R,2R)-2-methoxycyclohexoxy]-1-nitro-benzene

Intermediate 69 (1.36 g, 5.33 mmol) and trimethyloxoniumtetrafluoroborate (2.36 g, 16 mmol) were combined in DCM (30 ml) andstirred at room temperature overnight. The mixture was diluted withwater, the organic layer separated, dried over MgSO₄ and concentrated.Purification by column chromatography, eluting with 2-5% EtOAc/petroleumether gave a yellow oil (1 g, 70%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.16-1.43 (m, 3H), 1.50-1.65 (m, 1H), 1.66-1.85 (m, 2H), 2.01-2.21 (m,2H), 3.29-3.41 (m, 4H), 4.14-4.27 (m, 1H), 6.62-6.72 (m, 1H), 6.87-6.94(m, 1H), 7.82-7.91 (m, 1H).

Intermediate 72 4-Fluoro-2-[(1R,2R)-2-methoxycyclohexoxy]aniline

Intermediate 72 was prepared analogously to Intermediate 70 to give agolden oil (0.84 g, 95%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.18-1.39(m, 3H), 1.42-1.56 (m, 1H), 1.63-1.79 (m, 2H), 2.05-2.18 (m, 2H),3.28-3.38 (m, 1H), 3.44 (s, 3H), 3.94 (m, 1H), 6.49-6.58 (m, 1H),6.63-6.72 (m, 2H); (MH⁺) 240.2.

Intermediate 73 (1S,2S)-2-(5-fluoro-2-nitro-phenoxy)cyclohexanol

Prepared analogously to Intermediate 69 to give a yellow solid (1.9 g,29%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.14-1.41 (m, 4H), 1.51-1.63 (m,2H), 1.75-1.85 (m, 1H), 1.90-2.01 (m, 1H), 3.44-3.53 (m, 1H), 4.26-4.35(m, 1H), 4.94 (d, J=5.04 Hz, 1H), 6.84-6.92 (m, 1H), 7.39 (dd, J=11.45,2.29 Hz, 1H), 7.91 (dd, J=9.16, 5.95 Hz, 1H).

Intermediate 74 (1S,2S)-2-(2-amino-5-fluoro-phenoxy)cyclohexanol

Prepared analogously to Intermediate 70 to give(1S,2S)-2-(2-amino-5-fluoro-phenoxy)cyclohexanol as a brown gum (0.95g), which was used in the next step without further purification. ¹H NMR(400 MHz, DMSO-d₆) δ ppm 1.16-1.33 (m, 4H), 1.48-1.66 (m, 2H), 1.78-1.87(m, 1H), 1.93-2.04 (m, 1H), 3.45-3.54 (m, 1H), 3.71-3.80 (m, 1H), 4.63(s, 2H), 5.04 (d, J=4.58 Hz, 1H), 6.42-6.49 (m, 1H), 6.50-6.57 (m, 1H),6.65-6.72 (m, 1H); (MH⁺) 226.

Intermediate 754-fluoro-2-[(1S,2S)-2-methoxycyclohexoxy]-1-nitro-benzene

Intermediate 75 was prepared analogously to Intermediate 71 to a yellowoil (0.63 g, 66%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.22-1.41 (m,3H), 1.55 (m, 1H), 1.66-1.81 (m, 2H), 2.02-2.18 (m, 2H), 3.29-3.41 (m,4H), 4.13-4.25 (m, 1H), 6.62-6.72 (m, 1H), 6.91 (dd, J=10.53, 2.75 Hz,1H), 7.82-7.91 (m, 1H).

Intermediate 76 4-fluoro-2-[(1S,2S)-2-methoxycyclohexoxy]aniline

Prepared analogously to Intermediate 70 to give4-fluoro-2-[(1S,2S)-2-methoxycyclohexoxy]aniline as a brown oil (0.54 g,97%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.21-1.39 (m, 3H), 1.42-1.54(m, 1H), 1.63-1.81 (m, 2H), 2.03-2.17 (m, 2H), 3.28-3.36 (m, 1H), 3.44(s, 3H), 3.88-3.99 (m, 1H), 6.50-6.58 (m, 1H), 6.65-6.72 (m, 2H); (MH⁺)240.2.

Intermediate 77 Ethyl7-(5-nitro-2,3-dihydro-1H-indol-1-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxylate

A mixture of Intermediate 66 (50 mg, 0.205 mmol) and 5-nitroindoline (34mg, 0.205 mmol) in IPA (2 ml) was stirred and heated at 80° C. for 5hours. The mixture was cooled to rt and a yellow solid was isolated byfiltration (44 mg, 58%). ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.50 (t,J=7.33 Hz, 3H), 3.44 (t, J=8.70 Hz, 2H), 4.56 (q, J=7.33 Hz, 2H),5.03-5.12 (m, 2H), 8.14-8.18 (m, 1H), 8.23 (dd, J=8.93, 2.52 Hz, 1H),8.81 (s, 1H), 8.86 (d, J=8.70 Hz, 1H).

Intermediate 787-(5-Nitro-2,3-dihydro-1H-indol-1-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxylicacid

A mixture of Intermediate 77 (651 mg, 1.75 mmol) and 1 N NaOH (aq) in1:1 EtOH:THF (30 ml) was stirred at rt for 3 hours. The reaction mixturewas concentrated to a small volume and then diluted with water. 1 M HClwas added to pH=3-4. A yellow solid was isolated by filtration. Thesolid was diluted with MeOH and the mixture was concentrated to dryness(660 mg, 110%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.41 (t, J=8.47 Hz, 2H),4.92 (t, J=8.47 Hz, 2H), 8.16-8.25 (m, 2H), 8.74-8.80 (m, 1H), 8.83 (s,1H).

Intermediate 797-(5-Amino-2,3-dihydro-1H-indol-1-yl)-N-(1-methylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

A mixture of Example 45 (210 mg, 0.478 mmol), ammonium chloride (127 mg,2.39 mmol) and zinc powder (155 mg, 2.39 mmol) in 1:1:1 MeOH:THF:water(30 ml) was stirred and heated at 60° C. for 5 hours. The mixture wasthe cooled to rt and concentrated to dryness. The solid residue waspre-absorbed onto silica gel prior to purification by flash columnchromatography on silica gel eluting with 10:1 DCM:2M NH₃ in MeOH toprovide a yellow solid (62 mg, 32%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.71-1.85 (m, 4H), 1.89-2.03 (m, 2H), 2.18 (s, 3H), 2.82 (d, J=11.45 Hz,2H), 3.15-3.26 (m, 2H), 3.71-3.87 (m, 1H), 4.81 (t, J=8.24 Hz, 2H), 5.07(s, 2H), 6.46 (dd, J=8.70, 2.29 Hz, 1H), 6.58 (d, J=2.29 Hz, 1H), 8.37(d, J=8.70 Hz, 1H), 8.53 (s, 1H), 8.66 (d, J=8.24 Hz, 1H). (ES+APCI)⁺:410 [M+H]⁺.

Intermediate 80 Tert-butyl4-[[(7-chlorothiazolo[5,4-d]pyrimidine-2-carbonyl)amino]methyl]piperidine-1-carboxylate

To a stirred solution of Intermediate 3 (1.02 g, 2.4 mmol) inacetonitrile (40 ml) with ice cooling was added, dropwise, a solution ofSO₂Cl₂ (0.39 ml, 4.8 mmol). The resulting mixture was stirred at 0° C.for 2 h and then quenched with sat. NaHCO₃(aq). The layers wereseparated, and the aqueous phase was extracted with DCM and the combinedorganic extracts were washed (brine), dried (MgSO₄) and concentratedunder reduced pressure to give an off-white solid (1 g), which was usedin the next step without further purification.

Example 17-(4-Fluoro-2-isopropoxy-anilino)thiazolo[5,4-d]pyrimidine-2-carboxylicacid

To a solution of Intermediate 1 (326 mg, 0.87 mmol) in THF (6 ml) wasadded 2M NaOH_((aq)) (2 ml) and the mixture was stirred for 1 hours. Thereaction was acidified with 2M HCl_((aq)) and concentrated to remove THFand the resulting brown precipitate collected and dried via vacuumfiltration to give a dark yellow solid (285 mg, 95%); ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.23 (d, J=5.95 Hz, 6H), 4.69 (spt, J=6.00 Hz, 1H), 6.82(td, J=8.59, 2.52 Hz, 1H), 7.04-7.12 (m, 1H), 7.86-7.95 (m, 1H), 8.55(s, 1H), 9.42 (s, 1H); LC-MS (ESI): (MH⁺) 349.0.

Example 27-{[4-Fluoro-2-(propan-2-yloxy)phenyl]amino}-N-methyl[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

A mixture of Example 1 (100 mg, 0.287 mmol), methylamine hydrochloride(20 mg, 0.287 mmol), EDC hydrochloride (55 mg, 0.287 mmol) and HOBt (39mg, 0.287 mmol) in DCM (5 ml) was stirred at rt overnight. A further 47mg of methylamine hydrochloride was added and the reaction mixture wasstirred at rt overnight. The reaction mixture was diluted with DCM andwas pre-absorbed onto silica gel prior to purification by flash columnchromatography on silica gel, eluting with 1:1 petrol:EtOAc to provide ayellow solid (17 mg, 16%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.30 (d,J=6.41 Hz, 6H), 2.90 (d, J=5.04 Hz, 3H), 4.73 (dt, J=12.25, 6.01 Hz,1H), 6.85 (td, J=8.70, 2.75 Hz, 1H), 7.12 (dd, J=11.45, 2.75 Hz, 1H),8.15 (dd, J=9.16, 6.41 Hz, 1H), 8.59 (s, 1H), 8.76-8.99 (m, 2H). m/z(ES+APCI)⁺: 362 [M+H]⁺.

Example 3N-[3-(Dimethylamino)propyl]-7-(4-fluoro-2-isopropoxy-anilino)thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 1 (100 mg, 0.29 mmol), N,N-dimethylaminopropylamine (35 μL, 0.27mmol), HATU (153 mg, 0.40 mmol), DIPEA (0.32 ml, 1.7 mmol) and DMF (5ml) were combined and stirred overnight. The mixture was diluted withEtOAc and washed with water (×3). The organic layer was separated, driedand concentrated onto silica. The compound was purified via columnchromatography (0-30% MeOH in DCM) to give the product (6 mg, 5%); ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.47 (d, J=6.41 Hz, 6H), 2.15 (quin,J=6.64 Hz, 2H), 2.67 (s, 6H), 2.94 (t, J=6.87 Hz, 2H), 3.70 (q, J=6.30Hz, 2H), 4.62 (spt, J=6.00 Hz, 1H), 6.64-6.81 (m, 2H), 8.33 (br. t,J=5.50, 5.50 Hz, 1H), 8.43 (br. s, 1H), 8.48 (dd, J=8.70, 6.41 Hz, 1H),8.64 (s, 1H); LC-MS (ESI): (MH⁺) 433.1.

Example 47-(4-fluoro-2-isopropoxy-anilino)-N-(morpholin-2-ylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 1 (75 mg, 0.22 mmol), tert-butyl2-(aminomethyl)morpholine-4-carboxylate (46 mg, 0.22 mmol), HATU (115mg, 0.30 mmol), DIPEA (0.2 ml, 1.1 mmol) and DMF (1 ml) were combinedand stirred overnight. The mixture was diluted with EtOAc and washedwith water (×3). The organic layer was separated, dried and concentratedonto silica. The compound was purified via column chromatography(gradient elution from 40-100% EtOAc in Pet. Ether). The purified BOCprotected compound was taken up in DCM (1 ml), TFA (1 ml) added andstirred for 30 mins. The mixture was passed through an amino propylcartridge, eluting with 2M NH₃ in MeOH to give the product (28.9 mg,30%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48 (d, J=6.00 Hz, 6H),2.68-2.78 (m, 1H), 2.90-2.97 (m, 2H), 3.05 (d, J=11.45 Hz, 1H),3.36-3.46 (m, 1H), 3.69-3.85 (m, 3H), 3.94 (dt, J=11.00, 2.30 Hz, 1H),4.64 (quin, J=6.18 Hz, 1H), 6.69-6.82 (m, 2H), 7.59 (br. t, J=6.90, 6.90Hz, 1H), 8.60 (s, 1H), 8.67-8.72 (m, 2H); LC-MS (ESI): (MH⁺) 447.1.

Example 5-14

Example 5-14 in the table below were prepared analogously to Example 3and Example 4 from7-(4-fluoro-2-isopropoxy-anilino)thiazolo[5,4-d]pyrimidine-2-carboxylicacid and the appropriate, optionally BOC protected, amine.

LC- MS (ESI): Example R IUPAC Name (MH⁺) ¹H NMR 5

N-(8- azabicyclo[3.2.1]octan-3- yl)-7-(4-fluoro-2- isopropoxy-anilino)thiazolo[5,4- d]pyrimidine-2- carboxamide 457.2 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.45 (d, J = 6.00 Hz, 6 H), 1.93 (d, J = 14.20 Hz, 2H), 2.09 (s, 4 H), 2.25-2.37 (m, 2 H), 3.73 (br. s., 2 H), 4.42 (q, J =6.87 Hz, 1H), 4.66 (spt, J = 6.03 Hz, 1 H), 6.69-6.83 (m, 2 H), 7.69 (d,J = 7.78 Hz, 1 H), 8.47 (s, 1 H), 8.67- 8.69 (m, 1 H), 8.75 (dd, J =9.16, 6.41 Hz, 1 H) 6

tert-butyl 3-[[7-(4-fluoro- 2-isopropoxy- anilino)thiazolo[5,4-d]pyrimidine-2- carbonyl]amino]-8- azabicyclo[3.2.1]octane-8-carboxylate 557.2 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.44 (d, J =6.00 Hz, 6 H), 1.49 (s, 9 H), 1.80- 2.04 (m, 4 H), 2.11- 2.24 (m, 2 H),2.24- 2.48 (m, 2 H), 4.23- 4.45 (m, 3 H), 4.64 (spt, J = 6.00 Hz, 1 H),6.70- 6.81 (m, 2 H), 7.69 (d, J = 1.00 Hz, 1 H), 8.47 (s, 1 H), 8.66 (s,1 H), 8.69- 8.78 (m, 1 H) 7

2,6- diazaspiro[3.3]heptan-2- yl-[7-(4-fluoro-2- isopropoxy-anilino)thiazolo[5,4- d]pyrimidin-2- yl]methanone 429.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.51 (d, J = 5.95 Hz, 6 H), 3.86 (dd, J = 24.30,8.70 Hz, 4 H), 4.43 (s, 2 H), 4.69 (spt, J = 6.00 Hz, 1 H), 4.93 (s, 2H), 6.68- 6.84 (m, 2 H), 8.54- 8.63 (m, 1 H), 8.68 (s, 1 H), 8.79 (dd, J= 8.93, 6.18 Hz, 1 H) 8

7-(4-fluoro-2-isopropoxy- anilino)-N-(3- hydroxypropyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 406.2 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.46 (d, J = 6.00 Hz, 6 H), 1.91 (quin, J = 6.00 Hz, 2 H), 3.73 (q, J =6.41 Hz, 2 H), 3.83 (t, J = 5.50 Hz, 2 H), 4.63 (spt, J = 6.00 Hz, 1 H),6.69-6.81 (m, 2 H), 7.64 (br. t, J = 4.60, 4.60 Hz, 1 H), 8.50 (br. s.,1 H), 8.64 (dd, J = 8.93, 6.18 Hz, 1 H), 8.67 (s, 1 H) 9

7-(4-fluoro-2-isopropoxy- anilino)-N-(2-piperazin-1-ylethyl)thiazolo[5,4- d]pyrimidine-2- carboxamide 460.2 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.46 (d, J = 5.95 Hz, 6 H), 2.52 (br. s., 4 H), 2.65(t, J = 5.95 Hz, 2 H), 2.95 (t, J = 4.81 Hz, 4 H), 3.65 (q, J = 6.10 Hz,2 H), 4.63 (spt, J = 6.03 Hz, 1 H), 6.68-6.84 (m, 2 H), 7.56 (br. t, J =5.00, 5.00 Hz, 1 H), 8.43 (br. s, 1 H), 8.62 (dd, J = 8.93, 6.18 Hz, 1H), 8.66 (s, 1 H) 10

7-(4-fluoro-2-isopropoxy- anilino)-N-(4- piperidylmethyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 445.2 ¹H NMR (400 MHz, CHLOROFORM-d) δppm 1.22-1.37 (m, 2 H), 1.46 (d, J = 6.00 Hz, 6 H), 1.74-1.85 (m, 3 H),2.65 (td, J = 12.14, 2.29 Hz, 2 H), 3.14 (dt, J = 11.90, 2.30 Hz, 2 H),3.44 (t, J = 6.18 Hz, 2 H), 4.64 (spt, J = 6.03 Hz, 1 H), 6.69-6.84 (m,2 H), 7.33 (br. t, J = 6.00, 6.00 Hz, 1 H), 8.53 (s, 1 H), 8.63-8.73 (m,2 H) 11

[7-(4-fluoro-2- isopropoxy- anilino)thiazolo[5,4-d]pyrimidin-2-yl]-[4-(2 hydroxyethyl)-1- piperidyl]methanone 460.2 ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.46 (d, J = 6.00 Hz, 6 H), 2.49-2.60(m, 1 H), 2.60-2.74 (m, 6 H), 3.70 (br. t, J = 1.00, 1.00 Hz, 2 H),3.85-3.96 (m, 2 H), 4.50 (m, J = 4.60 Hz, 2 H), 4.64 (spt, J = 6.11 Hz,1 H), 6.68- 6.83 (m, 2 H), 8.53 (br. s, 1 H), 8.69 (s, 1 H), 8.77 (dd, J= 8.93, 6.18 Hz, 1 H) 12

N-(2,3-dihydroxypropyl)- 7-(4-fluoro-2-isopropoxy- anilino)thiazolo[5,4-d]pyrimidine-2- carboxamide 422.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.47 (d, J = 5.95 Hz, 6 H), 3.57-3.71 (m, 2 H), 3.74-3.84 (m, 2 H),3.95-4.05 (m, 1 H), 4.64 (spt, J = 6.00 Hz, 1 H), 6.68-6.82 (m, 2 H),7.69 (br. t, J = 5.50, 5.50 Hz, 1 H), 8.54 (s, 1 H), 8.62-8.69 (m, 2 H)13

7-(4-fluoro-2-isopropoxy- anilino)-N-(3-pyrrolidin-1-ylpropyl)thiazolo[5,4- d]pyrimidine-2- carboxamide 459.1 ¹H NMR (400MHz, CHLOROFORM-d) δ ppm 1.43 (d, J = 5.95 Hz, 6 H), 1.84-1.93 (m, 4 H),1.93-2.05 (m, 2 H), 2.70-2.97 (m, 6 H), 3.65 (q, J = 26.11 Hz, 2 H),4.61 (spt, J = 6.00 Hz, 1 H), 6.68-6.82 (m, 2 H), 8.20 (br. t, J = 4.70,4.70 Hz, 1 H), 8.37 (br. s, 1 H), 8.48 (dd, J = 8.93, 6.18 Hz, 1 H),8.65 (s, 1 H) 14

3-[[7-(4-fluoro-2- isopropoxy- anilino)thiazolo[5,4- d]pyrimidine-2-carbonyl]amino]propanoic acid 420.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.27(d, J = 5.95 Hz, 6 H), 2.58 (t, J = 6.40 Hz, 2 H), 3.56 (q, J = 6.41 Hz,2 H), 4.70 (spt, J = 6.00 Hz, 1 H), 6.84 (td, J = 8.70, 2.75 Hz, 1 H),7.10 (dd, J = 10.99, 2.75 Hz, 1 H), 8.04 (dd, J = 8.70, 6.41 Hz, 1 H),8.57 (s, 1 H), 8.70 (br. t, J = 6.00, 6.00 Hz, 1 H), 9.12 (br. s., 1 H)

Example 15N-[3-(dimethylamino)propyl]-7-[4-fluoro-2-[(1R,2R)-2-hydroxycyclohexoxy]anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 70 (36 mg, 0.16 mmol), Intermediate 4 (50 mg, 0.16 mmol),TFA (50 ul) and IPA (750 ul) were combined in a sealed microwave reactorvial and heated at 170 degrees in a Biotage microwave reactor for 45minutes. The mixture was evaporated and purified by preparative LCMS togive a yellow solid (20 mg, 26%). 1H NMR (400 MHz, DMSO-d6) δ ppm1.12-1.42 (m, 4H), 1.51-1.60 (m, 2H), 1.63-1.73 (m, 2H), 1.77-1.86 (m,1H), 1.98-2.07 (m, 1H), 2.12 (s, 6H), 2.27 (t, J=7.10 Hz, 2H), 3.32-3.43(m, 2H), 3.53-3.61 (m, 1H), 3.97-4.05 (m, 1H), 5.15-5.22 (m, 1H),6.81-6.88 (m, 1H), 7.14 (dd, J=10.53, 2.75 Hz, 1H), 8.16 (dd, J=8.70,6.41 Hz, 1H), 8.56 (s, 1H), 8.68-8.77 (m, 1H), 9.27 (s, 1H); (MH+)489.20.

Example 16N-[3-(dimethylamino)propyl]-7-[4-fluoro-2-[(3R)-tetrahydropyran-3-yl]oxy-anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 15 from Intermediate 4 (75 mg, 0.241mmol) and 4-fluoro-2-[(3R)-tetrahydropyran-3-yl]oxy-aniline (101 mg,0.721 mmol) to give the product as a yellow solid (18 mg, 21%). 1H NMR(400 MHz, DMSO-d6) δ ppm 1.38-1.52 (m, 1H), 1.64-1.73 (m, 2H), 1.75-1.88(m, 2H), 1.90-2.02 (m, 1H), 2.10-2.17 (m, 6H), 2.28 (t, J=6.87 Hz, 2H),3.34-3.43 (m, 2H), 3.50-3.60 (m, 3H), 3.69 (dd, J=11.91, 2.29 Hz, 1H),4.47-4.59 (m, 1H), 6.91 (td, J=8.70, 2.75 Hz, 1H), 7.22 (dd, J=10.53,2.75 Hz, 1H), 8.17 (dd, J=9.16, 6.41 Hz, 1H), 8.57-8.62 (m, 1H),8.62-8.72 (m, 1H), 9.15 (s, 1H); m/z (ES+APCI)⁺: 475 [M+H]⁺.

Example 17N-[3-(dimethylamino)propyl]-7-[4-fluoro-2-[(3S)-tetrahydropyran-3-yl]oxy-anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 15 from Intermediate 4 (75 mg, 0.241mmol) and 4-fluoro-2-[(3S)-tetrahydropyran-3-yl]oxy-aniline (101 mg,0.721 mmol) to give the product as a yellow solid (18 mg, 21%) ¹H NMR(400 MHz, DMSO-d₆) δ ppm 1.39-1.52 (m, 1H), 1.64-1.74 (m, 2H), 1.74-1.89(m, 2H), 1.91-2.01 (m, 1H), 2.10-2.17 (m, 6H), 2.28 (t, J=6.87 Hz, 2H),3.34-3.43 (m, 2H), 3.50-3.60 (m, 3H), 3.69 (dd, J=11.91, 2.29 Hz, 1H),4.50-4.57 (m, 1H), 6.90 (td, J=8.47, 2.75 Hz, 1H), 7.21 (dd, J=10.53,2.75 Hz, 1H), 8.17 (dd, J=9.16, 6.41 Hz, 1H), 8.60 (s, 1H), 8.62-8.70(m, 1H), 9.15 (s, 1H). m/z (ES+APCI)⁺: 475 [M+H]⁺.

Example 18N-[3-(dimethylamino)propyl]-7-(3-fluoro-2-isopropoxy-anilino)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 15 from Intermediate 4 (75 mg, 0.241mmol) 3-fluoro-2-isopropoxy-aniline (122 mg, 0.721 mmol) to give theproduct as a yellow solid (18 mg, 21%) ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.28 (d, J=5.95 Hz, 6H), 1.65-1.75 (m, 2H), 2.14 (s, 6H), 2.29 (t,J=6.87 Hz, 2H), 3.38 (q, J=6.56 Hz, 2H), 4.71 (spt, J=6.11 Hz, 1H), 6.85(td, J=8.70, 2.75 Hz, 1H), 7.12 (dd, J=10.99, 2.75 Hz, 1H), 8.10 (dd,J=8.93, 6.64 Hz, 1H), 8.56-8.59 (m, 1H), 8.89 (br. s., 1H), 8.96 (s,1H). m/z (ES+APCI)⁺: 433 [M+H]⁺.

Example 19N-[3-(dimethylamino)propyl]-7-[4-fluoro-2-[(1S,2S)-2-hydroxycyclohexoxy]anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 74 (54 mg, 0.24 mmol),N-[3-(dimethylamino)propyl]-7-methylsulfanyl-thiazolo[5,4-d]pyrimidine-2-carboxamide(75 mg, 0.24 mmol), TFA (50 ul) and NMP (500 ul) were combined in asealed microwave reactor vial and heated at 170 degrees in a Biotagemicrowave reactor for 15 minutes, then at 190 degrees for 30 minutes.The mixture was evaporated and purified by preparative LCMS to give ayellow solid (14 mg, 12%); 1H NMR (400 MHz, DMSO-d6) δ ppm 1.12-1.42 (m,4H), 1.50-1.61 (m, 2H), 1.63-1.73 (m, 2H), 1.78-1.85 (m, 1H), 1.99-2.07(m, 1H), 2.12 (s, 6H), 2.27 (t, J=7.10 Hz, 2H), 3.32-3.41 (m, 2H),3.53-3.61 (m, 1H), 3.98-4.05 (m, 1H), 5.18 (d, J=4.12 Hz, 1H), 6.82-6.88(m, 1H), 7.14 (dd, J=10.99, 2.75 Hz, 1H), 8.13-8.19 (m, 1H), 8.56 (s,1H), 8.72 (t, J=5.72 Hz, 1H), 9.27 (s, 1H); m/z (ES+APCI)⁺: (MH+) 489.2.

Example 20N-[3-(dimethylamino)propyl]-7-[4-fluoro-2-[(1R,2R)-2-methoxycyclohexoxy]anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 72 (115 mg, 0.48 mmol), Intermediate 4 (75 mg, 0.24 mmol),TFA (101 ul, 1.32 mmol) and IPA (700 ul) were combined in a sealedmicrowave reactor vial and heated at 170° C. in a Biotage microwavereactor for 30 minutes. The mixture was evaporated and purified bypreparative LCMS to give a yellow solid (57 mg, 47%); 1H NMR (400 MHz,DMSO-d6) δ ppm 1.10-1.35 (m, 3H), 1.37-1.48 (m, 1H), 1.49-1.60 (m, 2H),1.63-1.72 (m, 2H), 1.88-1.97 (m, 1H), 1.97-2.06 (m, 1H), 2.13 (s, 6H),2.27 (t, J=6.87 Hz, 2H), 3.19 (s, 3H), 3.33-3.44 (m, 3H), 4.20-4.27 (m,1H), 6.81-6.88 (m, 1H), 7.11-7.17 (m, 1H), 8.17-8.23 (m, 1H), 8.58 (s,1H), 8.79-8.86 (m, 1H), 8.99 (s, 1H); m/z (ES+APCI)⁺: (MH+) 503.3.

Example 21N-[3-(dimethylamino)propyl]-7-[2-[(1S,2S)-1-ethyl-2-methoxy-propoxy]-4-fluoro-anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 21 was prepared analogously to Example 19 from Intermediate 76and Intermediate 4 to give a gummy solid (55 mg, 45%); 1H NMR (400 MHz,DMSO-d6) δ ppm 1.11-1.36 (m, 3H), 1.36-1.48 (m, 1H), 1.49-1.61 (m, 2H),1.63-1.71 (m, 2H), 1.88-1.97 (m, 1H), 1.97-2.06 (m, 1H), 2.12 (s, 6H),2.24-2.31 (m, 2H), 3.19 (s, 3H), 3.33-3.45 (m, 3H), 4.19-4.29 (m, 1H),6.80-6.88 (m, 1H), 7.10-7.17 (m, 1H), 8.17-8.24 (m, 1H), 8.58 (s, 1H),8.79-8.86 (m, 1H), 8.99 (s, 1H); m/z (ES+APCI)⁺: (MH+) 503.3.

Example 227-[2-(Cyclopentoxy)-4-fluoro-anilino]-N-[3-(dimethylamino)propyl]thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 19 from Intermediate 4 (68 mg, 0.22mmol) and 2-cyclopentoxy-4-fluoro-aniline (170 mg, 0.87 mmol) to give ayellow solid (16 mg, 16%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.45-1.60 (m,4H), 1.63-1.78 (m, 4H), 1.79-1.95 (m, 2H), 2.11-2.19 (m, 6H), 2.24-2.35(m, 2H), 3.34-3.43 (m, 2H), 4.74-5.04 (m, 1H), 6.84 (td, J=8.70, 2.75Hz, 1H), 7.07 (dd, J=10.99, 2.75 Hz, 1H), 8.00 (dd, J=8.70, 6.41 Hz,1H), 8.56 (s, 1H), 8.75 (br. s., 1H), 9.06 (s, 1H); m/z (ES+APCI)⁺:(MH+) 459.

Example 23N-[3-(Dimethylamino)propyl]-7-(2-isopropoxyanilino)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 19 from Intermediate 4 (68 mg, 0.22mmol) and 2-isopropoxy-aniline (130 μl, 0.87 mmol) to give a yellowsolid (12 mg, 13%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33 (d, J=6.41 Hz,6H), 1.72 (quin, J=6.98 Hz, 2H), 2.16 (s, 6H), 2.31 (t, J=7.10 Hz, 2H),3.36-3.42 (m, 2H), 4.68 (quin, J=6.07 Hz, 1H), 7.03 (td, J=7.56, 1.83Hz, 1H), 7.10-7.21 (m, 2H), 8.35 (dd, J=7.78, 1.37 Hz, 1H), 8.64 (s,1H), 8.95 (s, 1H), 8.99 (t, J=5.72 Hz, 1H); m/z (ES+APCI)⁺: (MH+) 415.

Example 24N-[3-(Dimethylamino)propyl]-7-(2-ethoxy-4-fluoro-anilino)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 19 from Intermediate 4 (68 mg, 0.22mmol) and 2-ethoxy-4-fluoro-aniline (170 mg, 0.87 mmol) to give a yellowsolid (18 mg, 20%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.31 (t, J=6.87 Hz,3H), 1.71 (quin, J=6.98 Hz, 2H), 2.10-2.18 (m, 6H), 2.29 (t, J=7.10 Hz,2H), 3.38 (q, J=6.56 Hz, 2H), 4.18 (q, J=6.87 Hz, 2H), 6.86 (td, J=8.70,2.75 Hz, 1H), 7.10 (dd, J=10.99, 2.75 Hz, 1H), 8.08 (dd, J=8.70, 6.41Hz, 1H), 8.58 (s, 1H), 8.97 (s, 2H); m/z (ES+APCI)⁺: (MH+) 419.

Example 25N-[3-(Dimethylamino)propyl]-7-(3,3-dimethylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 19 from Intermediate 4 (50 mg, 0.16mmol) and 3,3-dimethylindoline (71 mg, 0.49 mmol) to give a yellow solid(25 mg, 38%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41 (s, 6H), 1.74 (quin,J=6.87 Hz, 2H), 2.18 (s, 6H), 2.33 (t, J=6.87 Hz, 2H), 3.42 (q, J=6.56Hz, 2H), 4.62 (s, 2H), 7.13 (td, J=7.33, 0.92 Hz, 1H), 7.28 (ddd,J=8.36, 7.21, 1.37 Hz, 1H), 7.37 (dd, J=7.33, 0.92 Hz, 1H), 8.59 (d,J=7.78 Hz, 1H), 8.65-8.71 (m, 1H), 9.02 (t, J=5.95 Hz, 1H); m/z(ES+APCI)⁺: (MH+) 411.2.

Example 267-(2,3-Dihydrobenzofuran-7-ylamino)-N-[3-(dimethylamino)propyl]thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 19 from Intermediate 4 (70 mg, 0.23mmol) and 2,3-dihydrobenzofuran-7-amine (91 mg, 0.65 mmol) to give ayellow solid (25 mg, 27%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.71 (quin,J=6.98 Hz, 2H), 2.11-2.21 (m, 6H), 2.31 (t, J=6.87 Hz, 2H), 3.28 (t,J=8.93 Hz, 2H), 3.39 (q, J=6.87 Hz, 2H), 4.62 (t, J=8.70 Hz, 2H),6.85-6.95 (m, 1H), 7.10 (dd, J=7.33, 0.92 Hz, 1H), 7.88 (d, J=8.24 Hz,1H), 8.60 (s, 1H), 8.82 (br. s., 1H), 9.14 (t, J=5.50 Hz, 1H); m/z(ES+APCI)⁺: (MH+) 399.

Example 27N-[3-(Dimethylamino)propyl]-7-indolin-1-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 19 from Intermediate 4 (60 mg, 0.19mmol) and indoline (65 μl, 0.57 mmol) to give an off-white solid (35 mg,48%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.58-1.79 (m, 2H), 2.16 (s, 6H),2.26-2.36 (m, 2H), 3.30-3.43 (m, 4H), 4.82-4.94 (m, 2H), 7.03-7.13 (m,1H), 7.23-7.31 (m, 1H), 7.36 (d, J=7.33 Hz, 1H), 8.62-8.70 (m, 2H), 9.15(t, J=5.95 Hz, 1H). m/z (ES+APCI)⁺: (MH+) 383.

Example 28N-(azetidin-3-yl)-7-{[4-fluoro-2-(propan-2-yloxy)phenyl]amino}[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Step 1:

Tert-butyl3-{[(7-{[4-fluoro-2-(propan-2-yloxy)phenyl]amino}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)carbonyl]amino}azetidine-1-carboxylate

A mixture of Example 1 (400 mg, 1.15 mmol), 3-amino-1-N-Boc-azetidine(197 mg, 1.15 mmol) and DIPEA (1.0 ml, 5.75 mmol) in DMF (10 ml) wasstirred at rt for 10 minutes. HATU (611 mg, 1.61 mmol) was added and themixture was stirred at rt overnight. The reaction mixture was thendiluted with EtOAc and water. The organic phase was washed with water(×3) and brine (×1), dried and concentrated. The crude product waspurified by flash column chromatography on silica gel eluting with 1:1petrol:EtOAc to give a yellow solid (280 mg, 49%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.29 (d, J=5.95 Hz, 6H), 1.39 (s, 9H), 3.90-4.01 (m, 2H),4.09-4.21 (m, 2H), 4.63-4.77 (m, 2H), 6.85 (td, J=8.47, 2.75 Hz, 1H),7.12 (dd, J=10.99, 2.75 Hz, 1H), 8.10 (dd, J=8.70, 6.41 Hz, 1H), 8.59(s, 1H), 9.01 (s, 1H), 9.54 (d, J=7.78 Hz, 1H). m/z (ES+APCI)⁺: 503[M+H]⁺

Step 2:

Tert-butyl3-{[(7-{[4-fluoro-2-(propan-2-yloxy)phenyl]amino}[1,3]thiazolo[5,4-d]pyrimidin-2-yl)carbon-yl]amino}azetidine-1-carboxylate(278 mg, 0.554 mmol) in 3:1 DCM:TFA (20 ml) was stirred at rt for 2hours. The reaction was concentrated to dryness. Toluene was added tothe residue and the mixture was concentrated to dryness again. Theresidue was dissolved in MeOH and the solution was passed through a SCXcartridge. The product was eluted with 2 M NH₃ in MeOH. The eluent wasconcentrated and the residue was purified by flash column chromatographyon silica gel eluting with 20:1 DCM:2 M NH₃ in MeOH to give a yellowsolid (176 mg, 79%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28 (d, J=5.95 Hz,6H), 3.52-3.72 (m, 4H), 4.62-4.82 (m, 2H), 6.85 (td, J=8.70, 2.75 Hz,1H), 7.12 (dd, J=10.99, 2.75 Hz, 1H), 8.04 (dd, J=8.93, 6.64 Hz, 1H),8.57 (s, 1H), 9.21 (br. s., 1H). m/z (ES+APCI)⁺: 403 [M+H]⁺.

Examples 29-31

Examples 29-31 of the general formula shown below were preparedanalogously to Example 28 by coupling Example 1 to the appropriateN—BOC-protected diamine followed by deprotection.

Example 297-{[4-Fluoro-2-(propan-2-yloxy)phenyl]amino}-N-[3-(methylamino)propyl][1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Amine starting material used: tert-butylN-(3-aminopropyl)-N-methyl-carbamate.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28 (d, J=6.41 Hz, 6H), 1.71 (quin,J=6.87 Hz, 2H), 2.30 (s, 3H), 2.54-2.62 (m, 2H), 3.40 (t, J=6.87 Hz,3H), 4.60-4.78 (m, 1H), 6.85 (td, J=8.70, 2.75 Hz, 1H), 7.12 (dd,J=10.99, 2.75 Hz, 1H), 8.10 (dd, J=8.93, 6.64 Hz, 1H), 8.57 (s, 1H),8.95 (br. s., 1H); m/z (ES+APCI)⁺: 419 [M+H]⁺.

Example 307-{[4-Fluoro-2-(propan-2-yloxy)phenyl]amino}-N-[2-(methylamino)ethyl][1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Amine starting material used: tert-butylN-(2-aminoethyl)-N-methyl-carbamate.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.20-1.34 (m, 6H), 2.33 (s, 3H), 2.72(t, J=6.18 Hz, 2H), 3.40-3.54 (m, 2H), 4.61-4.79 (m, 1H), 6.84 (td,J=8.70, 2.75 Hz, 1H), 7.10 (dd, J=10.99, 2.75 Hz, 1H), 8.07 (dd, J=9.16,6.41 Hz, 1H), 8.52-8.62 (m, 2H), 9.13 (br. s., 1H); m/z (ES+APCI)⁺: 405[M+H]⁺.

Example 317-{[4-Fluoro-2-(propan-2-yloxy)phenyl]amino}-N-(piperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Amine starting material used: tert-butyl4-aminopiperidine-1-carboxylate.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.18-1.32 (m, 6H), 1.38-1.55 (m, 2H),1.80 (d, J=9.16 Hz, 2H), 2.52-2.60 (m, 2H), 2.90-3.01 (m, 2H), 3.16 (br.s., 1H), 3.76-3.93 (m, 1H), 4.70 (spt, J=6.03 Hz, 1H), 6.84 (td, J=8.70,2.75 Hz, 1H), 7.11 (dd, J=10.99, 2.75 Hz, 1H), 7.96-8.04 (m, 1H), 8.46(br. s., 1H), 8.56 (s, 1H), 9.19 (br. s., 1H); m/z (ES+APCI)⁺: 431[M+H]⁺.

Examples 32-39

Examples 32-39 of the general formula shown below were preparedanalogously to Example 3 by amide coupling of Example 1 with theappropriate amine.

HPLC retention Example X IUPAC name [M + H]⁺ time (method)* 32

7-{[4-fluoro-2-(propan-2- yloxy)phenyl]amino}-N-(1- methylpiperidin-4-yl)[1,3]thiazolo[5,4- d]pyrimidine-2- carboxamide 445 1.88 mins (A) 33

7-{[4-fluoro-2-(propan-2- yloxy)phenyl]amino}-N- (tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4- d]pyrimidine-2- carboxamide^(>) 432 1.78 mins (C)34

N-(1,1-dioxidotetrahydro- 2H-thiopyran-4-yl)-7-{[4- fluoro-2-(propan-2-yloxy)phenyl]amino}[1,3] thiazolo[5,4-d]pyrimidine-2- carboxamide 4801.64 mins (C) 35

{4-[(dimethylamino) methyl]piperidin-1-yl}(7-{[4- fluoro-2-(propan-2-yloxy)phenyl]amino}[1,3] thiazolo[5,4-d]pyrimidin-2- yl)methanone 4732.01 mins (D) 36

7-{[4-fluoro-2-(propan-2- yloxy)phenyl]amino}-N-[(1- methylpiperidin-4-yl)methyl][1,3]thiazolo[5,4- d]pyrimidine-2- carboxamide 459 2.33 mins(B) 37

7-{[4-fluoro-2-(propan-2- yloxy)phenyl]amino}-N-[2-(1-methylpiperidin-4- yl)ethyl][1,3]thiazolo[5,4- d]pyrimidine-2-carboxamide 473 2.37 mins (B) 38

7-{[4-fluoro-2-(propan-2- yloxy)phenyl]amino}-N- (tetrahydro-2H-pyran-4-ylmethyl)[1,3]thiazolo[5,4- d]pyrimidine-2- carboxamide 446  .84 mins(D) 39

N-[2-(dimethylamino)ethyl]- 7-{[4-fluoro-2-(propan-2-yloxy)phenyl]amino}[1,3] thiazolo[5,4-d]pyrimidine-2- carboxamide 4191.78 mins (D) *Agilent 6120 quadrupole LC-MS with Xbridge C18 column(3.5 μm particle size and 4.6 × 30 mm) and a diode array UV detector.Flow rate 3 ml/min; Method A pH 1; Run time: 3.2 min: Solvent A: 0.1%Trifluoro Acetic acid in water, Solvent B: Methanol; Gradient - 10-100%Methanol; Gradient time: 2.35 min. Method B pH 10; Run time: 3.2 min:Solvent A: 0.1% Ammonium Hydroxide in water, Solvent B: Methanol;Gradient - 10-100% Methanol; Gradient time: 2.35 min. Method C pH 1; Runtime: 3.2 min: Solvent A: 0.1% Trifluoro Acetic acid in water, SolventB: Acetonitrile; Gradient - 10-100% Acetonitrile; Gradient time: 2.35min. Method D pH 10; Run time: 3.2 min: Solvent A: 0.1% AmmoniumHydroxide in water, Solvent B: Acetonitrile; Gradient - 10-100%Acetonitrile; Gradient time: 2.35 min.

Example 407-(1′-Methylspiro[indole-3,4′-piperidin]-1(2H)-yl)-N-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

A mixture of Intermediate 18 (78 mg, 0.262 mmol) and1′-methyl-1,2-dihydrospiro-[indole-3,4′-piperidine] (53 mg, 0.262 mmol)in IPA (3 ml) was stirred and heated at 80° C. for 4 hours. The mixturewas allowed to cool to rt, diluted with MeOH and the resulting solutionwas passed through a SCX cartridge. The product was eluted with 2 M NH₃in MeOH and the eluent was concentrated. The residue was purified byflash column chromatography on silica gel eluting with 50:1 to 25:1DCM:2 M NH₃ in MeOH. Recrystallization of the chromatographed materialfrom EtOAc gave a pale yellow solid (10 mg, 8%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.61-1.77 (m, 4H), 1.82-2.03 (m, 4H), 2.07-2.28 (m, 5H),2.75-2.87 (m, 2H), 3.46 (td, J=11.33, 2.06 Hz, 2H), 3.85-3.95 (m, 2H),4.00-4.15 (m, 1H), 4.79 (s, 2H), 7.09-7.17 (m, 1H), 7.27-7.35 (m, 1H),7.38 (d, J=7.33 Hz, 1H), 8.55 (d, J=8.24 Hz, 1H), 8.62-8.74 (m, 2H). m/z(ES+APCI)⁺: 465 [M+H]⁺.

Example 417-(Spiro[cyclopentane-1,3′-indol]-1′(2′H)-yl)-N-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 41 was prepared in analogous fashion to Example 40. The productwas isolated by filtration of the reaction mixture to provide a yellowsolid which required no further purification (yield 70%). ¹H NMR (400MHz, DMSO-d₆) δ ppm 1.59-2.07 (m, 12 H), 3.43 (td, J=11.45, 2.29 Hz,2H), 3.84-4.12 (m, 4H), 4.70 (s, 2H), 7.13 (td, J=7.33, 0.92 Hz, 1H),7.25-7.32 (m, 1H), 7.37 (dd, J=7.33, 0.92 Hz, 1H), 8.61 (dd, J=11.22,8.01 Hz, 2H), 8.69 (s, 1H). m/z (ES+APCI)⁺: 436 [M+H]⁺.

Example 427-(5-cyano-2,3-dihydro-1H-indol-1-yl)-N-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 42 was prepared in analogous fashion to Example 40. The productwas isolated by filtration of the reaction mixture to provide anoff-white solid which required no further purification (yield 68%). ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.69-1.88 (m, 4H), 3.31-3.46 (m, 4H),3.87-3.97 (m, 2H), 4.01-4.18 (m, 1H), 4.95 (t, J=8.70 Hz, 2H), 7.69-7.81(m, 2H), 8.70-8.86 (m, 3H). m/z (ES+APCI)⁺: 407 [M+H]⁺.

Example 437-(2,3-Dihydro-1H-pyrrolo[3,2-c]pyridin-1-yl)-N-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

A mixture of Intermediate 18 (100 mg, 0.334 mmol),2,3-dihydro-1H-pyrrolo[3,2-c]pyridine (52 mg, 0.435 mmol), binap (10.4mg, 0.017 mmol), sodium t-butoxide (96 mg, 1.00 mmol) and palladium (II)acetate (3.7 mg, 0.017 mmol) in toluene (2 ml) was degassed, placedunder nitrogen and stirred and heated at 100° C. overnight. The reactionwas then concentrated to dryness. The residue was diluted with EtOAc andwater. The organic phase was washed with water and brine. The aqueousphase was re-extracted with DCM. The organic extracts were combined,dried and concentrated. The crude product was purified by flash columnchromatography on silica gel eluting with 20:1 DCM:MeOH to give a yellowsolid (34 mg, 27%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.71-1.88 (m, 4H),3.34-3.48 (m, 4H), 3.87-3.97 (m, 2H), 4.02-4.18 (m, 1H), 4.89-4.99 (m,2H), 8.41 (d, J=5.50 Hz, 1H), 8.46-8.51 (m, 2H), 8.74-8.86 (m, 2H); m/z(ES+APCI)⁺: 383 [M+H]⁺.

Example 447-(2,3-Dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)-N-(tetrahydro-2H-pyran-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 44 was prepared in analogous fashion to Example 43. The crudeproduct was dissolved in MeOH/DCM and passed through a SCX cartridgeeluting the product with 2M NH₃ in methanol. The eluent was concentratedto dryness and the residue was triturated with Et₂O to give anorange/brown coloured solid (yield 27%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.68-1.92 (m, 4H), 3.34-3.51 (m, 4H), 3.84-3.99 (m, 2H), 4.00-4.19 (m,1H), 4.94 (t, J=8.47 Hz, 2H), 7.27 (dd, J=8.01, 4.81 Hz, 1H), 8.19 (dd,J=4.81, 1.14 Hz, 1H), 8.71 (s, 1H), 8.76-8.90 (m, 2H); m/z (ES+APCI)⁺:383 [M+H]⁺.

Example 45N-(1-methylpiperidin-4-yl)-7-(5-nitro-2,3-dihydro-1H-indol-1-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 78 (320 mg, 0.933 mmol) in thionyl chloride (4 ml) washeated under reflux for 3 hours. The reaction mixture was thenconcentrated to dryness. The crude acid chloride was dissolved in DCM (8ml) and TEA (0.919 ml, 2.80 mmol) was added. A solution of1-methylpiperidine-4-amine (160 mg, 1.40 mmol) in DCM (2 ml) was addeddropwise with ice-cooling. The mixture was allowed to warm to rt andstirred overnight. The mixture was diluted with DCM and water and theorganic phase was dried and concentrated. The crude product waspre-absorbed onto silica gel prior to purification by flash columnchromatography on silica gel eluting with 20:1 DCM:2 M NH₃ in methanolto give a yellow solid (268 mg, 65%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.73-1.86 (m, 4H), 1.96 (br. s., 2H), 2.19 (s, 3H), 2.76-2.90 (m, 2H),3.38-3.50 (m, 2H), 3.74-3.86 (m, 1H), 5.02 (t, J=8.70 Hz, 2H), 8.19-8.26(m, 2H), 8.73-8.86 (m, 3H); m/z (ES+APCI)⁺: 440 [M+H]⁺.

Example 467-[5-(Acetylamino)-2,3-dihydro-1H-indol-1-yl]-N-(1-methylpiperidin-4-yl)[1,3]thiazolo[5,4-d]pyrimidine-2-carboxamide

Acetyl chloride (16 μl, 0.216 mmol) was added to a mixture ofIntermediate 79 (59 mg, 0.144 mmol) and TEA (40 μl, 0.289 mmol) in DCM(4 ml). The reaction mixture was stirred for 4 hours at rt and was thenconcentrated to dryness. The residue was pre-absorbed onto silica gelprior to purification by flash column chromatography on silica geleluting with 10:1 DCM:2M NH₃ in methanol to give a yellow solid. Thechromatographed solid was further purified by trituration with EtOAc togive a yellow solid (30 mg, 46%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.71-1.93 (m, 4H), 1.97-2.42 (m, 8H), 2.78-3.05 (m, 2H), 3.25-3.42 (m,2H), 3.75-3.97 (m, 1H), 4.89 (t, J=8.24 Hz, 2H), 7.34 (d, J=8.70 Hz,1H), 7.74 (s, 1H), 8.51-8.66 (m, 2H), 8.76 (d, J=8.24 Hz, 1H), 9.99 (s,1H); m/z (ES+APCI)⁺: 452 [M+H]⁺.

Example 47N-[4-fluoro-2-(propan-2-yloxy)phenyl][1,3]thiazolo[5,4-d]pyrimidin-7-amine

A mixture of 7-chlorothiazole[5,4-d]pyrimidine (50 mg, 0.292 mmol),toluene-4-sulfonic acid (6 mg, 0.032 mmol), 4-fluoroisopropoxyaniline(49 mg, 0.290 mmol) and IPA (2 ml) were sealed in a microwave reactorvial and irradiated at 170° C. for 15 minutes in the Biotage I-60microwave reactor. The reaction mixture was concentrated and the residuetaken up in 20% MeOH in DCM and passed through an aminopropyl cartridge.The product was recovered by washing through with 20% MeOH in DCM. Thesolution was concentrated and the crude product purified by flash columnchromatography eluting with 10-20% EtOAc in petroleum ether to give apale pink solid (52 mg, 58%). ¹H NMR (400 MHz, CHLOROFORM-d) δ 1.44 (d,J=5.95 Hz, 6H), 4.56-4.64 (m, 1H), 6.69-6.77 (m, 2H), 8.58-8.62 (m, 1H),8.64-8.65 (m, 1H), 8.67-8.72 (m, 1H), 8.88 (s, 1H); m/z (ES+APCI)⁺: 304[M+H]⁺.

Example 48[7-(4-Fluoro-2-isopropoxy-anilino)thiazolo[5,4-d]pyrimidin-2-yl]methanol

To a solution of Intermediate 1 (50 mg, 0.13 mmol) in THF (10 ml) wasadded a 1M solution of lithium aluminium hydride (0.26 ml, 0.26 mmol)dropwise and stirred for 2 hours. Water (10 μL) was carefully addedfollowed by 10 μL of 15% NaOH_((aq)) and finally 0.5 ml of water. DCMwas added, the organic layer separated, dried and concentrated ontosilica. The compound was purified via column chromatography (gradientelution from 10-50% EtOAc in Pet. Ether) to give a light yellow solid(18 mg, 41%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.44 (d, J=6.00 Hz,6H), 4.61 (spt, J=6.03 Hz, 1H), 5.09 (s, 2H), 6.67-6.79 (m, 2H), 8.49(s, 1H), 8.62 (s, 1H), 8.66 (dd, J=8.93, 6.18 Hz, 1H); LC-MS (ESI):(MH⁺) 335.1.

Example 49N-(4-piperidylmethyl)-7-[4-[[3-(trifluoromethyl)phenyl]carbamoylamino]anilino]thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution of Intermediate 3 (75 mg, 0.18 mmol) in DCM (10 ml) wasadded m-CPBA (79 mg, 0.36 mmol) and the mixture was stirred for 2 hours.1-(4-aminophenyl)-3-[3-(trifluoromethyl)-phenyl]urea (52 mg, 0.18 mmol)in dioxane (5 ml) was added and heated at 60° C. overnight. The mixturewas cooled, DCM and water was added, the organic layer, separated, driedand concentrated onto silica. The compound was purified via columnchromatography (gradient elution from 30-100% EtOAc in Pet. Ether) togive a yellow solid. The solid was taken up in DCM (5 ml), TFA (0.75 ml)added and stirred for 15 mins. The mixture was concentrated and purifiedby HPLC to give a yellow solid; ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.08-1.22 (m, 2H), 1.62-1.76 (m, 2H), 1.73 (s, 1H), 2.51-2.60 (m, 2H),3.01 (d, J=11.5 Hz, 2H), 3.25 (t, J=6.2 Hz, 2H), 7.29 (d, J=7.8 Hz, 1H),7.45-7.54 (m, 3H), 7.55-7.62 (m, 1H), 7.78 (d, J=8.7 Hz, 2H), 8.04 (s,1H), 8.57 (s, 1H), 8.66 (br. t, 1H), 9.01 (br. s., 1H), 9.23 (br. s.,1H), 9.84 (br. s., 1H); LC-MS (ESI): (MH⁺) 571.1.

Example 507-(1H-indazol-5-ylamino)-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 50 was prepared analogously to Example 49 from Intermediate 3and 5-aminoindazole.

¹H NMR (400 MHz, MeOD) δ ppm 1.25-1.39 (m, 2H) 1.79-1.93 (m, 3H) 2.68(td, J=12.48, 2.52 Hz, 2H) 3.09-3.19 (m, 2H) 3.38 (d, J=6.41 Hz, 2H)7.57-7.63 (m, 1H) 7.66-7.73 (m, 1H) 8.08 (d, J=0.92 Hz, 1H) 8.28 (d,J=1.83 Hz, 1H) 8.51 (s, 1H); LC-MS (ESI): (MH⁺) 409.2.

Examples 51-54

To a solution of Intermediate 3 (400 mg, 0.90 mmol) in DCM (20 ml) wasadded m-CPBA (317 mg, 1.8 mmol) and the resulting mixture was stirredfor 2.5 hours and then concentrated under reduced pressure. The residuewas dissolved in 1,4-dioxane (16 ml) divided into four equal portionsheated to 90° C. in sealed tubes in the presence of the appropriateamine (0.45 mmol) overnight. The solvent was evaporated and the residuewas suspended in 4M HCl in dioxane (4 ml) and stirred at roomtemperature for 3 h. The solvent was concentrated under reduced pressureand the residues were purified by preparative LCMS to give the desiredcompounds.

LC-MS (ESI): Example # R IUPAC Name (MH⁺) ¹H NMR 51

7-[2-(cyclopentoxy)-4- fluoro-anilino]-N-(4- piperidylmethyl)thiazolo[5,4-d] pyrimidine-2- 471 ¹H NMR (400 MHz, DMSO- d₆) δ ppm0.99-1.13 (m, 2 H), 1.45-1.78 (m, 9 H), 1.80-1.92 (m, 2 H), 2.36- 2.45(m, 2 H), 2.85-3.01 carboxamide (m, 2 H), 3.14-3.19 (m, 1 H), 3.22 (t, J= 6.41 Hz, 2 H), 4.10 (d, J = 4.58 Hz, 1 H), 4.84-5.07 (m, 1 H), 6.85(td, J = 8.70, 2.75 Hz, 1 H), 7.07 (dd, J = 10.99, 2.75 Hz, 1 H),7.96-8.17 (m, 1 H), 8.44-8.67 (m, 2 H), 9.10 (br. s., 1 H) 52

7-[4-fluoro-2-[2- fluoro-1-(fluoromethyl) ethoxy]anilino]-N-(4-piperidylmethyl) thiazolo[5,4- d]pyrimidine-2- carboxamide 481 ¹H NMR(400 MHz, DMSO- d₆) δ ppm 1.01-1.16 (m, 2 H), 1.63 (d, J = 12.82 Hz, 3H), 2.44 (t, J = 11.45 Hz, 2 H), 2.94 (d, J = 11.91 Hz, 2 H), 3.15-3.28(m, 3 H), 4.58-4.81 (m, 4 H), 4.95- 5.14 (m, 1 H), 6.95 (td, J = 8.70,2.75 Hz, 1 H), 7.29 (dd, J = 10.99, 2.75 Hz, 1 H), 8.08 (dd, J = 9.16,6.41 Hz, 1H), 8.57 (s, 1 H), 8.63 (br. s., 1 H), 9.10 (s, 1 H) 53

7-(2-ethoxy-4-fluoro- anilino)-4-(4- piperidylmethyl) 431 ¹H NMR (400MHz, DMSO- d₆) δ ppm 0.99-1.14 (m, 2 H), 1.31 (t, J = 6.87 Hz, 3 H),1.53- thiazolo[5,4-d] 1.75 (m, 3 H), 2.41 (td, J = 12.02, pyrimidine-2-2.06 Hz, 2 H), 2.92 (d, J = 11.91 carboxamide Hz, 2 H), 3.11-3.27 (m, 3H), 4.15 (q, J = 7.02 Hz, 2 H), 6.86 (td, J = 8.70, 2.75 Hz, 1 H),7.02-7.15 (m, 1 H), 8.06 (dd, J = 8.70, 6.41 Hz, 1 H), 8.57 (s, 1 H),8.72 (br. s., 1 H), 9.06 (br. s., 1 H) 54

7-[4-fluoro-2-[(3S)- tetrahydrofuran-3-yl]oxy- anilino]-N-(4-piperidylmethyl) thiazolo[5,4- 473 ¹H NMR (400 MHz, DMSO- d₆) δ ppm0.98-1.15 (m. 2 H), 1.54-1.72 (m, 3H), 1.93-2.05 (m, 1 H), 2.13- 2.29(m, 1 H), 2.34-2.46 d]pyrimidine-2- (m, 2H), 2.93 (d, J = 12.36carboxamide Hz, 2 H), 3.17 (d, J = 2.75 Hz, 1 H), 3.22 (t, J = 6.18 Hz,2 H), 3.64-3.90 (m, 4 H), 5.11-5.20 (m, 1 H), 6.89 (td, J = 8.70. 2.75Hz, 1 H), 7.11 (dd, J = 10.53, 2.75 Hz, 1 H), 8.06 (dd, J = 8.70, 6.41Hz, 1 H), 8.57 (s, 1 H), 8.65 (br. s., 1 H), 9.14 (br. s., 1 H)

Example 557-[(2-Isopropoxy-3-pyridyl)amino]-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Examples 51-54. ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.02-1.16 (m, 2H), 1.32 (d, J=6.41 Hz, 6H), 1.58-1.72 (m, 3H), 2.38-2.48(m, 2H), 2.89-2.98 (m, 2H), 3.20-3.27 (m, 2H), 5.33 (quin, J=6.18 Hz,1H), 7.02-7.10 (m, 1H), 7.94-8.00 (m, 1H), 8.50 (dd, J=7.79, 1.37 Hz,1H), 8.65 (s, 1H), 8.71-8.81 (m, 1H); LC-MS (ESI): (MH⁺) 428.

Examples 56-63 Prepared Analogously to Example 51 Using the AppropriateAmine

LCMS LC-MS retention time (ESI): Example # R IUPAC Name (Method) (MH⁺)56

7-(7-fluoro-2,3-dihydro-1,4- benzoxazin-4-yl)-N-(4-piperidylmethyl)thiazolo[5,4- d]pyrimidine-2-carboxamide 1.61 (D) 429 57

7-(6-fluoro-4-methyl-2,3- dihydroquinoxalin-1-yl)-N-(4-piperidylmethyl)thiazolo[5,4- d]pyrimidine-2-carboxamide 1.88 (D) 442 58

7-(5-fluoroindolin-1-yl)-N-(4- piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide 2.2  (D) 413 59

7-[4-fluoro-2- (trifluoromethoxy)anilino]-N-(4-piperidylmethyl)thiazolo[5,4- d]pyrimidine-2-carboxamide 1.73 (D) 471 60

7-[4-fluoro-2-[(1R,3S)-3- methoxycyclohexoxy]anilino]-N-(4-piperidylmethyl)thiazolo[5,4- d]pyrimidine-2-carboxamide 2.06 (D) 515 61

7-[4-fluoro-2-[(1S,3R)-3- methoxycyclohexoxy]anilino]-N-(4-piperidylmethyl)thiazolo[5,4- d]pyrimidine-2-carboxamide 2.06 (D) 515 62

7-[2-(2-furyl)anilino]-N-(4- piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide 1.85 (D) 435 63

7-(5-methoxyindolin-1-yl)-N-(4- piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide 2.57 (B) 425 *Agilent 6120 quadrupole LC-MSwith Xbridge C18 column (3.5 μm particle size and 4.6 × 30 mm) and adiode array UV detector. Flow rate 3 ml/min; Method A pH 1; Run time:3.2 min: Solvent A: 0.1% Trifluoro Acetic acid in water, Solvent B:Methanol; Gradient - 10-100% Methanol; Gradient time: 2.35 min. Method BpH 10; Run time: 3.2 min: Solvent A: 0.1% Ammonium Hydroxide in water,Solvent B: Methanol; Gradient - 10-100% Methanol; Gradient time: 2.35min. Method C pH 1; Run time: 3.2 min: Solvent A: 0.1% Trifluoro Aceticacid in water, Solvent B: Acetonitrile; Gradient - 10-100% Acetonitrile;Gradient time: 2.35 min. Method D pH 10; Run time: 3.2 min: Solvent A:0.1% Ammonium Hydroxide in water, Solvent B: Acetonitrile; Gradient -10-100% Acetonitrile; Gradient time: 2.35 min.

Example 64N-[3-(dimethylamino)propyl]-7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 8 (50 mg, 0.16 mmol) and thionyl chloride (2 ml) wereheated at reflux for 4 hours. The mixture was cooled and concentrated togive an orange solid, which was taken up in DCM (3 ml). Triethylamine(65 μL, 2.3 mmol) was added followed by N,N-Dimethylaminopropylamine (24mg, 0.32 mmol) and the resulting mixture was stirred overnight. Themixture was concentrated and purified by HPLC to give the product (7.5mg, 6%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.68 (quin, J=7.3 Hz, 2H), 2.13(s, 6H), 2.28 (t, J=6.9 Hz, 2H), 3.30-3.39 (m, 4H), 4.87 (t, J=8.2 Hz,2H), 7.07 (td, J=9.7, 2.8 Hz, 1H), 7.19 (dd, J=8.2, 2.8 Hz, 1H),8.60-8.66 (m, 2H), 9.11 (t, J=5.7 Hz, 1H); LC-MS (ESI): (MH⁺) 401.1.

Examples 65-80 in the table below were prepared analogously to Example64 from Intermediate 8 and the appropriate, optionally BOC protected,amine.

LC-MS Example (ESI): # R IUPAC Name (MH⁺) ¹H NMR 65

[7-(5-fluoroindolin-1- yl)thiazolo[5,4- d]pyrimidin-2-yl]-(4-methylpiperazin-1- yl)methanone 399.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm2.20 (s, 3 H), 2.42 (br. s., 4 H), 3.23-3.28 (m, 2 H), 3.67 (br. s., 2H), 4.20 (br. s., 2 H), 4.71 (t, J = 8.47 Hz, 2 H), 7.06 (td, J = 9.16,2.75 Hz, 1 H), 7.19 (dd, J = 8.24, 2.75 Hz, 1 H), 8.57 (dd, J = 8.93,4.81 Hz, 1 H), 8.64 (s, 1 H) 66

7-(5-fluoroindolin-1-yl)-N- tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 400.1 ¹H NMR (400 MHz, DMSO-d₆)δ ppm 1.66- 1.80 (m, 4 H), 3.31- 3.42 (m, 4 H), 3.78- 3.91 (m, 2 H),3.98- 4.13 (m, 1 H), 4.83- 4.97 (m, 2 H), 7.07 (td, J = 8.93, 2.75 Hz, 1H), 7.20 (dd, J = 8.47, 2.98 Hz, 1 H), 8.59-8.67 (m, 2 H), 8.72 (d, J =8.70 Hz, 1 H) 67

7-(5-fluoroindolin-1-yl)-N- (1-methyl-4- piperidyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 413.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.70-1.78 (m, 4 H), 1.87- 1.96 (m, 2 H), 2.14 (s, 3 H), 2.77 (d, J = 11.45Hz, 2 H), 3.31-3.34 (m, 2 H), 3.70-3.82 (m, 1 H), 4.89 (t, J = 7.80 Hz,2 H), 7.02-7.10 (m, 1 H), 7.17-7.23 (m, 1 H), 8.59-8.64 (m, 2 H), 8.67(d, J = 8.24 Hz, 1 H) 68

N-[3- (dimethylamino)propyl]- 7-(5-fluoroindolin-1- yl)thiazolo[5,4-d]pyrimidine-2- carboxamide 427.1 H NMR (400 MHz, CHLOROFORM-d) δ ppm1.72-1.82 (m, 3 H) 1.87 (quin, J = 6.53 Hz, 2 H) 2.49-2.60 (m, 4 H) 2.64(t, J = 6.64 Hz, 2 H) 3.33 (t, J = 8.24 Hz, 2 H) 3.63 (q, J = 6.11 Hz, 2H) 4.81-4.95 (m, 2 H) 6.90- 7.04 (m, 2 H) 7.91 (t, J = 5.72 Hz, 1 H)8.56- 8.79 (m, 2 H) 69

7-(5-fluoroindolin-1-yl)-N- methyl-thiazolo[5,4- d]pyrimidine-2-carboxamide 330.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.90 (d, J = 4.58 Hz,3 H) 3.35 (s, 2 H) 4.89-4.96 (m, 2 H) 7.07-7.14 (m, 1 H) 7.20-7.26 (m, 1H) 8.63- 8.70 (m, 2 H) 8.94- 9.00 (m, 1 H) 70

7-(5-fluoroindolin-1-yl)- N,N-dimethyl- thiazolo[5,4-d]pyrimidine-2-carboxamide 344.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.66 (s, 1 H), 8.62(dd, J = 9.16, 5.04 Hz, 1 H), 7.22 (dd, J = 8.70, 2.75 Hz, 1 H), 7.08(dd, J = 9.16, 3.21 Hz, 1 H), 4.78 (m, 2 H), 3.55 (s, 3 H), 3.29 (m, 2H), 3.11 (s, 3 H) 71

7-(5-fluoroindolin-1-yl)-N- [2- (methylamino)ethyl] thiazolo[5,4-d]pyrimidine-2- carboxamide 373.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.91 (m,NH), 8.63 (m, 2 H), 7.19 (dd, J = 8.24, 2.75 Hz, 1 H), 7.07 (td, J =9.20, 2.00 Hz, 1 H), 4.88 (t, J = 8.47 Hz, 2 H), 3.30 (m, 4 H), 2.66 (t,J = 6.64 Hz, 2 H), 2.28 (s, 3 H) 72

7-(5-fluoroindolin-1-yl)-N- [3- (methylamino)propyl] thiazolo[5,4-d]pyrimidine-2- carboxamide 387.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.32 (m,NH), 8.67 (m, 2 H), 7.23 (dd, J = 8.47, 2.98 Hz, 1 H), 7.10 (td, J =9.16, 2.75 Hz, 1 H), 4.91 (t, J = 8.47 Hz, 2 H), 3.40 (dt, J = 7.33,1.00 Hz, 3 H), 3.34 (m, 2 H), 2.57 (t, J = 6.87 Hz, 2 H), 2.29 (s, 3 H),1.71 (quin, J = 6.60 Hz, 2 H) 73

N-[2- (dimethylamino)ethyl]-7- (5-fluoroindolin-1- yl)thiazolo[5,4-d]pyrimidine-2- carboxamide 387.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.52-2.65 (m, 6 H) 2.84-3.06 (m, 2 H) 3.37 (m, 2 H) 3.59 (q, J = 6.11 Hz, 2H) 4.87-4.95 (m, 2 H) 7.07- 7.15 (m, 1 H) 7.20- 7.27 (m, 1 H) 8.63- 8.71(m, 2 H) 9.00-9.08 (m, 1 H) 74

7-(5-fluoroindolin-1-yl)-N- (2-pyrrolidin-1- ylethyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 413.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.04(d, J = 6.00 Hz, NH), 8.67 (m, 2 H), 7.24 (dd, J = 8.70, 2.75 Hz, 1 H),7.11 (td, J = 9.04, 2.98 Hz, 1 H), 4.91 (t, J = 8.47 Hz, 2 H), 3.59 (q,J = 6.11 Hz, 2 H), 3.37 (m, 2 H), 2.94 (br. s., 2 H), 2.56 (br. s, 6 H)75

7-(5-fluoroindolin-1-yl)-N- (3-pyrazol-1- ylpropyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 424.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.06(t, J = 6.18 Hz, NH), 8.67 (m, 2 H), 7.78 (m, 1 H), 7.46 (dd, J = 1.83,0.92 Hz, 1 H), 7.23 (dd, J = 8.24, 2.75 Hz, 1 H), 7.11 (td, J = 9.16,2.75 Hz, 1 H), 6.24 (d, J = 2.29 Hz, 1 H), 4.92 (t, J = 8.20 Hz, 2 H),4.20 (t, J = 6.87 Hz, 2 H), 3.36 (m, J = 3.70 Hz, 2 H), 3.33 (m, 2 H),2.09 (quin, J = 6.98 Hz, 2 H) 76

7-(5-fluoroindolin-1-yl)-N- (oxetan-3-yl)thiazolo[5,4- d]pyrimidine-2-carboxamide 372.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.56 (d, J = 6.87 Hz,NH), 8.68 (m, 2 H), 7.25 (dd, J = 8.70, 3.21 Hz, 1 H), 7.12 (td, J =9.04, 2.98 Hz, 1 H), 5.11 (sxt, J = 7.14 Hz, 1 H), 4.96 (t, J = 8.70 Hz,2 H), 4.81 (t, J = 6.40 Hz, 2 H), 4.77 (t, J = 6.90 Hz, 2 H), 3.37 (t, J= 8.70 Hz, 2 H) 77

7-(5-fluoroindolin-1-yl)-N- tetrahydrofuran-3-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 386.1 ¹H NMR (400 MHz, DMSO-d₆)δ ppm 8.95 (d, J = 7.33 Hz, NH), 8.63 (m, 2 H), 7.20 (dd, J = 8.70, 2.75Hz, 1 H), 7.07 (td, J = 8.93, 2.75 Hz, 1 H), 4.90 (t, J = 8.70 Hz, 2 H),4.52 (m, 1 H), 3.88 (m, 2 H), 3.69 (m, 2 H), 3.32 (t, J = 8.70 Hz, 2 H),2.19 (m, 1 H), 2.02 (m, 1 H) 78

7-(5-fluoroindolin-1-yl)-N- (4-piperidyl)thiazolo[5,4- d]pyrimidine-2-carboxamide 399.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.67 (d, J = 8.24 Hz,NH), 8.62 (m, 2 H), 7.20 (dd, J = 8.70, 2.75 Hz, 1 H), 7.06 (td, J =9.60, 2.70 Hz, 1 H), 4.88 (t, J = 8.24 Hz, 2 H), 3.85 (m, 1 H), 3.30 (m,2 H), 2.96 (dt, J = 12.36, 3.21 Hz, 2 H), 2.51 (td, J = 13.30, 2.30 Hz,2 H), 1.72 (m, 2 H), 1.58 (qd, J = 10.50, 6.00 Hz, 2 H) 79

7-(5-fluoroindolin-1-yl)-N- (2-piperazin-1- ylethyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 428.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm2.40-2.60 (m, 4 H), 2.61-2.70 (m, 2 H), 2.94 (t, J = 4.58 Hz, 4 H), 3.36(t, J = 8.24 Hz, 2 H), 3.60 (q, J = 5.50 Hz, 2 H), 4.95 (t, J = 8.50 Hz,2 H), 6.94-7.05 (m, 2 H), 7.97 (br. t, J = 4.60, 4.60 Hz, 1 H),8.60-8.75 (m, 2 H) 80

7-(5-fluoroindolin-1-yl)-N- ((tetrahydrofuran-3- yl)methyl)thiazolo[5,4-d]pyrimidine-2-carboxamide 400.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.00(t, J = 6.18 Hz, 1 H), 8.63 (m, 2 H), 7.19 (dd, J = 8.70, 2.75 Hz, 1 H),7.07 (td, J = 9.16, 2.75 Hz, 1 H) 4.88 (t, J = 8.47 Hz, 2 H), 4.02(quin, J = 6.41 Hz 1 H), 3.76 (dd, J = 15.10, 7.10 Hz, 1 H), 3.61 (dd, J= 16.03, 7.03, 1 H), 3.35 (m, 2 H), 3.32 (m, 1 H), 1.77 (m, 4 H)

Example 81[7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl]methanol

To a solution of Intermediate 7 (250 mg, 7.3 mmol) in THF (25 ml) wasadded a 1M solution of lithium aluminium hydride in THF (0.15 ml, 0.15mmol) dropwise and stirred for 2.5 hours. To the mixture was carefullyadded 0.15 ml of water, followed by 0.15 ml of 15% NaOH_((aq)) andfinally 3 ml of water. The mixture was filtered to remove the solids.The filtrate diluted with EtOAc and water, the organic layer separated,dried and concentrated to give a yellow solid. This was triturated withminimal EtOAc to give a yellow solid (60 mg, 27%); ¹H NMR (400 MHz,DMSO-d₆) δ ppm 3.23 (t, J=8.47 Hz, 2H), 4.76 (t, J=8.47 Hz, 2H), 4.82(d, J=5.95 Hz, 2H), 6.37 (t, J=6.00 Hz, 1H), 7.03 (td, J=9.20, 2.80 Hz,1H), 7.16 (dt, J=8.20, 1.40 Hz, 1H), 8.50-8.59 (m, 2H); LC-MS (ESI):(MH⁺) 303.0.

Example 822-[7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl]propan-2-ol

To a solution of Intermediate 7 (250 mg, 7.3 mmol) in THF (5 ml) wasadded a 3M solution of methyl magnesium chloride in THF (0.74 ml, 2.2mmol) drop wise and stirred for 30 minutes. Saturated ammonium chloridewas then added, followed by EtOAc. The organic layer was separated,dried and concentrated to give a yellow solid. This was triturated witha minimal amount of EtOAc and the solid filtered off to give2-[7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl]propan-2-ol, anoff white solid (138 mg, 58%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.57 (s,6H), 3.27 (t, J=8.40 Hz, 2H), 4.80 (t, J=8.50 Hz, 2H), 6.34 (s, 1H),7.05 (td, J=9.16, 2.75 Hz, 1H), 7.14-7.24 (m, 1H), 8.49-8.61 (m, 2H);LC-MS (ESI): (MH⁺) 331.0.

Example 83 7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-amine

To a suspension of Intermediate 10 (100 mg, 0.20 mmol) in MeOH (20 ml)was added NaOMe (110 mg, 2.0 mmol) and the mixture refluxed overnight.The reaction mixture was cooled, a precipitate formed which wascollected and dried via vacuum filtration to give7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-amine, a light pinksolid (36 mg, 46%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.13-3.20 (m, 2H),4.71 (t, J=8.70 Hz, 2H), 6.99 (td, J=9.04, 2.98 Hz, 1H), 7.13 (dd,J=8.47, 2.98 Hz, 1H), 7.72 (s, 2H), 8.30 (s, 1H), 8.34 (dd, J=8.70, 5.04Hz, 1H); LC-MS (ESI): (MH⁺) 288.0.

Example 84N-(7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl)tetrahydrofuran-3-carboxamide

Tetrahydro-3-furoic acid (30 mg, 0.250 mmol) was added to a stirringsuspension of Example 83 (75 mg, 0.248 mmol), HATU (141 mg, 0.366 mol),DIPEA (0.29 mL, 1.57 mmol) and DMF (4 mL) at room temperature. Theresultant suspension was stirred at room temperature for 24 hours togive an orange suspension. The solid was filtered off and the filtratepurified by HPLC to give a yellow solid (12 mg, 13%); ¹H NMR (400 MHz,DMSO-d₆) δ ppm 8.50 (s, 2H), 7.15 (dd, J=9.16, 2.75 Hz, 1H), 7.02 (dd,J=9.16, 2.75 Hz, 1H), 4.80 (t, J=9.16 Hz, 2H), 4.58 (d, J=2.75 Hz, 1H),3.94 (m, 1H), 3.81 (m, 1H), 3.23 (t, J=8.24 Hz, 2H), 2.20 (m, 1H), 1.97(m, 1H), 1.86 (m, 2H), 1.71 (m, 1H); LC-MS (ESI): (MH⁺) 386.0.

Example 85N1-(7-(5-fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl)-N3,N3-dimethylpropane-1,3-diamine

3-Dimethylamino-1-propyl chloride hydrochloride (33 mg, 0.209 mmol) wasadded to a stirring suspension of Intermediate 11 (50 mg, 0.174 mmol)and potassium carbonate (47 mg, 0.348 mmol) in DMF (2 mL) at roomtemperature. The resultant suspension was stirred for 24 hours at 80° C.to give an orange suspension. The solid was filtered off and thefiltrate purified by HPLC to give a yellow solid (15 mg, 24%); ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.27 (m, 3H), 7.08 (dd, J=8.70, 2.75 Hz, 1H),6.95 (d, J=3.21 Hz, 1H), 4.70 (t, J=8.70 Hz, 2H), 3.36 (m, 2H), 3.16 (t,J=8.24 Hz, 2H), 2.28 (t, J=6.87, 2 H), 2.12 (s, 6H), 1.71 (t, J=7.10 Hz,2H); LC-MS (ESI): (MH⁺) 373.2.

Examples 86-88 in the table below were prepared analogously to Example85 from Intermediate 11 and the appropriate amine.

LC-MS (ESI): Example R IUPAC Name (MH⁺) ¹H NMR 86

N-[7-(5-fluoroindolin-1- yl)thiazolo[5,4-]pyrimidin-2-yl]-N′,N′-dimethyl- propane-1,3-diamine 359.2 ¹H NMR (400 MHz,DMSO-d₆) δ ppm 8.43 (t, J = 5.50 Hz, NH), 8.31 (m, 2 H), 7.11 (dd, J =8.70, 2.75 Hz, 1 H), 6.98 (td, J = 9.16, 3.21 Hz, 1 H), 4.71 (t, J =8.70 Hz, 2 H), 3.72 (q, J = 5.95 Hz, 2 H), 3.32 (q, J = 5.50 Hz, 2 H),3.17 (t, J = 9.20 Hz, 2 H), 2.81 (d, J = 5.04 Hz, 6 H) 87

4-[7-(5-fluoroindolin-1- yl)thiazolo[5,4-d]pyrimidin- 2-yl]morpholine358.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.40 (m, 2 H), 6.92 (m, 2 H),4.79 (t, J = 8.70 Hz, 2 H), 3.86 (t, J = 5.04 Hz, 4 H), 3.61 (t, 4 H),3.22 (s, 2 H) 88

7-(5-fluoroindolin-1-yl)-2- (4-methylpiperazin-1-yl)thiazolo[5,4-d]pyrimidine 371.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.40 (m, 2 H), 6.92 (m, 2 H), 4.79 (m, 2 H), 3.64 (m, 4 H), 3.21 (m, 2H), 2.56 (s, 4 H), 2.38 (s, 3 H)

Example 893-((7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropan-1-amine

A 60% dispersion of NaH in mineral oil (6 mg, 0.149 mmol) was added to asolution of 3-dimethylamino-1-propanol (16 mg, 0.157 mmol) in THF (10mL) and left to stir at room temperature for one hour. This was thentreated with Intermediate 11 (50 mg, 0.142 mmol) and stirred overnightat room temperature. A green precipitation was collected and dried viavacuum filtration, which was purified by HPLC. The product was obtainedas a white solid (5 mg, 9%); ¹H NMR (400 MHz, ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.97-2.05 (m, 2H) 2.23-2.27 (m, 6H) 2.45 (t, J=7.10Hz, 2H) 3.18-3.26 (m, 2H) 4.58 (t, J=6.41 Hz, 2H) 4.73-4.79 (m, 2H)6.87-6.96 (m, 2H) 8.41-8.49 (m, 2H); LCMS: (MH⁺) 374.1.

Example 907-(7-Fluoroindolin-1-yl)-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Thionyl chloride (2 ml) was added to Intermediate 14 (75 mg, 0.24 mmol)and heated at 80° C. for 3 hours. The mixture was cooled andconcentrated to give an orange gum. This was taken up in DCM,4-aminotetrahydropyran (48 mg, 0.048 mmol) added and stirred overnight.The mixture was diluted with DCM and water, the organic layer separated,dried and concentrated to give a yellow solid. This was purified viaHPLC purification to give a yellow solid (26 mg, 28%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.55-1.67 (m, 2H), 1.96-2.09 (m, 2H), 3.30 (t,J=7.79 Hz, 2H), 3.56 (td, J=11.56, 2.06 Hz, 2H), 3.94-4.07 (m, 2H),4.12-4.28 (m, 1H), 4.67 (t, J=7.80 Hz, 2H), 6.92-7.05 (m, 2H), 7.06-7.17(m, 2H), 8.68 (s, 1H); LC-MS (ESI): (MH⁺) 400.0.

Example 917-(5-Chloro-7-fluoro-indolin-1-yl)-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 91 was isolated as by product during the formation of Example90. (7.1 mg); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.59-1.70 (m, 2H),2.04 (dd, J=12.59, 2.52 Hz, 2H), 3.29 (t, J=7.79 Hz, 2H), 3.57 (td,J=11.56, 2.06 Hz, 2H), 3.97-4.07 (m, 2H), 4.14-4.28 (m, 1H), 4.69 (t,J=8.01 Hz, 2H), 6.99 (d, J=7.80 Hz, 1H), 7.05 (dd, J=10.08, 1.83 Hz,1H), 7.13 (d, J=1.40 Hz, 1H), 8.69 (s, 1H); LC-MS (ESI): (MH⁺) 434/436.

Examples 92 and 93 in the table below were prepared analogously toExample 90 from Intermediate 14 and the appropriate amine.

LC-MS (ESI): Example # R IUPAC Name (MH⁺) ¹H NMR 92

N-[3- (dimethylamino)propyl]- 7-(7-fluoroindolin-1- yl)thiazolo[5,4-d]pyrimidine-2- carboxamide 401.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.80 (quin, J = 6.18 Hz, 2 H), 2.25 (s, 6 H), 2.47 (t, J = 6.18 Hz, 2H), 3.28 (t, J = 7.80 Hz, 2 H), 3.61 (q, J = 6.40 Hz, 2 H), 4.71 (t, J =7.80 Hz, 2 H), 6.99- 7.08 (m, 1 H), 7.08- 7.13 (m, 2 H), 8.62 (br. t, J= 5.00, 5.00 Hz, 1 H), 8.67 (s, 1 H) 93

7-(7-fluoroindolin-1-yl)-N- [(1-methyl-4- piperidyl)methyl]thiazolo[5,4-d]pyrimidine-2- carboxamide 427.1 ¹H NMR (400 MHz, CHLOROFORM-d) δppm 1.28-1.44 (m, 2 H), 1.55-1.66 (m, 1 H), 1.70-1.79 (m, 2 H), 1.93(td, J = 11.68, 2.29 Hz, 2 H), 2.28 (s, 3 H), 2.88 (m, J = 11.90 Hz, 2H), 3.27 (t, J = 7.80 Hz, 2 H), 3.38 (t, J = 6.64 Hz, 2 H), 4.65 (t, J =7.80 Hz, 2 H), 6.94- 7.02 (m, 1 H), 7.04- 7.13 (m, 2 H), 7.22 (t, J =6.18 Hz, 1 H), 8.67 (s, 1 H)

Example 947-Indolin-1-yl-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Thionyl chloride (5 ml) was added to Intermediate 16 (50 mg, 0.17 mmol)and the suspension heated under reflux for 1 hour. The resultantsolution was concentrated to give a dark orange solid. The acid chloridewas taken up in DCM (2 mL), triethylamine (51 mg, 0.50 mmol) addedfollowed by 4-(aminomethyl)-1-BOC-piperidine. The mixture was stirredroom temperature for 30 minutes. TFA (1 ml) was added to the mixture andstirred for 30 minutes. The mixture was concentrated purified by HPLC.togive a yellow solid (4.7 mg, 8%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.68 (s, 1H), 8.66 (d, J=8.70 Hz, 1H), 7.32 (d, J=7.79 Hz, 2H), 7.24 (t,J=6.41 Hz, 1H), 7.11 (td, J=7.79, 1.83 Hz, 1H), 4.84 (t, J=8.24 Hz, 2H),3.43 (t, J=6.87 Hz, 2H), 3.37 (t, J=8.70 Hz, 2H), 3.14 (dt, J=11.90,4.10 Hz, 2H), 2.64 (td, J=12.36, 2.75 Hz, 2H), 1.85 (m, 1H), 1.78 (m,2H), 1.28 (qd, J=11.91, 3.66 Hz, 2H); LC-MS (ESI): (MH⁺) 395.1.

Examples 95-104

Examples 95-104 in the table below were prepared analogously to Example94 from Intermediate 16 and the appropriate, optionally BOC protected,amine

General procedure: Thionyl chloride (30 ml) was added to Intermediate 16(650 mg, 2.18 mmol) and the suspension heated under reflux for 30 mins.The resultant solution was concentrated to give a dark orange solid. Theacid chloride was taken up in DCM (32 mL) and triethylamine (0.13 mL,0.94 mmol) added. Aliquots were added to 11 reaction vials containing asolution of the desired amine (0.24 mmol) in DCM (0.2 mL). The mixturewas stirred overnight at room temperature.

Work-up for all except Examples 97 and 98: The solid was collected byvacuum filtration and purified by column chromatography or preparativeLCMS.

Work-up for Examples 97 and 98: TFA (1 ml) was added to the mixture andstirred for 30 min. The mixture was concentrated purified by preparativeLCMS.

LC-MS Example (ESI): # x IUPAC Name (MH⁺) ¹H NMR  95

7-(Indolin-1-yl)-N- ((tetrahydrofuran-3- yl)methyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 382.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.00(t, J = 6.40 Hz, NH), 8.63 (m, 2 H), 7.32 (d, J = 7.30 Hz, 1 H), 7.23(t, J = 8.70 Hz, 1 H), 7.05 (t, J = 8.20 Hz, 1 H), 4.86 (t, J = 8.70 Hz,2 H), 3.76 (m, 1 H), 3.61 (m, 1 H), 3.36 (t, J = 6.40 Hz, 2 H), 3.30 (t,J = 7.80 Hz, 2 H), 1.84 (m, 3 H), 1.59 (m, 1 H)  96

(7-indolin-1- ylthiazolo[5,4- d]pyrimidin-2-yl)-(4- methylpiperazin-1-yl)methanone 381.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.68 (s, 1 H),8.64 (d, J = 8.70 Hz, 1 H), 7.29 (m, 2 H), 7.10 (td, J = 6.87, 0.92 Hz,1 H), 4.74 (t, J = 8.24 Hz, 2 H), 4.37 (t, J = 4.58 Hz, 2 H), 3.88 (t, J= 5.04 Hz, 2 H), 3.33 (t, J = 8.24 Hz, 2 H), 2.55 (dt, J = 13.62, 5.09Hz, 4 H), 2.37 (s, 3 H)  97

7-indolin-1-yl-N-[3- (methylamino)propyl] thiazolo[5,4-d]pyrimidine-2-carboxamide 369.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.34 (br. s, NH), 8.68(m, 2 H), 7.37 (d, J = 7.33 Hz, 1 H), 7.28 (t, J = 7.33 Hz, 1 H), 7.10(td, J = 7.78, 0.92 Hz, 1 H), 4.89 (t, J = 8.70 Hz, 2 H), 3.42 (t, J =6.41 Hz, 2 H), 3.34 (m, 2 H), 2.57 (t, J = 6.41 Hz, 2 H), 2.29 (s, 3 H),1.72 (t, J = 6.87 Hz, 2 H)  98

7-indolin-1-yl-N-(4- piperidyl)thiazolo[5,4- d]pyrimidine-2- carboxamide381.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.68 (s, 1 H), 8.65 (d, J =7.78 Hz, 1 H), 7.31 (d, J = 7.78 Hz, 2 H), 7.12 (td, J = 7.33, 1.37 Hz,1 H), 7.01 (d, J = 8.70 Hz, NH), 4.83 (t, J = 8.24 Hz, 2 H), 4.12 (m, 1H), 3.37 (t, J = 8.70 Hz, 2 H), 3.16 (dt, J = 12.82, 3.66 Hz, 2 H), 2.79(td, J = 11.91, 1.83 Hz, 2 H), 2.09 (m, 2 H), 1.54 (qd, J = 13.30, 4.12Hz, 2 H)  99

N-cyclopropyl-7-indolin- 1-yl-thiazolo[5,4- d]pyrimidine-2- carboxamide338.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.00 (m, 1 H), 8.66 (m, 2 H), 7.35(d, J = 6.87 Hz, 1 H), 7.26 (td, J = 7.80, 0.90 Hz, 1 H), 7.09 (td, J =7.33, 0.92 Hz, 1 H), 4.87 (t, J = 8.24 Hz, 2 H), 3.30 (m, 2 H), 2.86 (m,1 H), 0.74 (s, 4 H) 100

7-indolin-1-yl-N-(oxetan- 3-yl)thiazolo[5,4- d]pyrimidine-2- carboxamide354.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.54 (d, J = 6.87 Hz, NH), 8.64(m, 2 H), 7.34 (d, J = 7.33 Hz, 1 H), 7.24 (td, J = 7.79, 1.37 Hz, 1 H),7.07 (td, J = 7.33, 0.92 Hz, 1 H), 5.07 (sxt, J = 7.33 Hz, 1 H), 4.90(t, J = 8.24 Hz, 2 H), 4.76 (t, J = 7.79 Hz, 2 H), 4.73 (t, J = 6.87 Hz,2 H), 3.34 (t, J = 8.70 Hz, 2 H) 101

N-[(1S)-1- (hydroxymethyl)-2- methyl-propyl]-7-indolin-1-yl-thiazolo[5,4- d]pyrimidine-2- carboxamide 384.1 ¹H NMR (400 MHz,DMSO-d₆) δ ppm 8.68 (s, 1 H), 8.65 (d, J = 8.70 Hz, 1 H), 8.33 (d, J =9.62 Hz, NH), 7.35 (d, J = 6.87 Hz, 1 H), 7.27 (t, J = 7.79 Hz, 1 H),7.09 (t, J = 7.78 Hz, 1 H), 4.88 (m, 3 H), 3.79 (m, 1 H), 3.62 (t, J =5.04 Hz, 2 H), 1.98 (m, 1 H), 0.96 (d, J = 6.87 Hz, 3 H), 0.91 (d, J =6.87 Hz, 3 H) 102

(2,2-dimethylmorpholin- 4-yl)-(7-indolin-1- ylthiazolo[5,4-d]pyrimidin-2- yl)methanone 396.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.69(s, 1 H), 8.61 (d, J = 8.70 Hz, 1 H), 7.35 (d, J = 7.79 Hz, 1 H), 7.27(t, J = 7.33 Hz, 1 H), 7.09 (t, J = 7.33 Hz, 1 H), 4.73 (q, J = 7.79 Hz,2 H), 4.24 (dd, J = 5.95, 4.58 Hz, 1 H), 4.19 (s, 1 H), 3.76 (q, J =4.58 Hz, 2 H), 3.56 (s, 1 H), 3.30 (m, 2 H), 1.20 (d, J = 4.58 Hz, 7 H)103

7-indolin-1-yl-N- (tetrahydropyran-4- ylmethyl)thiazoto[5,4-d]pyrimidine-2- carboxamide 396.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 9.05(t, J = 6.41 Hz, NH), 8.67 (m, 2 H), 7.36 (d, J = 7.33 Hz, 1 H), 7.27(t, J = 8.24 Hz, 1 H), 7.08 (td, J = 7.78, 0.92 Hz, 1 H), 4.89 (t, J =8.47 Hz, 2 H), 3.85 (dt, J = 10,10, 4.60 Hz, 2 H), 3.36 (m, 1 H), 3.26(d, J = 6.41 Hz, 5 H), 1.88 (m, 1 H), 1.60 (m, 2 H), 1.22 (qd, J =12.40, 10.50 Hz, 2 H) 104

N-(2,3-dihydroxypropyl- 7-indolin-1-yl- thiazolo[5,4-d]pyrimidine-2-carboxamide 372.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.90 (t, J = 6.41Hz, NH), 8.68 (m, 2 H), 7.36 (d, J = 6.87 Hz, 1 H), 7.28 (t, J = 8.24Hz, 1 H), 7.09 (t, J = 7.79 Hz, 1 H), 4.97 (d, J = 5.04 Hz, 1 H), 4.89(t, J = 8.24 Hz, 2 H), 4.73 (t, J = 5.95 Hz, 1 H), 3.73 (m, 1 H), 3.39(s, 4 H), 3.29 (m, 2 H)

Example 1057-(5-Fluoro-3,3-dimethyl-indolin-1-yl)-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

5-Fluoro-3,3-dimethyl-indoline (28 mg, 0.17 mmol), Intermediate 18 (50mg, 0.17 mmol) and propan-2-ol (2 ml) were combined, sealed in amicrowave tube and heated at 80° C. in a heating block for 4 hours. Themixture was cooled, at which point a yellow precipitate formed. This wascollected via vacuum filtration, loaded onto silica and purified viacolumn chromatography (gradient elution from 0-5% MeOH in DCM) to give ayellow solid (24 mg, 33%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39 (s, 6H),1.76-1.85 (m, 4H), 3.36-3.45 (m, 2H), 3.85-3.96 (m, 2H), 3.97-4.14 (m,1H), 4.65 (s, 2H), 7.11 (td, J=9.16, 2.75 Hz, 1H), 7.29 (dd, J=8.70,2.75 Hz, 1H), 8.57 (dd, J=8.93, 4.81 Hz, 1H), 8.62 (d, J=8.24 Hz, 1H),8.67 (s, 1H); LC-MS (ESI): (MH⁺) 428.1.

Example 1067-Indolin-1-yl-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 18 (50 mg, 0.17 mmol), indoline (20 mg, 0.17 mmol) andpropan-2-ol (2 ml) were combined, sealed in a microwave tube and heatedat 80° C. thermally for 1.5 hours. The mixture was cooled, at whichpoint a yellow precipitate formed. This was collected and dried viavacuum filtration to a yellow solid (45 mg, 70%); ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.71-1.86 (m, 4H), 3.34-3.37 (m, 2H), 3.37-3.45 (m, 2H),3.87-3.96 (m, 2H), 4.02-4.19 (m, 1H), 4.91 (t, J=8.40 Hz, 2H), 7.09 (td,J=7.33, 0.92 Hz, 1H), 7.28 (t, J=7.33 Hz, 1H), 7.37 (d, J=7.33 Hz, 1H),8.62-8.71 (m, 2H), 8.77 (d, J=8.70 Hz, 1H); LC-MS (ESI): (MH⁺) 382.0.

Examples 107-113 in the table below were prepared analogously to Example105 from Intermediate 18 and the appropriate indoline

LC-MS Example (ESI): # R IUPAC Name (MH⁺) ¹H NMR 107

7-(5′- fluorospiro[cyclopropane- 1,3′-indoline]-1′-yl)-N-tetrahydropyran-4-yl- thiazolo[5,4-d]pyrimidine- 2-carboxamide 426.0 ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.21-1.26 (m, 4 H), 1.61-1.71 (m, 2H), 2.06 (dd, J = 12.36, 2.29 Hz, 2 H), 3.57 (td, J = 11.68, 2.29 Hz, 2H), 4.01-4.08 (m, 2 H), 4.18-4.29 (m, 1 H), 4.79 (s, 2 H), 6.48 (dd, J =8.24, 2.75 Hz, 1 H), 6.88 (d, J = 8.24 Hz, 1 H), 6.95 (td, J = 8.70,2.75 Hz, 1 H), 8.64 (dd, J = 8.93, 4.81 Hz, 1 H), 8.69 (s, 1 H) 108

7-spiro[indoline-3,4′- tetrahydropyran]-1-yl-N- tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 452.1 ¹H NMR (400 MHz, DMSO-d₆)δ ppm 1.60 (d, J = 12.82 Hz, 2 H), 1.64-1.74 (m, 2 H), 1.78-1.85 (m, 2H), 1.95 (td, J = 12.82, 4.58 Hz, 2 H), 3.41 (td, J = 11.45, 2.29 Hz, 2H), 3.59 (t, J = 11.45 Hz, 2 H), 3.84-3.92 (m, 4 H), 3.96-4.08 (m, 1 H),4.85 (s, 2 H), 7.07-7.14 (m, 1 H), 7.25-7.31 (m, 1 H), 7.37-7.42 (m, 1H), 8.61 (d, J = 7.78 Hz, 1 H), 8.64 (d, J = 8.24 Hz, 1 H), 8.67 (s, 1H) 109

7-[3- (hydroxymethyl)indolin-1- yl]-N-tetrahydropyran-4-yl-thiazolo[5,4- d]pyrimidine-2- carboxamide 412.0 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.69-1.78 (m, 2 H), 2.00-2.12 (m, 2 H), 3.57 (td, J= 11.79, 1.60 Hz, 2 H), 3.70-3.81 (m, 1 H), 3.88 (dd, J = 11.00, 6.90Hz, 1 H), 3.98 (dd, J = 10.50, 5.00 Hz, 1 H), 4.01-4.09 (m, 2 H),4.17-4.31 (m, 1 H), 4.79-4.94 (m, 2 H), 7.06 (d, J = 8.24 Hz, 1 H),7.11-7.17 (m, 1 H), 7.33-7.40 (m, 2 H), 8.65-8.73 (m, 2 H) 110

7-[3-(2- hydroxyethyl)indolin-1- yl]-N-tetrahydropyran-4-yl-thiazolo[5,4- d]pyrimidine-2- carboxamide 426.1 ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.67- 1.82 (m, 5 H), 1.91- 2.00 (m, 1 H), 3.34- 3.43 (m,2 H), 3.53- 3.65 (m, 3 H), 3.88 (d, J = 10.99 Hz, 2 H), 3.97- 4.09 (m, 1H), 4.56 (dd, J = 12.36, 5.95 Hz, 1 H), 4.62 (t, J = 5.27 Hz, 1 H), 5.03(dd, J = 12.40, 9.20 Hz, 1 H), 7.08 (td, J = 7.44, 1.14 Hz, 1 H), 7.25(t, J = 7.33 Hz, 1 H), 7.34 (d, J = 7.78 Hz, 1 H), 8.55 (d, J = 8.20 Hz,1 H), 8.60 (d, J = 8.20 Hz, 1 H), 8.64 (s, 1 H) 111

7-[3-(2- aminoethyl)indolin-1-yl]- N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 425.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.60-1.71 (m, 2 H), 1.76-1.86 (m, 1 H), 1.99-2.10(m, 3 H), 2.83-3.01 (m, 2 H), 3.52-3.67 (m, 3 H), 3.98-4.08 (m, 2 H),4.16-4.30 (m, 1 H), 4.53 (dd, J = 11.91, 5.95 Hz, 1 H), 4.96 (dd, J =11.91, 9.16 Hz, 1 H), 7.06 (d, J = 8.24 Hz, 1 H), 7.11 (td, J = 7.33,0.92 Hz, 1 H), 7.26- 7.35 (m, 2 H), 8.60 (d, J = 8.24 Hz, 1 H), 8.66 (s,1 H) 112

N-(tetrahydro-2H-pyran- 4-yl)-7-(5- (trifluoromethyl)indolin-1-yl)thiazolo[5,4- d]pyrimidine-2- carboxamide ¹H NMR (400 MHz, DMSO-d) δppm 8.79 (d, J = 8.24 Hz, 1 H), 8.74 (s, 1 H), 7.70 (s, 1 H), 7.64 (d, J= 8.70 Hz, 1 H), 4.96 (t, J = 8.47 Hz, 2 H), 4.09 (m, 1 H), 3.93 (d, J =10.99 Hz, 2 H), 3.41 (m, 4 H), 1.84 (m, 2 H), 1.79 (m, 2 H) 113

7-[3-(2-hydroxyethyl)-3- methyl-indolin-1-yl]-N- tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 440.0 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.47 (s, 3 H), 1.63- 1.73 (m, 2 H), 2.02- 2.07 (m, 4H), 3.56 (m, 2 H), 3.76-3.82 (m, 2 H), 3.97-4.05 (m, 2 H), 4.15-4.28 (m,1 H), 4.51 (d, J = 11.90 Hz, 1 H), 5.02 (d, J = 11.91 Hz, 1 H),7.09-7.18 (m, 2 H), 7.20-7.24 (m, 1 H), 7.29- 7.35 (m, 1 H), 8.59 (d, J= 8.24 Hz, 1 H), 8.65 (s, 1 H) 114

7-(5-hydroxyindolin-1-yl)- N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 398   ¹H NMR (400 MHz, DMSO-d₆)δ ppm 1.72- 1.85 (m, 4 H), 3.26 (t, J = 8.24 Hz, 2 H), 3.35- 3.45 (m, 2H), 3.86- 3.95 (m, 2 H), 4.82- 4.89 (m, 2 H), 6.66 (dd, J = 8.70, 2.29Hz, 1 H), 6.77 (d, J = 2.29 Hz, 1 H), 8.48 (d, J = 8.70 Hz, 1 H), 8.57(s, 1 H), 8.73 (d, J = 8.70 Hz, 1 H).

Example 1157-[3-[2-(Methylamino)ethyl]indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution of Example 110 (23 mg, 0.05 mmol) in DCM (1 ml) was addedtriethylamine (15 μL, 0.1 mmol) and mesyl chloride (6 mg, 0.05 mmol) andstirred for 45 mins. A 33% solution of methylamine in EtOH (1 ml) wasadded and stirred overnight. The mixture was concentrated and submittedfor HPLC purification. To give7-[3-[2-(methylamino)ethyl]indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide(8.8 mg, 37%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.62-1.74 (m, 2H),1.85-1.91 (m, 1H), 2.01-2.05 (m, 2H), 2.11-2.16 (m, 1H), 2.53 (s, 3H),2.77-2.94 (m, 2H), 3.50-3.66 (m, 3H), 3.97-4.08 (m, 2H), 4.15-4.29 (m,1H), 4.52 (dd, J=11.91, 5.50 Hz, 1H), 4.92 (dd, J=11.91, 9.16 Hz, 1H),7.04-7.13 (m, 1H), 7.22-7.25 (m, 1H), 7.27-7.32 (m, 2H), 8.61 (d, J=8.24Hz, 1H), 8.67 (s, 1H); LC-MS (ESI): (MH⁺) 439.1.

Example 1167-(5-Isopropoxyindolin-1-yl)-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 114 (26 mg, 0.06 mmol), K₂CO₃ (18 mg, 0.13 mmol) and2-bromopropane (9 μl, 0.09 mmol) were stirred in DMF (1 ml) at roomtemperature for 18 h. A further 2 equivalents of 2-bromopropane and 1equivalent of K₂CO₃ was added and stirring was continued for a further 4h. The mixture was quenched with water and extracted with DCM. Theorganic phases was washed with water and concentrated. Purification byflash chromatography gave a yellow solid (25 mg, 94%). ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.22-1.31 (m, 6H), 1.70-1.87 (m, 4H), 3.24-3.47 (m, 4H),3.84-3.99 (m, 2H), 4.08 (d, J=7.78 Hz, 1H), 4.50-4.67 (m, 1H), 4.88 (t,J=8.24 Hz, 2H), 6.82 (dd, J=8.93, 2.52 Hz, 1H), 6.95 (d, J=2.29 Hz, 1H),8.57 (d, J=9.16 Hz, 1H), 8.60 (s, 1H), 8.74 (d, J=8.70 Hz, 1H); LC-MS(ESI): (MH⁺) 440.

Example 1177-Indol-1-yl-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution of Intermediate 18 (50 mg, 0.17 mmol) in dioxane (3 ml)was added Indole (20 mg, 0.17 mmol), Cs₂CO₃ (109 mg, 0.34 mmol) andXantphos (9.7 mg, 0.017 mmol). The mixture was degassed, prior toaddition of Pd(OAc)₂ (7.7 mg, 0.0085 mmol). The reaction mixture waspurged with nitrogen and then heated 10 90° C. for 18 h. The mixture wasallowed to cool to room temperature, concentrated onto silica gel andsubjected to flash chromatography (gradient elution from 0 to 50% ethylacetate in petroleum ether) to give a brown solid, which was trituratedwith methanol and dried to give an off-white solid (25 mg, 39%). ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 1.65-1.85 (m, 2H), 2.09 (dd, J=12.59, 2.06Hz, 2H), 3.59 (td, J=11.91, 2.29 Hz, 2H), 4.07 (dd, J=9.85, 2.06 Hz,2H), 4.19-4.37 (m, 1H), 6.91 (d, J=3.66 Hz, 1H), 7.14 (d, J=8.24 Hz,1H), 7.31-7.39 (m, 1H), 7.39-7.47 (m, 1H), 7.69 (d, J=6.87 Hz, 1H), 8.90(d, J=3.66 Hz, 1H), 8.94-9.00 (m, 1H), 9.05 (s, 1H); LC-MS (ESI): (MH⁺)380.

Example 1187-[3-Methyl-3-[2-(methylamino)ethyl]indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 118 was prepared in an analogous manner to Example 115 fromExample 113. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45 (s, 3H),1.62-1.74 (m, 2H), 1.86-2.00 (m, 2H), 2.00-2.10 (m, 2H), 2.34 (s, 3H),2.43-2.53 (m, 1H), 2.57-2.67 (m, 1H), 3.55 (td, J=11.68, 1.83 Hz, 2H),4.02 (d, J=11.45 Hz, 2H), 4.16-4.30 (m, 1H), 4.42 (d, J=11.45 Hz, 1H),4.76 (d, J=11.45 Hz, 1H), 7.05-7.16 (m, 2H), 7.18-7.23 (m, 1H),7.27-7.33 (m, 1H), 8.55 (d, J=8.24 Hz, 1H), 8.62-8.67 (m, 1H); LC-MS(ESI): (MH⁺) 453.1.

Example 1197-[3-(Aminomethyl)indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution of Example 109 (50 mg, 0.12 mmol) in THF (3 ml) was addedtriethylamine (35 μL, 2.4 mmol) and mesyl chloride (10 μL, 0.12 mmol)and stirred for 1 hour. The mixture was concentrated, taken up in DMFand potassium phthalimide (27 mg, 0.15 mmol) added and the reaction washeated at 80° C. overnight. The mixture was cooled, EtOAc and wateradded, the organic phase separated, dried and concentrated. The residuewas taken up in EtOH, 2 equivalents of hydrazine added and heated atreflux for 3 hours. The mixture was cooled, the precipitated solidremoved via filtration and the filtrate concentrated. Purification byLCMS gave the desired product (2.3 mg, 5%); ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.64-1.76 (m, 2H), 1.99-2.07 (m, 2H), 2.94-3.06 (m,1H), 3.09-3.20 (m, 1H), 3.51-3.64 (m, 3H), 4.03 (m, J=10.50 Hz, 2H),4.19-4.29 (m, 1H), 4.76 (dd, J=11.90, 4.60 Hz, 1H), 4.89 (dd, J=11.90,9.20 Hz, 1H), 7.08-7.15 (m, 1H), 7.26 (d, J=5.04 Hz, 1H), 7.30-7.36 (m,2H), 8.63-8.70 (m, 2H); LC-MS (ESI): (MH⁺) 411.1.

Example 1207-[3-(Methylaminomethyl)indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution of Example 109 (50 mg, 0.12 mmol) in THF (3 ml) was addedtriethylamine (35 μL, 2.4 mmol) and mesyl chloride (10 μL, 0.12 mmol)and stirred for 1 hour. To the mixture was added an excess of 33%methylamine in ethanol, the vial sealed and heated at 50° C. overnight.The mixture was concentrated and submitted for HPLC purification to give7-[3-(methylaminomethyl)indolin-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide(12.6 mg, 24%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.72 (dd, J=12.82,3.66 Hz, 2H), 1.96-2.08 (m, 2H), 2.50 (s, 3H), 2.82 (dd, J=11.91, 8.70Hz, 1H), 3.03 (dd, J=11.68, 4.81 Hz, 1H), 3.56 (td, J=11.68, 2.29 Hz,2H), 3.63-3.72 (m, 1H), 3.99-4.06 (m, 2H), 4.19-4.32 (m, 1H), 4.76 (dd,J=11.91, 5.50 Hz, 1H), 4.91 (dd, J=11.90, 9.20 Hz, 1H), 7.11 (td,J=7.30, 1.40 Hz, 1H), 7.28-7.35 (m, 2H), 7.47-7.54 (m, 1H), 8.63-8.70(m, 2H); LC-MS (ESI): (MH⁺) 425.0.

Example 1217-[3-[(dimethylamino)methyl]indol-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution of Example 109 (100 mg, 0.24 mmol) in THF (5 ml) wasadded, at 0° C., Dess-Martin Periodinane (113 mg, 0.27 mmol) and stirredovernight. The reaction mixture was concentrated and used in the nextstep without further purification. The residue was taken up in DCM (5ml), dimethyl amine (40 mg, 0.48 mmol), sodium triacetoxyborohydride (78mg, 0.37 mmol) and acetic acid (15 mg, 0.25 mmol) added and stirredovernight. Analysis indicated oxidation of the indoline to the indole.The mixture diluted with DCM and water, the organic layer separated,dried and concentrated. The residue was submitted for HPLC purificationto give7-[3-[(dimethylamino)methyl]indol-1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide(1.7 mg, 2%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.74-1.83 (m, 2H),1.98-2.07 (m, 2H), 2.40 (s, 6H), 3.52-3.61 (m, 2H), 3.71 (s, 2H),3.99-4.11 (m, 2H), 4.21-4.34 (m, 1H), 7.30-7.36 (m, 1H), 7.38-7.45 (m,1H), 7.64-7.70 (m, 1H), 7.94-8.03 (m, 1H), 8.97 (d, J=8.70 Hz, 1H),9.00-9.02 (m, 2H); LC-MS (ESI): (MH⁺) 437.1.

Example 1227-(2-Methylindolin-1-yl)-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Thionyl chloride (5 ml) was added to Intermediate 36 (200 mg, 0.64 mmoL)and the reaction heated at reflux for 1 hour. The mixture was cooled,concentrated and taken up in DCM. To the solution was addedtriethylamine (0.18 ml, 1.3 mmol) and 4-aminotetrahydropyran (194 mg,1.9 mmol) and stirred for 2 hours. The mixture was diluted with DCM andwater, the organic phase was separated, dried and concentrated ontosilica. The compound was purified via column chromatography (gradientelution from 15-45% EtOAc in Pet. Ether) gave a light yellow solid (56mg, 22%); ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.22 (d, J=6.41 Hz, 3H),1.68-1.84 (m, 4H), 2.85 (d, J=15.57 Hz, 1H), 3.32-3.43 (m, 2H), 3.50(dd, J=15.80, 8.93 Hz, 1H), 3.80-3.92 (m, 2H), 4.00-4.11 (m, 1H),6.01-6.11 (m, 1H), 7.03-7.12 (m, 1H), 7.20-7.30 (m, 1H), 7.33-7.40 (m,1H), 8.55-8.66 (m, 3H); LC-MS (ESI): (MH⁺) 396.1.

Example 1237-(2-Methylindolin-1-yl)-N-(1-methyl-4-piperidyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 123 was prepared in an analogous manner to Example 122 from giveIntermediate 36 and 1-methylpiperidin-4-amine. ¹H NMR (400 MHz, DMSO-d₆)δ ppm 1.26 (d, J=6.41 Hz, 3H), 1.71-1.89 (m, 4H), 1.92-2.04 (m, 2H),2.19 (s, 3H), 2.75-2.85 (m, 2H), 2.89 (d, J=15.57 Hz, 1H), 3.54 (dd,J=15.57, 8.70 Hz, 1H), 3.73-3.91 (m, 1H), 6.04-6.19 (m, 1H), 7.12 (td,J=7.33, 0.92 Hz, 1H), 7.30 (t, J=7.56 Hz, 1H), 7.40 (d, J=7.33 Hz, 1H),8.59 (d, J=8.24 Hz, 1H), 8.66 (d, J=8.20 Hz, 1H), 8.68 (s, 1H); LC-MS(ESI): (MH⁺) 409.2.

Example 124

Example 124 was prepared in an analogous manner to Example 122 from giveIntermediate 36 and N,N-dimethyl-3-propylamine. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.40 (d, J=6.41 Hz, 3H), 1.91 (br. s., 3H), 2.39(br. s., 6H), 2.63 (br. s., 2H), 2.82-2.91 (m, 1H), 3.51-3.62 (m, 3H),3.66-3.78 (m, 1H), 5.92-6.02 (m, 1H), 7.06-7.13 (m, 1H), 7.28-7.34 (m,2H), 8.42 (br. s., 1H), 8.62-8.72 (m, 2H); LC-MS (ESI): (MH⁺) 397.1.

Example 1257-(3-Methylindolin-1-yl)-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 125 was prepared in an analogous manner to Example 122 fromIntermediate 35 and 4-aminotetrahydropyran. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.47 (d, J=6.90 Hz, 2H), 1.63-1.77 (m, 2H), 2.07 (m,J=12.40, 2.30 Hz, 2H), 2.08 (s, 1H), 3.58 (td, J=11.68, 2.29 Hz, 2H),3.61-3.71 (m, 1H), 3.99-4.11 (m, 2H), 4.20-4.28 (m, 1H), 4.31 (dd,J=11.45, 6.41 Hz, 1H), 5.01 (dd, J=11.91, 9.16 Hz, 1H), 6.99 (d, J=8.20Hz, 1H), 7.14 (td, J=7.30, 1.00 Hz, 1H), 7.28-7.35 (m, 2H), 8.59 (d,J=7.80 Hz, 1H), 8.68 (s, 1H); LC-MS (ESI): (MH⁺) 396.1.

Example 1267-(3-Methylindolin-1-yl)-N-(1-methyl-4-piperidyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Example 126 was prepared in an analogous manner to Example 122 fromIntermediate 35 and 1-methylpiperidin-4-amine. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.45 (d, J=6.90 Hz, 3H), 1.62-1.70 (m, 2H), 2.10(dd, J=12.82, 4.12 Hz, 2H), 2.21 (t, J=11.22 Hz, 2H), 2.34 (s, 3H),2.77-2.92 (m, 2H), 3.59-3.70 (m, 1H), 3.98-4.11 (m, 1H), 4.30 (dd,J=11.40, 6.90 Hz, 1H), 5.01 (dd, J=11.68, 9.39 Hz, 1H), 6.95-7.07 (m,1H), 7.13 (td, J=7.33, 0.92 Hz, 1H), 7.28-7.34 (m, 2H), 8.60 (d, J=7.78Hz, 1H), 8.67 (s, 1H); LC-MS (ESI): (MH⁺) 409.2.

Example 127(R)-7-(2-Methylindolin-1-yl)-N-(piperidin-4-ylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 43 (350 mg, 1.08 mmol) and SOCl₂ (10 mL) were heated underreflux for 3 hours. The resultant solution was concentrated to give adark orange gum. The acid chloride was taken up in DCM (10 mL) and a 1.4ml aliquot of the resulting solution was added to a reaction vialcontaining a solution of triethylamine (0.20 mL, 1.57 mmol) and4-aminomethyl-1-BOC-piperidine (168 mg, 7.87 mmol). The mixture wasstirred overnight to give a green solution. This was treated with TFA (1mL) and left to stir for 30 mins. To the resultant solution was addedsat. NaHCO_(3 (aq)) (5 mL) until pH 7 was achieved. The organic layerwas separated and concentrated before being sent for HPLC purification.The product,(R)-7-(2-methylindolin-1-yl)-N-(piperidin-4-ylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide,was obtained as a yellow solid after purification (30.2 mg, 14%). ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 8.64 (s, 1H), 8.59 (d, J=7.78 Hz, 1H),7.31 (d, J=7.79 Hz, 1H), 7.25 (t, J=8.70 Hz, 1H), 7.11 (t, J=8.20 Hz,1H), 5.75 (m, 1H), 3.54 (dd, J=15.11, 8.70 Hz, 1H), 3.42 (dd, J=13.74,6.87 Hz, 2H), 3.27 (m, 2H), 2.84 (d, J=15.57 Hz, 1H), 2.75 (t, J=13.30Hz, 2H), 1.89 (m, 3H), 1.47 (m, 2H), 1.42 (d, J=5.95 Hz, 4H); LC-MS(ESI): (MH⁺) 409.1.

Examples 128-129 were made in an analogous manner to Example 127, fromIntermediate 43 and the appropriate, BOC protected, amine. Example 130was prepared analogously to Example 122 from Intermediate 43 and4-aminotetrahydropyran.

LC- MS Example (ESI): # Structure IUPAC Name (MH⁺) ¹H-NMR 128

N-[3- (methylamino)propyl]-7- [(2R)-2-methylindolin-1- yl]thiazolo[5,4-d]pyrimidine-2- carboxamide 383.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.65 (d, J = 8.70 Hz, 1 H), 8.63 (s, 1 H), 8.47 (t, J = 6.40 Hz, NH),7.30 (m, 2 H), 7.10 (td, J = 7.33, 0.92 Hz, 1 H), 5.87 (m, 1 H), 3.64(m, 2 H), 3.53 (dd, J = 16.03, 9.16 Hz, 1 H), 2.82 (m, 3 H), 2.47 (s, 3H), 1.83 (quin, J = 5.95 Hz, 3 H), 1.39 (d, J = 5.95 Hz, 3 H) 129

7-[(2R)-2-methylindolin- 1-yl]-N-(4-piperidyl)thiazolo[5,4-d]pyrimidine- 2-carboxamide 395.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 8.63 (s, 1 H), 8.55 (d, J = 8.24 Hz, 1 H), 7.31 (d,J = 7.33 Hz, 2 H), 7.10 (td, J = 7.33, 0.92 Hz, 1 H), 7.01 (d, J = 8.70Hz, NH), 5.71 (m, 1 H), 4.09 (m, 1 H), 3.54 (dd, J = 15.57, 8.70 Hz, 1H), 3.11 (m, 2 H), 2.80 (m, 2 H), 2.07 (t, J = 13.70 Hz, 2 H), 1.52 (qd,J = 11.45, 4.12 Hz, 2 H), 1.43 (d, J = 5.95 Hz, 3 H) 130

7-[(2R)-2-methylindolin- 1-yl]-N-tetrahydropyran- 4-yl-thiazolo[5,4-d]pyrimidine-2-carboxamide 396.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.63 (s, 1 H), 8.55 (d, J = 8.24 Hz, 1 H), 7.31 (m, J = 7.80 Hz, 2 H),7.11 (td, J = 7.79, 0.92 Hz, 1 H), 7.00 (d, J = 8.24 Hz, 1 H), 5.70 (m,1 H), 4.21 (d, J = 8.24 Hz, 1 H), 4.01 (dq, J = 13.28, 3.21 Hz, 2 H),3.56 (m, 3 H), 2.83 (d, J = 15.57 Hz, 1 H), 2.05 (m, 2 H), 1.65 (s, 2H), 1.43 (d, J = 6.41 Hz, 3 H)

Examples 131-134 were made in an analogous manner to Example 127, from(S)-7-(2-methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxylic acid,itself made in an analogous manner to Intermediate 43, and theappropriate amine

LC- MS Example (ESI): # X IUPAC Name (MH⁺) ¹H NMR 131

N-[3- (methylamino)propyl]-7- [(2S)-2-methylindolin-1- yl]thiazolo[5,4-d]pyrimidine-2- carboxamide 383.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.64 (s, 2 H), 8.34 (t, J = 5.04 Hz, 1 H), 7.31 (m, 2 H), 7.10 (td, J =7.33, 1.37 Hz, 1 H), 5.87 (m, 1 H), 3.65 (m, 2 H), 3.53 (dd, J = 16.49,9.16 Hz, 1 H), 2.87 (m, 3 H), 2.53 (s, 3 H), 1.90 (quin, J = 6.41 Hz, 2H), 1.40 (d, J = 6.41 Hz, 3 H) 132

7-[(2S)-2-methylindolin- 1-yl]-N-(4-piperidyl)thiazolo[5,4-d]pyrimidine- 2-carboxamide 395.0 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 8.64 (s, 1 H), 8.56 (d, J = 7.78 Hz, 1 H), 7.30 (s,2 H), 7.11 (td, J = 7.79, 0.92 Hz, 1 H), 7.01 (d, J = 9.16 Hz, 1 H),5.72 (m, 1 H), 4.11 (m, 1 H), 3.54 (dd, J = 16.03, 8.24 Hz, 1 H), 3.14(dq, J = 12.36, 4.12 Hz, 2 H), 2.79 (m, 2 H), 2.09 (m, 2 H), 1.55 (q, J= 11.91 Hz, 2 H), 1.44 (d, J = 6.41 Hz, 3 H) 133

7-[(2S)-2-methylindolin-1- yl]-N-tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 396.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 8.64 (s, 1 H), 8.55 (d, J = 7.78 Hz, 1 H), 7.32 (d,J = 7.79 Hz, 2 H), 7.13 (m, 1 H), 6.99 (m, 1 H), 5.72 (m, 1 H), 4.22 (m,1 H), 4.02 (dq, J = 11.91, 3.66 Hz, 2 H), 3.57 (m, 3 H), 2.84 (d, J =15.11 Hz, 1 H), 2.06 (m, 2 H), 1.65 (s, 2 H), 1.44 (d, J = 6.41 Hz, 3H)134

7-[(2R)-2-methylindolin- 1-yl]-N-(4-piperidyl- methyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 409.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.64 (s, 1 H), 8.58 (d, J = 8.24 Hz, 1 H), 7.31 (d, J = 7.79 Hz, 2 H),7.21 (t, J = 6.41 Hz, 1 H), 7.12 (td, J = 7.33, 0.92 Hz, 1 H), 5.75 (m,1 H), 3.54 (dd, J = 15.57, 8.70 Hz, 1 H), 3.40 (m, 2 H), 3.19 (dt, J =11.91, 3.21 Hz, 2 H), 2.83 (d, J = 15.11 Hz, 1 H), 2.67 (td, J = 13.28,1.83 Hz, 2 H), 1.87 (m, 1 H), 1.80 (m, 2 H), 1.43 (d, J = 6.41 Hz, 3 H),1.34 (qd, J = 12.36, 3.66 Hz, 2 H)

Example 1357-[3-(Hydroxymethyl)indolin-1-yl]-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 45 (50 mg, 0.12 mmol), Intermediate 29 (18 mg, 0.12 mmol)and propan-2-ol (2 ml) were sealed in a vial and heated at 80° C. for 3hours. The mixture was cooled, concentrated and the BOC group removedusing TFA (1 ml) in DCM (5 ml). The mixture was neutralised with sat.NaHCO_(3(aq)), the organic layer separated, dried and concentrated. Theresidue was purified by preparative LCMS to give a yellow solid (19 mg,36%); ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.28-1.44 (m, 2H), 1.69-1.78(m, 2H), 1.79-1.88 (m, 1H), 2.59-2.69 (m, 2H), 3.12 (td, J=8.01, 4.12Hz, 2H), 3.38 (dt, J=13.51, 5.84 Hz, 1H), 3.47-3.54 (m, 1H), 3.70-3.81(m, 2H), 3.94-4.02 (m, 1H), 4.81-4.95 (m, 2H), 7.09 (td, J=7.30, 0.90Hz, 1H), 7.26-7.35 (m, 2H), 7.40 (br. t, J=6.00, 6.00 Hz, 1H), 8.62-8.69(m, 2H); LC-MS (ESI): (MH⁺) 425.1.

Examples 136-146

Examples 136-146 in the table below were prepared analogously to Example135 from Intermediate 45 and the appropriate indoline

LC-MS Example R (ESI): # (IUPAC Name) (MH⁺) ¹H NMR 136

439.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.56- 1.71 (m, 4 H),1.79-1.94 (m, 2 H), 2.19-2.28 (m, 1 H), 2.66-2.74 (m, 2 H), 3.13-3.23(m, 2 H), 3.45-3.61 (m, 2 H), 3.62-3.71 (m, 1 H), 3.77-3.84 (m, 1 H),3.89-3.96 (m, 1 H), 4.76 (dd, J = 12.80, 7.30 Hz, 1 H), 5.20 (dd, J =12.80, 9.60 Hz, 1 H), 7.11 (td, J = 7.33, 0.92 Hz, 1 H), 7.25-7.33 (m, 3H), 8.64 (s, 1 H), 8.73 (d, J = 8.20 Hz, 1 H) 137

425.0 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.30-1.43 (m, 1 H), 1.47-1.60(m, 1 H), 1.64-1.75 (m, 2 H), 1.76-1.88 (m, 1 H), 2.61 (tdd, J = 11.91,11.91, 4.81, 2.52 Hz, 2 H), 3.02-3.15 (m, 2 H), 3.19 (d, J = 15.57 Hz, 1H), 3.27 (dt, J = 13.74, 4.58 Hz, 1 H), 3.44-3.53 (m, 1 H), 3.56-3.67(m, 2 H), 4.09 (dd, J = 9.16, 3.66 Hz, 1 H), 5.52-5.60 (m, 1 H),7.06-7.13 (m, 1 H), 7.30 (t, J = 8.01 Hz, 2 H), 7.59-7.72 (m, 1 H), 8.38(d, J = 7.79 Hz, 1 H), 8.64 (s, 1 H) 138

425.0 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.28-1.41 (m, 1 H), 1.44-1.58(m, 1 H), 1.70 (t, J = 12.14 Hz, 2 H), 1.75-1.87 (m, 1 H), 2.60 (tdd, J= 11.91, 11.91, 4.58, 2.75 Hz, 2 H), 3.01-3.14 (m, 2 H), 3.18 (d, J =16.03 Hz, 1 H), 3.27 (dt, J = 13.28, 4.58 Hz, 1 H), 3.43-3.53 (m, 1 H),3.55-3.68 (m, 2 H), 4.09 (dd, J = 9.39, 3.89 Hz, 1 H), 5.56 (td, J =8.13, 3.89 Hz, 1 H), 7.05-7.13 (m, 1 H), 7.29 (t, J = 8.01 Hz, 2 H),7.59-7.75 (m, 1 H), 8.38 (d, J = 8.20 Hz, 1 H), 8.63 (s, 1 H) 139

457.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.59-1.73 (m, 4 H), 1.78-1.93(m, 2 H), 2.12-2.22 (m, 1 H), 2.73 (br. s., 2 H), 2.98-3.00 (m, 1 H),3.16-3.27 (m, 2 H), 3.49-3.60 (m, 2 H), 3.60-3.69 (m, 1 H), 3.79 (td, J= 9.27, 3.43 Hz, 1 H), 3.92 (ddd, J = 9.96, 5.61, 4.12 Hz, 1 H), 4.76(dd, J = 12.36, 7.33 Hz, 1 H), 5.23 (dd, J = 12.59, 9.39 Hz, 1 H),6.93-7.03 (m, 2 H), 7.26-7.33 (m, 1 H), 8.63 (s, 1 H), 8.70 (dd, J =8.70, 4.58 Hz, 1 H) 140

439.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.35-1.50 (m, 5 H), 1.73-1.95(m, 3 H), 2.61-2.74 (m, 2 H), 3.13-3.25 (m, 2 H), 3.32-3.44 (m, 1 H),3.45-3.58 (m, 1 H), 3.70 (q, J = 10.30 Hz, 2 H), 4.37 (d, J = 11.90 Hz,1 H), 5.08 (d, J = 11.90 Hz, 1 H), 7.10-7.16 (m, 1 H), 7.19-7.24 (m, 1H), 7.29-7.36 (m, 1 H), 7.49-7.56 (m, 1 H), 8.61- 8.68 (m, 2 H) 141

457.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.02-1.14 (m, 2 H), 1.40 (s, 3 H),1.55-1.77 (m, 3 H), 2.35- 2.48 (m, 2 H), 2.93 (d, J = 12.36 Hz, 2 H),3.21-3.28 (m, 2 H), 3.48-3.57 (m, 2 H), 4.48 (d, J = 12.82 Hz, 1 H),4.88 (d, J = 12.80 Hz, 1 H), 7.12 (td, J = 8.93, 2.75 Hz, 1 H), 7.24(dd, J = 8.70, 2.75 Hz, 1 H), 8.59 (dd, J = 8.93, 4.81 Hz, 1 H), 8.65(s, 1 H), 8.79-8.90 (m, 1 H) 142

467.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.31 (s, 3 H), 1.35 (s, 3 H),1.60-1.72 (m, 4 H), 1.82-1.94 (m, 2 H), 1.95-2.02 (m, 1 H), 2.66-2.76(m, 3 H), 3.21 (td, J = 7.33, 3.21 Hz, 2 H), 3.43-3.50 (m, 1 H),3.51-3.59 (m, 1 H), 3.66-3.76 (m, 1 H), 4.73 (dd, J = 12.80, 7.30 Hz, 1H), 5.19 (dd, J = 12.80, 9.20 Hz, 1 H), 7.09 (td, J = 7.30, 0.90 Hz, 1H), 7.21 (d, J = 7.33 Hz, 1 H), 7.26-7.35 (m, 2 H), 8.62 (s, 1 H), 8.72(d, J = 8.20 Hz, 1 H) 143

485.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.09-1.20 (m, 2 H), 1.24 (s, 6 H),1.59-1.78 (m, 4 H), 1.97- 2.10 (m, 1 H), 2.46 (br. s., 2 H), 2.92-3.05(m, 2 H), 3.17-3.28 (m, 2 H), 3.63-3.77 (m, 1 H), 4.59-4.65 (m, 1 H),5.17-5.30 (m, 1 H), 7.10 (td, J = 9.10, 2.80 Hz, 1 H), 7.24 (dd, J =9.20, 2.30 Hz, 1 H), 8.46 (t, J = 6.00 Hz, 1 H), 8.60 (dd, J = 9.20,5.00 Hz, 1 H), 8.66 (s, 1 H) 144

453.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.41 (s, 3 H), 1.55-1.74 (m,4 H), 1.82-1.96 (m, 2 H), 2.02-2.11 (m, 1 H), 2.63-2.76 (m, 2 H),3.12-3.24 (m, 2 H), 3.36-3.45 (m, 1 H), 3.60- 3.69 (m, 1 H), 3.76-3.93(m, 2 H), 4.63 (d, J = 11.90 Hz, 1 H), 5.15 (d, J = 11.91 Hz, 1 H), 7.11(td, J = 7.30, 0.90 Hz, 1 H), 7.19 (dd, J = 7.30, 0.90 Hz, 1 H),7.27-7.39 (m, 2 H), 8.64 (s, 1 H), 8.70 (d, J = 7.80 Hz, 1 H) 145

463.0 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 9.07 (t, J = 6.41 Hz, NH),8.79 (d, J = 8.70 Hz, 1 H), 8.76 (s, 1 H), 7.70 (s, 1 H), 7.65 (d, J =8.24 Hz, 1 H), 4.95 (t, J = 8.24 Hz, 2 H), 3.41 (t, J = 8.70 Hz, 2 H),3.24 (t, J = 6.87 Hz, 2 H), 3.02 (m, 2 H), 2.55 (m, 2 H), 1.77 (m, 1 H),1.66 (m, 2 H), 1.15 (qd, J = 13.70, 4.58 Hz, 2 H) 146

409.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.65 (s, 1 H), 8.59 (d, J =7.78 Hz, 1 H), 7.27 (m, 2 H), 7.11 (td, J = 7.33, 1.00 Hz, 1 H), 4.99(dd, J = 9.62, 5.50 Hz, 1 H), 4.29 (dd, J = 11.45, 6.41 Hz, 1 H), 3.63(sxt, J = 6.90 Hz, 1 H), 3.42 (m, 2 H), 3.20 (dt, J = 11.91, 2.75 Hz, 2H), 2.67 (td, J = 12.36, 2.75 Hz, 2 H), 1.88 (m, 1 H), 1.81 (d, J =13.28 Hz, 2 H), 1.45 (d, J = 6.87 Hz, 3 H), 1.36 (qd, J = 12.36, 3.66Hz, 2 H)

Examples 147-151

To a solution of Intermediate 63 (250 mg, 0.68 mmol) and triethylamine(0.2 ml, 1.35 mmol) in DCM (5 ml) was added mesyl chloride (55 μL, 0.074mmol) drop wise and stirred for 2 hours. The mixture was diluted withDCM, washed with water, the organic phase separated, dried andconcentrated. The residue was taken up in DMF (10 ml) and the solutiondispensed into five separate vials. To each of these vials was addedK₂CO₃ (4 mg, 0.11 mmol) and the desired amine (0.23 mmol). The vialswere sealed and heated at 80° C. overnight. The mixtures were cooled,submitted to an aqueous work, the organic layer separated, dried andconcentrated. Samples were purified via HPLC to give the desiredproducts as yellow solids.

LC- MS Example (ESI): # R IUPAC Name (MH⁺) ¹H NMR 147

7-[5-fluoro-3-[2-(methyl- amino)ethyl]indolin-1-yl]-N-tetrahydropyran-4-yl- 457.0 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.63-1.77 (m, 2 H), 1.81-1.94 (m, 2 H) 1.98-2.07 (m, 2 H), 2.07-2.19 (m, 1H), 2.53 (s, 3 H), 2.76-2.93 (m, 2 H), thiazolo[5,4-d]pyrimidine-3.50-3.58 (m, 2 H), 3.59-3.67 (m, 1 H), 3.96-4.06 2-carboxamide (m, 3H), 4.16-4.30 (m, 1 H), 4.55 (dd, J = 11.90, 6.00 Hz, 1 H), 4.97 (dd, J= 11.90, 9.60 Hz, 1 H), 6.91-7.00 (m, 2 H), 7.37 (d, J = 8.20 Hz, 1 H),8.56-8.67 (m, 2 H) 148

7-[3-[2-(dimethyl- amino)ethyl]-5-fluoro- indolin-1-yl]-N-tetrahydro-pyran-4-yl-thiazolo[5,4- 471.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm1.65-1.78 (m, 2 H), 1.82-1.93 (m, 1 H), 2.01-2.09 (m, 2 H), 2.09-2.16(m, 1 H), 2.35 (s, 6 H), 2.41- 2.50 (m, 1 H), 2.51-2.61 (m, 1 H),3.53-3.60 (m, d]pyrimidine-2- 2 H), 3.61-3.68 (m, 1 H), 4.01-4.10 (m, 2H), carboxamide 4.18-4.32 (m, 1 H), 4.63 (dd, J = 11.91, 5.95 Hz, 1 H),4.98 (dd, J = 11.91, 9.16 Hz, 1 H), 6.96-7.05 (m, 2 H), 7.16-7.26 (m, 1H), 8.60-8.68 (m, 2 H) 149

7-[5-fluoro-3-(2-pyrrolidin- 1-ylethyl)indolin-1-yl]-N-tetrahydropyran-4-yl- thiazolo[5,4-d]pyrimidine- 2-carboxamide 497.1 ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.69 (dd, J = 12.59, 4.35 Hz, 2 H).1.77-1.84 (m, 4 H), 1.84-1.93 (m, 1 H), 2.00-2.09 (m, 2 H), 2.10- 2.18(m, 1 H), 2.48-2.63 (m, 5 H), 2.65-2.75 (m, 1 H), 3.51-3.60 (m, 2 H),3.61-3.68 (m, 1 H), 3.97- 4.09 (m, 2 H), 4.16-4.32 (m, 1 H), 4.59 (dd, J= 11.90, 6.00 Hz, 1 H), 4.95 (dd, J = 11.90, 9.20 Hz, 1 H), 6.94-7.03(m, 2 H), 7.13 (d, J = 7.80 Hz, 1 H), 8.56-8.67 (m, 2 H) 150

7-[5-fluoro-3-[2-(4- methylpiperazin-1- yl)ethyl]indolin-1-yl]-N-tetrahydropyran-4-yl- thiazolo[5,4-d]pyrimidine- 2-carboxamide 526.1 ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 1.61-1.76 (m, 2 H), 1.81-1.94 (m, 1H), 2.02-2.13 (m, 3 H), 2.31 (s, 3 H), 2.39-2.70 (m, 9 H), 3.51- 3.67(m, 3 H), 3.97-4.10 (m, 2 H), 4.17-4.30 (m, 1 H), 4.64 (dd, J = 11.90,6.00 Hz, 1 H), 4.92 (dd, J = 11.90, 9.20 Hz, 1 H), 6.95-7.02 (m, 2 H),7.04- 7.12 (m, 1 H), 8.60 (dd, J = 9.39, 4.81 Hz, 1 H), 8.65 (s, 1 H)151

7-[5-fluoro-3-(2- morpholinoethyl)indolin- 1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4- d]pyrimidine-2- carboxamide 513.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.57-1.70 (m, 2 H), 1.80-1.90 (m, 1 H), 1.95-2.11(m, 3 H), 2.37-2.60 (m, 6 H), 3.55 (td, J = 11.68, 1.83 Hz, 3 H), 3.69(t, J = 4.58 Hz, 4 H), 3.96-4.05 (m, 2 H), 4.15-4.28 (m, 1 H), 4.56 (dd,J = 11.90, 5.50 Hz, 1 H), 4.90 (dd, J = 11.90, 9.20 Hz, 1 H), 6.92-7.05(m, 3 H), 8.51-8.60 (m, 1 H), 8.62 (s, 1 H)

Examples 152-155

To a solution of Intermediate 64 (210 mg, 0.49 mmol) in DCM (5 mL) wasadded triethylamine (0.14 mL, 0.99 mmol) and mesyl chloride (0.04 mL,0.49 mmol). The mixture was stirred for 1 hour. The mixture was dilutedwith DCM (5 mL) and partitioned with water (10 mL). The organic phasewas washed with water (2×10 mL). The combined organic layers were driedand concentrated to give an orange solid. This was taken up in DMF (9mL) and an aliquot added to a vial containing the desired amine (0.14mmol) and K₂CO₃ (19 mg, 0.14 mmol). The resultant mixture was heated at80° C. for four hours. Once cooled EtOAc (5 mL) and water (5 mL) wereadded and the organic phase separated. The organic phase was washed withwater (2×10 mL), dried and concentrated. Samples were purified via HPLCto give the desired products as yellow solids.

LC- MS Example (ESI): # R IUPAC Name (MH⁺) ¹H NMR 152

7-[3-[2-(dimethylamino) ethyl]-indolin-1-yl]-N- tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 453.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm8.66 (s, 1 H), 8.63 (d, J = 8.24 Hz, 1 H), 7.31 (t, J = 7.33 Hz, 1 H),7.27 (d, J = 7.33 Hz, 1 H), 7.12 (td, J = 7.33, 0.92 Hz, 1 H), 4.91 (dd,J = 11.91, 9.16 Hz, 2-carboxamide 1 H), 4.60 (m, 1 H), 4.24 (m, 1 H),4.03 (dq, J = 11.45, 1.83 Hz, 2 H), 3.63 (m, 1 H), 3.54 (td, J = 12.36,2.29 Hz, 2 H), 2.64 (m, 2 H), 2.41 (br. s, 6H), 2.17 (m, 1 H), 2.03 (m,2 H), 1.88 (m, 1 H), 1.73 (qd, J = 12.40, 5.00 Hz, 2 H) 153

7-[3-(2-pyrrolidin-1- ylethyl)indolin-1-yl]-N- tetrahydropyran-4-yl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 479.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 8.66 (m, 2 H), 7.31 (t, J = 8.20 Hz, 2 H), 7.25 (d,J = 6.41 Hz, 1H), 7.10 (td, J = 7.79, 0.92 Hz, 1 H), 4.88 (dd, J = 8.70,5.95 Hz, 1 H), 4.64 (dd, J = 11.45, 5.50 Hz, 1 H), 4.23 (m, 1 H), 4.02(dq, J = 10.53, 1.83 Hz, 2 H), 3.63 (m, 1 H), 3.55 (td, J = 11.91, 2.29Hz, 2 H), 2.90 (m, 6 H), 2.21 (m, 2 H), 2.01 (m, 2 H), 1.93 (m, 4 H),1.74 (m, 2 H) 154

7-[3-(2- morpholinoethyl)indolin- 1-yl]-N-tetrahydropyran-4-yl-thiazolo[5,4- d]pyrimidine-2- carboxamide 495.1 ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.59-1.77 (m, 4 H) 1.80-2.27 (m, 4 H) 2.49 (m, 4 H)3.45-3.50 (m, 1 H) 3.55 (t, J = 11.68 Hz, 2 H) 3.59-3.89 (m, 4 H) 4.02(d, J = 11.45 Hz, 2 H) 4.17-4.29 (m, 1 H) 4.43-4.74 (m, 1 H) 4.82-4.90(m, 1 H) 7.08-7.13 (m, 1 H) 7.25-7.28 (m, 1 H) 7.29-7.34 (m, 1 H)8.51-8.71 (m, 2 H) 155

7-[3-[2-(4- methylpiperazin-1- yl)ethyl]indolin-1-yl]-N-tetrahydropyran-4-yl- thiazolo[5,4-d]pyrimidine- 2-carboxamide 508.1 ¹HNMR (400 MHz, CHLOROFORM-d) δ ppm 8.66 (s, 1 H), 8.59 (d, J = 8.24 Hz, 1H), 7.31 (t, J = 8.24 Hz, 1 H), 7.27 (m, 1 H), 7.11 (td, J = 7.33, 0.92Hz, 1 H), 4.86 (dd, J = 9.16, 5.95 Hz, 1 H), 4.57 (m, 1 H), 4.22 (m, 1H), 4.01 (m, 2 H), 3.56 (td, J = 12.82, 2.29 Hz, 2 H), 2.55 (m, 6 H),2.33 (br. s, 3 H), 2.13 (m, 1 H), 2.03 (m, 2 H), 1.86 (m, 1 H), 1.69 (m,2 H), 1.59 (br. s., 4 H)

Example 156N-methyl-7-(3-methylindolin-1-yl)thiazolo[5,4-d]pyrimidine-2-carboxamide

To a solution 3-methylindoline (54 mg, 0.41 mmol) in IPA (2 mL) wasadded Intermediate 65 (93 mg, 0.41 mmol) and the mixture stirred at 70°C. for 16 hours. The mixture was concentrated and by preparative LCMS togive the desired product (23 mg, 17%); ¹H NMR (400 MHz, CHLOROFORM-d) δppm 8.67 (s, 1H), 8.62 (d, J=7.79 Hz, 1H), 7.32 (m, 2H), 7.16 (td,J=8.24, 0.92 Hz, 1H), 7.11 (br.s, NH), 5.07 (dd, J=9.16, 6.41 Hz, 1H),4.35 (t, J=6.41 Hz, 1H), 3.65 (sxt, J=7.33 Hz, 1H), 3.12 (d, J=5.04 Hz,3H), 1.47 (d, J=6.87 Hz, 3H); LC-MS (ESI): (MH⁺) 326.0.

Examples 157-158

Examples 157-158 in the table below were prepared analogously to Example156 from Intermediate 65 and the appropriate indoline

LC- MS Example R (ESI): # (IUPAC Name) (MH⁺) ¹H NMR 157

356.0 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 2.05-2.14 (m, 1 H), 2.39-2.47(m, 1 H), 3.06 (d, J = 5.00 Hz, 3 H), 3.73-3.78 (m, 1 H), 4.46 (m, 1 H),4.54- 4.62 (m, 2 H), 5.23 (dd, J = 12.36, 9.16 Hz, 1 H), 7.12 (td, J =7.33, 0.92 Hz, 1 H), 7.25-7.28 (m, 1 H), 7.31-7.36 (m, 1 H), 7.59 (m, 1H), 8.67 (s, 1 H), 8.73 (d, J = 8.24 Hz, 1 H) 158

— ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 8.75 (d, J = 8.70 Hz, 1 H), 8.70(s, 1 H), 7.53 (d, J = 8.00 Hz, 1 H), 7.51 (s, 1 H), 7.15 (m, NH), 4.89(t, J = 8.70 Hz, 2 H), 3.38 (t, J = 8.70 Hz, 2 H), 3.10 (d, J = 5.50 Hz,3 H) * LC-MS (pH10, MeCN) retention time 1.90 mins

Examples 159-163

Examples 159, 161 and 162 were prepared analogously to Example 127 fromIntermediate 68 and the appropriate BOC-protected amine. Examples 160and 163 were prepared analogously to Example 122 from Intermediate 68and the appropriate amine.

LC- MS Example R (ESI): # (IUPAC Name) (MH⁺) ¹H NMR 159

397.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.46 (s, 6 H), 1.85 (quin, J= 6.00 Hz, 2 H), 2.48 (s, 3 H), 2.83 (t, J = 6.00 Hz, 2 H), 3.65 (q, J =6.00 Hz, 2 H), 4.55 (s, 2 H), 7.12 (td, J = 7.30, 0.90 Hz, 1 H), 7.24(dd, J = 7.30, 0.90 Hz, 1 H), 7.26-7.32 (m, 1 H), 8.50 (br. t, J = 5.20,5.20 Hz, 1 H), 8.56 (d, J = 7.80 Hz, 1 H), 8.65 (s, 1 H) 160

437.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45 (s, 6 H), 1.80-1.86 (m,4 H), 1.93 (quin, J = 6.40 Hz, 2 H), 2.54-2.79 (m, 6 H), 3.64 (q, J =6.41 Hz, 2 H), 4.55 (s, 2 H), 7.12 (td, J = 7.80, 0.90 Hz, 1 H), 7.24(dd, J = 7.80, 0.90 Hz, 1 H), 7.26-7.31 (m, 1 H), 7.86 (br. s., 1 H),8.55 (d, J = 8.24 Hz, 1 H), 8.62-8.67 (m, 1H) 161

423.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.22-1.35 (m, 2 H), 1.44 (s,6 H), 1.77 (br. m., 3 H), 2.59-2.69 (m, 2 H), 3.10-3.19 (m, 2 H), 3.42(t, J = 6.40 Hz, 2 H), 4.51 (s, 2 H), 7.12 (td, J = 7.30, 0.90 Hz, 1 H),7.18-7.25 (m, 2 H), 7.26-7.32 (m, 1 H), 8.53 (d, J = 8.24 Hz, 1 H), 8.66(s, 1 H) 162

409.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45 (s, 6 H), 1.58-1.69 (m,2 H), 2.09-2.18 (m, 2 H), 2.78-2.89 (m, 2 H), 3.18-3.28 (m, 2 H),4.08-4.21 (m, 1 H), 4.53 (s, 2 H), 7.01 (d, J = 8.70 Hz, 1 H), 7.13 (td,J = 7.30, 0.90 Hz, 1 H), 7.22-7.25 (m, 1 H), 7.27-7.32 (m, 1 H), 8.54(d, J = 8.24 Hz, 1 H), 8.66 (s, 1 H) 163

384.1 ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45 (s, 6 H), 1.91 (quin, J= 5.90 Hz, 3 H), 3.71 (q, J = 6.00 Hz, 2 H), 3.83 (t, J = 5.50 Hz, 2 H),4.54 (s, 2 H), 7.13 (td, J = 7.30, 0.90 Hz, 1 H), 7.24 (dd, J = 7.30,0.90 Hz, 1 H), 7.27- 7.32 (m, 1 H), 7.74 (br. t, J = 5.90, 5.90 Hz, 1H), 8.58 (d, J = 8.24 Hz, 1 H), 8.66 (s, 1 H)

Examples 164-167

General Procedure (Part of an Array)

Step 1

Intermediate 2 (640 mg, 2.80 mmol) was refluxed in SOCl₂ (10 mL) at 85°C. for 3 hours giving a yellow solution. Once cooled the solution wasconcentrated to give a yellow solid. The acid chloride was taken up inDCM (12 mL) and triethylamine (0.77 mL, 5.60 mmol) added. A 2 ml aliquotwas added to a vial containing the appropriate amine (0.47 mmol) underN₂. The reaction mixture was stirred at room temperature for 4 hoursafter which it was diluted with DCM and partitioned with water. Theorganic phase was washed with water (2×10 mL), dried and concentratedonto silica. The compound was purified by column chromatography and usedin Step 2.

Step 2

To a solution of Step 1 (0.10 mmol) in IPA (2 mL) was added Intermediate32 (27 mg, 0.10 mmol) and the mixture heated at 80° C. for 7 hours. Oncecooled the solution was concentrated in vacuo, and taken up in DCM (2mL), TFA (1 mL) added and the solution stirred for 1 hour at roomtemperature. The solution was then concentrated in vacuo and theresultant residue was purified by preparative LCMS

LC- MS Example (ESI): # R IUPAC Name (MH⁺) ¹H NMR 164

7-(3-(2-Aminoethyl) indolin-1-yl)-N-cyclo- propylthiazolo[5,4-d]pyrimidine-2- 381.1 ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.97 (d, J = 4.12Hz, 1 H), 8.64 (s, 1 H), 8.59 (d, J = 7.79 Hz, 1 H), 7.32 (d, J = 7.33Hz, 1 H), 7.26 (t, J = 7.79 Hz, 1 H), 7.08 (td, J = 6.87, carboxamide1.37 Hz, 1 H), 4.99 (dd, J = 13.74, 8.70 Hz, 1 H), 4.51 (dd, J = 13.28,5.50 Hz, 1 H), 3.57 (m, 1 H), 2.81 (m, 3 H), 1.95 (m, 1 H), 1.75 (m, 1H), 0.77 (m, 2 H), 0.69 (m, 2 H) 165

7-[3-(2-aminoethyl) indolin-1-yl]-N-isopentyl-thiazolo[5,4-d]pyrimidine- 2-carboxamide 411.1 ¹H NMR (400 MHz, DMSO-d₆)δ ppm 8.90 (t, J = 6.41 Hz, NH), 8.62 (s, 1 H), 8.56 (d, J = 7.79 Hz, 1H), 7.31 (d, J = 7.33 Hz, 1 H), 7.24 (td, J = 7.79, 0.92 Hz, 1 H), 7.06(td, J = 7.44, 1.15 Hz, 1 H), 4.95 (dd, J = 12.36, 9.62 Hz, 1 H), 4.53(dd, J = 12.82, 5.50 Hz, 1 H), 3.56 (m, 1 H), 3.33 (q, J = 8.20 Hz, 2H), 2.69 (t, J = 6.87 Hz, 2 H), 1.82 (m, 1 H), 1.67 (m, 1 H), 1.59 (m, 1H), 1.46 (q, J = 7.79 Hz, 2 H), 0.90 (d, J = 5.95 Hz, 6 H) 166

7-[3-(2-amino- ethyl)indolin-1-yl]-N- (3-methoxypropyl) 413.1 ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.91 (t, J = 5.95 Hz, NH), 8.63 (s, 1 H), 8.57(d, J = 8.24 Hz, 1 H), 7.32 (d, J = 7.79 Hz, thiazolo[5,4-d]pyrimidine-1 H), 7.24 (t, J = 7.33 Hz, 1 H), 7.07 (td, J = 2-carboxamide 7.33, 1.37Hz, 1 H), 4.95 (dd, J = 13.28, 10.53 Hz, 1 H), 4.53 (dd, J = 12.36, 5.50Hz, 1 H), 3.56 (m, 1 H), 3.38 (m, 4 H), 3.23 (s, 3 H), 2.69 (t, J = 6.87Hz, 2 H), 1.82 (m, 4 H), 1.66 (m, 1 H) 167

7-[3-(2-aminoethyl) indolin-1-yl]-N-(3,3,3- trifluoropropyl)thiazolo[5,4-d]pyrimidine-2- carboxamide 437.0 ¹H NMR (400 MHz, DMSO-d₆) δ ppm9.14 (m, 1 H), 8.65 (s, 1 H), 8.58 (d, J = 8.70 Hz, 1 H), 7.33 (d, J =7.79 Hz, 1 H), 7.27 (td, J = 8.24, 1.83 Hz, 1 H), 7.09 (td, J = 6.87,0.92 Hz, 1 H), 4.95 (dd, J = 8.70, 6.41 Hz, 1 H), 4.55 (dd, J = 5.95,4.58 Hz, 1 H), 3.59 (m, 3 H), 2.80 (m, 2 H), 2.62 (m, 2 H), 1.92 (m, 1H), 1.75 (m, 1 H)

Example 1687-(5-Chloroindolin-1-yl)-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Intermediate 80 (29 mg, 0.07 mmol) and 5-chloroindoline (11 mg, 0.07mmol) were combined in isopropanol (2 ml) and stirred at roomtemperature for 21 h. The mixture was dissolved in DCM and concentratedonto SiO₂ and subjected to flash chromatography to give the N—BOCintermediate as a yellow solid. The solid was dissolved in DCM (5 ml)and treated with 4M HCl in dioxane (0.5 ml) for 2 h at room temperature.The solvents were removed under reduced pressure and the residue wastaken up in 1:1 DCM-MeOH and loaded onto an SCX cartridge and elutedwith DCM-MeOH 1:1 followed by 2M ammonia in methanol. The ammoniacalsolution was concentrated and the residue was triturated with MeOH togive the product as a pale yellow solid (15 mg, 50%). 1H NMR (400 MHz,DMSO-d6) δ ppm 0.98-1.15 (m, 2H), 1.60 (d, J=10.99 Hz, 2H), 1.70 (br.s., 1H), 2.35-2.47 (m, 2H), 2.93 (d, J=11.45 Hz, 2H), 3.13-3.26 (m, 3H),4.91 (t, J=8.47 Hz, 2H), 7.32 (dd, J=8.70, 2.29 Hz, 1H), 7.42 (d, J=1.83Hz, 1H), 8.65 (d, J=8.70 Hz, 1H), 8.68 (s, 1H), 9.03 (t, J=6.18 Hz, 1H);LC-MS (ESI): (MH⁺) 429/431.

Example 1697-(5-Bromoindolin-1-yl)-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 168 from Intermediate 80 (100 mg, 0.24mmol) and 5-bromoindoline (48 mg, 0.24 mmol) to give the product as ayellow solid (20 mg, 17%). 1H NMR (400 MHz, DMSO-d6) δ ppm 0.96-1.11 (m,2H), 1.57 (d, J=12.36 Hz, 2H), 1.67 (br. s., 1H), 2.34-2.43 (m, 2H),2.49-2.65 (m, 1H), 2.90 (d, J=12.36 Hz, 2H), 3.18 (t, J=6.64 Hz, 2H),4.87 (t, J=8.47 Hz, 2H), 7.42 (dd, J=8.70, 2.29 Hz, 1H), 7.51 (d, J=2.29Hz, 1H), 8.56 (d, J=8.70 Hz, 1H), 8.65 (s, 1H), 8.99 (t, J=5.95 Hz, 1H).LC-MS (ESI): (MH+) 473/475.

Example 1707-(5-Methylindolin-1-yl)-N-(4-piperidylmethyl)thiazolo[5,4-d]pyrimidine-2-carboxamide

Prepared analogously to Example 168 from Intermediate 80 (100 mg, 0.24mmol) and 5-methylindoline (32 mg, 0.24 mmol) to give the product as ayellow solid (50 mg, 50%). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.11-1.27 (m,3H), 1.68 (d, J=11.91 Hz, 2H), 1.78 (br. s., 1H), 2.31 (s, 3H),2.52-2.60 (m, 2H), 2.98-3.07 (m, 2H), 3.22-3.33 (m, 4H), 4.83-4.91 (m,2H), 7.06 (d, J=8.70 Hz, 1H), 7.16 (s, 1H), 8.52 (d, J=8.24 Hz, 1H),8.62 (s, 1H), 8.76-8.84 (m, 1H). LC-MS (ESI): (MH+) 409.

Example 171 7-(5-Fluoroindolin-1-yl)thiazolo[5,4-d]pyrimidine

7-Chlorothiazolo[5,4-d]pyrimidine (50 mg, 0.29 mmol), 5-fluoroindoline(42 mg, 0.31 mmol), 4M HCl in dioxane (0.075 ml) in IPA (0.7 ml) wereirradiated in the microwave at 100° C. for 30 min. The precipitate wasfiltered and washed with methanol. The residue was purified byfiltration through an aminopropyl cartridge eluting with DCM:MeOH (10:1)to give a green solid (23 mg, 27%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 3.29(t, J=8.47 Hz, 2H), 4.74-4.92 (m, 2H), 7.08 (td, J=9.16, 2.75 Hz, 1H),7.15-7.26 (m, 1H), 8.61 (dd, J=8.93, 4.81 Hz, 1H), 8.64 (s, 1H), 9.34(s, 1H).

MNK1 and 2 Biochemical IC50 Assays

The effects of compounds on MNK1 and MNK2 activity was determined in abiochemical assay by monitoring the phosphorylation of Serine/ThreonineKinase peptide 5FAM-RRRLSSLRA-NH2. The phosphorylated peptide productand unphosphorylated peptide substrate were detected using a CaliperMobility Shift Assay using the Caliper LabChip EZ Reader II.

The Caliper Mobility Shift Assay technology is based on the utilisationof a microfluidic chip to measure the conversion of a fluorescentnon-phosphorylated peptide substrate to phosphorylated product byelectrophoresis separation of substrate and product and detection viaLaser-induced fluorescence. The LabChip EZ Reader software calculatesthe relative heights of substrate and product peaks and reports the peakratio (Product peak(P) divided by the sum of Product peak(P) andSubstrate peak(S)). The percent-conversion is calculated as100×[(P/(P+S)]. All assays were set up to run in the linear phase with amaximum of 10 percent substrate conversion.

Reagents

The enzymes, MNK1 and MNK2 used for all screening activities weresourced from Carna Biosciences (Product codes 02-145 and 02-146respectively). These were N-terminal GST fusion proteins expressed inbaculovirus expression system and purified by glutathione sepharoseaffinity chromatography. Specifically these constructs comprised ofFull-length human MNK1 [1-424(end) amino acids and T344D of accessionnumber BAA19885.1] and Full-length human MNK2 [1-465(end) amino acidsand T379D of accession number NP_951009.1]. A FAM-labelled genericser/thr kinase peptide substrate was purchased fromAnaspec—5-FAM-RRRLSSLRA-NH₂. Detection reagents for use on theCaliper-Labchip EZ reader 12-sipper (cat No. 760404), separating bufferand coating reagent-8 (CR-8)—were purchased from Perkin Elmer. All otherassay reagents were sourced from Sigma.

MNK1 Assay

Compounds were serially diluted in DMSO to generate a 10-point half logdilution curve with a final top concentration of 100 uM in the assay.Reactions were set up in a total volume of 30 uL inpolypropylene-384-well U-bottomed plates (Thermo Scientific 4340).Compounds were pre-incubated with enzyme and peptide in reaction bufferfor 30 mins prior to addition of ATP to initiate the reaction. Finalassay concentrations were 3 nM MNK1, 2 uM peptide substrate, 50 uM ATP,50 mM Hepes pH 7.0, 0.01% BSA, 10 mM MgCl₂, 1 mM dithiothrietol. Plateswere incubated at room temperature and the reaction was stopped by theaddition of 2 volumes (60 ul) of 50 mM EDTA at a point whereapproximately 10% substrate conversion had been achieved.

The assay incubation times were adjusted depending on the concentrationof ATP used. Assays were performed at low (50 uM) and high (1 mM) ATP.The low ATP values were selected to run at Km conditions for thestandard assay to allow relative potencies to be compared across otherkinases. The high ATP concentration was selected as representative ofcellular ATP concentrations, and for an indication of ATP competition,where a significant shift (greater than half log) in apparent potencywould be expected compared to Km conditions. All IC50 values reportedare the average of at least two independent experiments.

MNK2 Assay

Reactions were performed as above using 10 nM MNK2 in the assay.Standard assays contained 50 uM ATP and high concentration ATP assayscontained 1 mM ATP. Time to achieve 10% conversion varied. All otherconditions were the same.

MNK Cellular Activity Phospho-eIF4E Detection Assay

MNK activity in cells was measured by monitoring the phosphorylation ofeIF4E at ser209, the known endogenous substrate of MNK1/2, in celllysates. An amplified luminescent proximity homogeneous assay(Alphascreen Surefire p-eIF4E kit, Perkin Elmer) was used to enabledose-dependent responses to be quantified in a 384 format cell basedassay. The assay detection is based on the formation of sandwichantibody complexes coupled to donor and acceptor beads. Excitation at680 nm causes the transfer of a singlet oxygen species between donor andacceptor beads when they are in close proximity by binding to theanalyte (p-eIF4a-ser209), which results in the emission of light at520-620 nm.

A number of cancer cell lines were investigated, and the MV4.11 cellline (ATCC, CRL-9591), a biphenotypic B myelomonocytic leukemia cellline was selected for routine profiling of compounds. Compound dilutionswere prepared in IMDM-10% FBS medium to generate a 10 point half logserial dilution starting at a final top concentration in the assay of 30uM. Frozen cells were suspended in IMDM-10% FBS medium at aconcentration of 1.2×10⁶/ml. 4 ul (4,800 cells per well) was dispensedinto each well of a 384-tissue culture Proxiplate plates (Perkin Elmer6008238) and 4 ul of compound media dilution was added to the cells andincubated for 1.5 hr at 37 C, 5% CO₂. Cells were then lysed and theAlphascreen Surefire protocol followed according to manufacturer'srecommendations. 8 ul Acceptor beads (1:50 dilution in kit activationbuffer) was added to lysate, shaken 150 rpm for 2 min and incubated for1.5 hr at room temperature. 3 ul Donor beads (1:20 dilution in kitdilution buffer) were then added, shaken 150 rpm for 2 min and incubatedfor a further 1.5 hr at room temperature after which the plates wereread on Pherastar FS using Alphascreen optic module.

Data were normalised relative to untreated DMSO only controls and curvesrepeated in duplicate within experiments. Data reported are averages ofat least 2 independent experiments.

Kinase Selectivity Screen

Kinase screening was carried out using commercially available reagentsand protocols, by way of a third party kinase profiling service, such asEurofins KinaseProfiler™ (see www.eurofins.com/pharmadiscovery) orsimilar such service provider.

The results of a kinase selectivity screen for Examples 10, 58 and 64are shown in Table 2. Data are expressed as % inhibition of eachspecific kinase in the presence of 1 μM compound.

Various modifications and variations of the described aspects of theinvention will be apparent to those skilled in the art without departingfrom the scope and spirit of the invention. Although the invention hasbeen described in connection with specific preferred embodiments, itshould be understood that the invention as claimed should not be undulylimited to such specific embodiments. Indeed, various modifications ofthe described modes of carrying out the invention which are obvious tothose skilled in the relevant fields are intended to be within the scopeof the following claims.

REFERENCES

-   Buxade, M., et al. (2008). “The Mnks: MAP kinase-interacting kinases    (MAP kinase signal-integrating kinases).” Front Biosci 13:    5359-5373.-   Buxade, M., et al. (2005). “The Mnks are novel components in the    control of TNF alpha biosynthesis and phosphorylate and regulate    hnRNP A1.” Immunity 23(2): 177-189.-   Cherla, R. P., et al. (2006). “Shiga toxin 1-induced cytokine    production is mediated by MAP kinase pathways and translation    initiation factor eIF4E in the macrophage-like THP-1 cell line.” J    Leukoc Biol 79(2): 397-407.-   Chrestensen, C. A., et al. (2007). “Loss of MNK function sensitizes    fibroblasts to serum-withdrawal induced apoptosis.” Genes Cells    12(10): 1133-1140.-   Jauch, R., et al. (2006). “Mitogen-activated protein kinases    interacting kinases are autoinhibited by a reprogrammed activation    segment.” EMBO J 25(17): 4020-4032.-   Kjellerup, R. B., et al. (2008). “Pro-inflammatory cytokine release    in keratinocytes is mediated through the MAPK signal-integrating    kinases.” Exp Dermatol 17(6): 498-504.-   Konicek, B. W., et al. (2008). “Targeting the eIF4F translation    initiation complex for cancer therapy.” Cell Cycle 7(16): 2466-2471.-   Konicek, B. W., et al. (2011). “Therapeutic inhibition of MAP kinase    interacting kinase blocks eukaryotic initiation factor 4E    phosphorylation and suppresses outgrowth of experimental lung    metastases.” Cancer Res 71(5): 1849-1857.-   Nikolcheva, T., et al. (2002). “A translational rheostat for RFLAT-1    regulates RANTES expression in T lymphocytes.” J Clin Invest 110(1):    119-126.-   Noubade, R., et al. (2011). “Activation of p38 MAPK in CD4 T cells    controls IL-17 production and autoimmune encephalomyelitis.” Blood    118(12): 3290-3300.-   Rowlett, R. M., et al. (2008). “MNK kinases regulate multiple TLR    pathways and innate proinflammatory cytokines in macrophages.” Am J    Physiol Gastrointest Liver Physiol 294(2): G452-459.-   Teo, T., et al. (2015). “Pharmacologic Inhibition of MNKs in Acute    Myeloid Leukemia.” Mol Pharmacol 88(2): 380-389.-   Teo, T., et al. (2015). “Pharmacologic co-inhibition of Mnks and    mTORC1 synergistically suppresses proliferation and perturbs cell    cycle progression in blast crisis-chronic myeloid leukemia cells.”    Cancer Lett 357(2): 612-623.-   Ueda, T., et al. (2010). “Combined deficiency for MAP    kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor    development.” Proc Natl Acad Sci USA 107(32): 13984-13990.-   Wendel, H. G., et al. (2007). “Dissecting eIF4E action in    tumorigenesis.” Genes Dev 21(24): 3232-3237.

TABLE 1 Selected compounds according to the invention P(IC50) STRUCTUREExample # elF4E MNK1 MNK2

 1 7.6 7.3 7.5

 2 6.4 6.3 6.6

 3 7.3 7.2 7.3

 4 7.0 7.3 7.4

 5 7.0 6.8 7.1

 6 6.6 6.1 6.4

 7 6.5 6.6 6.6

 8 7.2 7.3 7.3

 9 7.4 7.3 7.5

 10 7.1 7.3 7.3

 11 6.5 6.4 6.5

 12 7.3 6.9 7.2

 13 7.4 7.3 7.4

 14 6.4 6.8 7.1

 15 6.6 6.1 6.2

 16 6.8 7.0 7.0

 17 7.0 6.9 7.0

 18 7.4 7.3 7.3

 19 6.6 6.1 6.1

 20 6.5 6.1 6.4

 21 6.5 5.7 5.9

 22 7.2 7.0 7.2

 23 7.2 7.0 7.2

 24 7.1 7.0 7.0

 25 7.8 8.2 8.4

 26 6.0 5.8 5.8

 27 7.5 8.0 8.1

 28 7.1 6.9 7.1

 29 7.4 7.2 7.3

 30 7.0 6.7 6.9

 31 7.3 7.2 7.3

 32 7.4 7.3 7.4

 33 7.1 7.0 7.1

 34 7.1 6.7 6.8

 35 6.5 6.8 6.7

 36 7.3 7.3 7.3

 37 7.6 7.4 7.4

 38 7.1 7.0 7.2

 39 7.2 6.8 6.9

 40 7.3 7.9 7.7

 41 7.7 7.6 7.9

 42 7.5 7.5 7.7

 43 7.6 7.4 7.5

 44 7.0 6.8 7.0

 45 7.5 7.8 7.7

 46 7.0 6.3 6.7

 47 6.9 6.6 6.7

 48 7.7 7.2 7.4

 49 7.1 6.8 7.2

 50 6.1 7.7 7.5

 51 6.9 6.9 7.0

 52 7.0 7.2 7.2

 53 6.9 7.0 6.9

 54 6.7 7.1 7.0

 55 6.5 6.5 6.6

 56 6.1 6.0 6.1

 57 6.6 6.6 6.6

 58 8.1 8.3 8.4

 59 6.2 5.7 5.8

 60 6.2 6.1 6.0

 61 7.1 7.0 6.9

 62 6.5 6.2 6.5

 63 7.4 7.1 7.2

 64 8.1 8.6 8.7

 65 6.6 7.1 7.1

 66 8.0 8.3 8.4

 67 8.4 8.4 8.5

 68 8.2 8.7 8.7

 69 8.2 8.2 8.3

 70 7.2 7.3 7.7

 71 7.8 8.0 8.2

 72 8.3 8.3 8.3

 73 7.8 8.3 8.3

 74 7.7 8.2 8.3

 75 7.8 8.5 8.5

 76 8.1 8.2 8.5

 77 8.4 8.7 8.7

 78 8.5 8.7 8.7

 79 8.0 8.5 8.5

 80 7.7 8.1 8.3

 81 7.0 7.4 7.7

 82 6.8 7.5 7.5

 83 6.9 7.5 7.4

 84 7.3 8.4 8.3

 85 7.0 8.0 7.7

 86 6.6 7.2 7.1

 87 6.7 6.9 7.1

 88 6.6 7.1 7.3

 89 6.7 7.4 7.2

 90 6.8 6.9 6.9

 91 7.0 7.2 7.3

 92 6.6 6.8 6.9

 93 6.6 6.7 6.8

 94 8.1 8.2 8.4

 95 7.0 7.4 7.6

 96 6.3 6.4 6.6

 97 7.8 8.1 8.1

 98 8.4 8.5 8.4

 99 7.8 7.9 8.3

100 7.8 7.6 7.7

101 7.5 8.0 7.9

102 6.2 6.8 6.7

103 7.2 8.0 8.0

104 8.0 7.7 7.9

105 8.6 8.7 8.5

106 7.7 7.9 8.1

107 8.7 8.8 8.5

108 7.5 7.2 7.4

109 7.9 7.9 8.1

110 8.0 8.0 8.0

111 7.2 8.3 8.2

112 6.5 6.7 6.9

113 7.4 7.4 7.4

114 8.8 8.6 8.6

115 6.9 7.5 7.8

116 6.3 5.7 6.2

117 7.3 7.3 7.5

118 6.6 6.9 6.8

119 7.7 7.9 7.8

120 6.9 7.3 7.5

121 7.1 7.4 7.1

122 7.3 7.4 7.5

123 7.7 7.6 7.8

125 8.4 8.5 8.4

124 7.5 7.6 7.7

126 8.4 8.4 8.2

127 7.8 7.9 7.8

128 7.1 7.7 7.9

129 7.1 7.8 7.8

130 7.3 7.3 7.4

131 7.4 7.0 7.5

132 7.6 7.7 7.8

133 7.3 7.1 7.4

134 7.4 7.5 7.6

135 7.5 8.0 8.1

136 8.2 8.1 8.3

137 6.8 6.7 6.9

138 6.7 6.4 6.5

139 7.5 8.6 8.5

140 7.4 8.2 8.2

141 7.7 8.5 8.3

142 8.0 7.8 7.8

143 8.3 8.1 8.2

144 7.7 7.9 7.8

145 6.3 6.9 7.0

146 8.3 8.2 8.1

147 7.8 8.1 8.0

148 7.2 7.3 7.2

149 7.2 7.5 7.3

150 7.6 7.2 7.2

151 7.5 7.0 7.0

152 7.3 7.0 7.1

153 7.0 7.3 7.3

154 7.0 7.1 7.1

155 7.3 6.9 7.1

156 8.3 8.0 8.1

157 8.0 7.5 7.7

158 6.3 6.5 6.9

159 8.3 8.3 8.5

160 8.1 8.2 8.2

161 8.5 8.5 8.6

162 8.1 8.2 8.3

163 8.3 8.0 8.4

164 8.3 8.3 8.3

165 7.8 8.0 8.0

166 8.4 8.3 8.3

167 7.8 8.1 8.3

168 7.5 8.5 8.5

169 7.5 8.1 8.1

170 7.1 7.2 7.6

171 6.6 7.1 7.2

TABLE 2 Kinase selectivity data for Examples 10, 58 and 64 Compound IDCompound ID Example Example Example Example Example Example Kinase 10 5864 Kinase 10 58 64 MKNK2 81 93 96 MAPK8 5 1 0 STK10 28 71 81 PIP5K1A 2 10 STK17A 2 41 70 PLK1 0 1 0 RPS6KA1 30 36 49 PRKAA2 1 1 45 NUAK1 15 3343 RAF1 0 1 0 MAP3K9 11 24 1 AKT1 0 0 0 SGK1 14 24 41 EPHA5 11 0 0 DYRK27 21 44 ACVR1B 6 0 15 ULK2 0 21 81 BLK 18 0 1 INSR 8 20 0 FER 4 0 0TYRO3 0 20 0 PAK7 1 0 0 CAMK2B 2 17 57 PIK3CG 6 0 3 TBK1 14 17 7 BMX 0 06 FES 13 16 1 FGFR3 0 0 3 MYLK 10 15 15 CDK1/CCNB1 8 0 4 MAP3K7 20 14 0CDK6/CCND3 3 0 9 YES1 4 14 4 PTK2 16 0 0 INSRR 10 13 0 PTK6 0 0 4 PIM2 713 42 RPS6KA5 0 0 24 CDK9/CCNT1 2 11 4 EEF2K 4 0 0 CaMK1 11 11 18 EGFR 00 5 IGF1R 12 11 0 FGFR1 1 0 2 FGFR4 0 10 0 RET 0 0 0 BTK 6 9 0 SRC 5 0 0PAK1 0 9 0 ABL2 0 0 0 ROCK2 1 8 18 DMPK 0 0 0 ALK 10 7 3 PRKCA 8 0 0 KIT0 7 0 ROCK1 0 0 4 MAP2K1 0 7 5 RPS6KB1 0 0 0 PIP4K2A 12 7 0 EPHB4 4 0 8STK11 21 7 10 PAK4 15 0 4 ABL1 4 6 4 PRKCE 4 0 0 CHEK1 0 6 35 LCK 12 0 0FLT1 12 6 27 MTOR 4 0 3 PIP5K1C 6 6 3 NTRK1 10 0 5 AURKC 14 5 15 PRAK 00 0

The invention claimed is:
 1. A compound of formula (I), or apharmaceutically acceptable salt or ester thereof,

wherein: R₁ is selected from: CO—NR₁₂R₁₃, wherein R₁₂ and R₁₃ are eachindependently selected from H, alkyl, cycloalkyl and heterocycloalkyl,wherein said alkyl group is optionally substituted by one or more R₁₄groups, and said heterocycloalkyl is optionally substituted by one ormore R₁₀ groups; or R₁₂ and R₁₃ are linked, together with the nitrogento which they are attached, to form a heterocycloalkyl group optionallycontaining one or more additional heteroatoms, and optionallysubstituted by one or more R₁₀ groups; hydroxyalkyl; H; NH₂; NH-alkyl,wherein said alkyl group is optionally substituted with one or more R₁₄groups; NH—CO-heterocycloalkyl; heterocycloalkyl optionally substitutedby one or more R₁₀ groups; and alkoxy optionally substituted with one ormore R₁₄ groups; R₂, R₃, R₄ and R₅ are each independently selected fromH, alkyl, hydroxyalkyl and (CH₂)_(n)—R_(12′); or R₂ and R₃ are linked toform a cycloalkyl or heterocycloalkyl group each of which may beoptionally further substituted with one or more R₁₀ groups; or R₄ and R₅are linked to form a cycloalkyl or heterocycloalkyl group each of whichmay be optionally further substituted with one or more R₁₀ groups; orone of R₂ and R₃ is absent, one of R₄ and R₅ is absent, and the dashedline is a double bond; Z₁, Z₂, Z₃ and Z₄ are all C; R₆, R₇, R₈ and R₉are each independently selected from H, CN, NO₂, OH, alkoxy, NHCO-alkyl,halo and haloalkyl; or Z₁, Z₃ and Z₄ are all C, Z₂ is N, R₇ is absentand R₆, R₈ and R₉ are as defined above; or Z₂, Z₃ and Z₄ are all C, Z₁is N, R₆ is absent and R₇, R₈ and R₉ are as defined above; n is aninteger from 1 to 10; each R_(12′) is independently selected from NH₂,NHR₁₀, NR₁₀R₁₁ and heterocycloalkyl, wherein said heterocycloalkyl isoptionally further substituted by one or more R₁₀ groups; each R₁₀ andR₁₁ is independently alkyl; and each R₁₄ is independently selected fromOH, alkoxy, haloalkyl, NH₂, NHR₁₀, NR₁₀R₁₁, heteroaryl andheterocycloalkyl, wherein said heterocycloalkyl is optionally furthersubstituted by one or more R₁₀ groups.
 2. A compound according to claim1 wherein Z₁, Z₂, Z₃ and Z₄ are all C.
 3. A compound according to claim1 wherein R₂, R₃, R₄ and R₅ are each independently selected from H,alkyl, and (CH₂)_(n)—R_(12′).
 4. A compound according to claim 1wherein: R₂, R₃, R₄ and R₅ are all H; or R₂ and R₃ are both H, and R₄and R₅ are both Me; or R₂ and R₃ are both H, and R₄ and R₄ are linked toform a cycloalkyl or heterocycloalkyl group.
 5. A compound according toclaim 1 wherein R₆, R₇, R₈ and R₉ are each independently selected from Hand halo.
 6. A compound according to claim 1 wherein: Z₁, Z₂, Z₃ and Z₄are all C; R₆, R₇, R₈ and R₉ are all H; or R₆, R₈ and R₉ are all H andR₇ is selected from fluoro, chloro, bromo, and CF₃; and R₂, R₃, R₄ andR₅ are each independently selected from H, alkyl, and (CH₂)_(n)—R_(12′).7. A compound according to claim 1 wherein: R₂, R₃, R₄ and R₅ are eachindependently selected from H, hydroxyalkyl, alkyl, and(CH₂)_(n)—R_(12′), where n is 1 or 2 and R_(12′) is selected from NH₂,NMe, NMe₂, pyrrolidin-1-yl, piperidin-1-yl and 4-methylpiperazin-1-yl.8. A compound according to claim 1 wherein R₁ is CO—NR₁₂R₁₃.
 9. Acompound according to claim 1 where R₁ is CO—NR₁₂R₁₃ wherein: one of R₁₂and R₁₃ is H and the other is selected from: tetrahydropyran-4-yl;piperdin-4-yl; cyclopropyl; tetrahydrofuran-4-yl;N-methylpiperidin-4-yl; alkyl optionally substituted by one or moregroups selected from NHMe, NH₂, NMe₂, piperidin-4-yl,N-methylpiperidin-4-yl, tetrahydrofuranyl, OH, CF₃, OMe andpyrrolidin-1-yl; or R₁₂ and R₁₃ are linked, together with the nitrogento which they are attached, to form a piperazinyl or morpholinyl groupoptionally substituted by one or more R₁₀ groups.
 10. A compound offormula (II), or a pharmaceutically acceptable salt or ester thereof,

wherein: R_(b) is alkyl; R_(1a) is selected from: CO—NR_(12a)R_(13a),wherein R_(12a) and R_(13a) are each independently selected from H,alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein saidalkyl group is optionally substituted by one or more (CH₂)_(m)R_(14a)groups, and said heterocycloalkyl is optionally substituted by one ormore groups selected from R₁₀ and (CH₂)_(m)R_(14a); or R_(12a) andR_(13a) are linked, together with the nitrogen to which they areattached, to form a heterocycloalkyl group optionally containing one ormore additional heteroatoms, and optionally substituted by one or moregroups select from R₁₀ and (CH₂)_(m)R_(14a); hydroxyalkyl; and COOH; Z₁,Z₂, Z₃ and Z₄ are all C; R₆, R₇, R₈ and R₉ are each independentlyselected from H, CN, NO₂, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; orZ₁, Z₃ and Z₄ are all C, Z₂ is N, R₇ is absent and R₆, R₈ and R₉ are asdefined above; or Z₂, Z₃ and Z₄ are all C, Z₁ is N, R₆ is absent and R₇,R₈ and R₉ are as defined above; m is an integer from 1 to 10; each R₁₀and R₁₁ is independently alkyl; each R_(14a) is independently selectedfrom CO₂R₁₀, COOH, OH, alkoxy, haloalkyl, NH₂, NHR₁₀, NR₁₀R₁₁,heteroaryl and heterocycloalkyl, wherein said heterocycloalkyl isoptionally further substituted by one or more R₁₀ groups.
 11. A compoundaccording to claim 10 wherein Z₁, Z₂, Z₃ and Z₄ are all C; R₆, R₇, R₈and R₉ are all H; or R₆, R₈ and R₉ are all H and R₇ is halo.
 12. Acompound according to claim 10 wherein Z₁, Z₂, Z₃ and Z₄ are all C, R₆,R₈ and R₉ are all H, and R₇ is fluoro.
 13. A compound according to claim10 wherein R_(1a) is CO—NR_(12a)R_(13a) wherein: one of R_(12a) andR_(13a) is H and the other is selected from: alkyl optionallysubstituted by one or more (CH₂)_(m)R_(14a) groups, wherein each R_(14a)is independently selected from NR₁₀R₁₁, COOH, OH and heterocycloalkyl;and mono or bicyclic heterocycloalkyl optionally substituted by one ormore groups selected from R₁₀ and (CH₂)_(m)CO₂R₁₀; or R_(12a) andR_(13a) are linked, together with the nitrogen to which they areattached, to form a piperidinyl group optionally substituted by one ormore groups selected from R₁₀ and (CH₂)_(m)R_(14a).
 14. A compound offormula (II), or a pharmaceutically acceptable salt or ester thereof,

wherein: R_(b) is selected from alkyl, cycloalkyl and heterocycloalkyl,each of which may be optionally substituted by one or more groupsselected from halo and alkoxy; R_(1a) is a heterocycloalkyl groupselected from, piperidinyl, quinuclidinyl, azetidinyl, morpholinyl,piperazinyl, pyrrolidinyl and tetrahydropyranyl, each of which isoptionally substituted by one or more R₁₀ groups; Z₁, Z₂, Z₃ and Z₄ areall C; R₆, R₇, R₈ and R₉ are each independently selected from H, CN,NO₂, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z₁, Z₃ and Z₄ areall C, Z₂ is N, R₇ is absent and R₆, R₈ and R₉ are as defined above; orZ₂, Z₃ and Z₄ are all C, Z₁ is N, R₆ is absent and R₇, R₈ and R₉ are asdefined above; each R₁₀ is independently alkyl.
 15. A compound which isselected from the following:

and pharmaceutically acceptable salts or esters thereof.
 16. Apharmaceutical composition comprising a compound according to claim 1and a pharmaceutically acceptable carrier, diluent or excipient.
 17. Amethod of treating a proliferatative disorder selected from ahaematological tumour, a solid tumour and/or metastases thereof,comprising administering to a subject in need thereof a compound ofclaim
 1. 18. A method of treating a disease of uncontrolled cell growth,proliferation and/or survival, an inappropriate cellular immuneresponse, or an inappropriate cellular inflammatory response, or aneurodegenerative disorder in a mammal, said method comprisesadministering to a mammal a therapeutically effective amount of acompound according to claim
 1. 19. A method of treating a mammal havinga disease state alleviated by the inhibition of MNK, wherein the methodcomprises administering to a mammal a therapeutically effective amountof a compound according to claim
 1. 20. A combination comprising acompound according to claim 1 and a further therapeutic agent.